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A) Clinical Studies and collaborations 
Cystic fibrosis (CF) study
The first study involved a cohort of children with cystic fibrosis from Great Ormond 
Street Hospital, London, UK, in which I was wholly responsible for the ethics 
application, patient recruitment, sample processing and data analysis. The second was 
performed in collaboration with Dr Jane Davies (Senior Lecturer and Paediatric 
respiratory consultant) and involved a cohort of adults and children with CF, managed 
at the Royal Brompton Hospital (RBH), London, UK and recruited by Dr Jane Davies. 
In the second study I performed all of the work on the patients with Burkholderia 
cepacia complex and part of the DNA extraction, MBL haplotyping and discussion of 
results. Parts of these results, relevant to my own, are presented in this thesis. I was not 
involved in the clinical care of any of these patients and therefore “blinded” to their 
outcome until data analysis.
Bronchoalveolar lavage (BAL) study
I was responsible for the study design (in collaboration with Dr Jane Davies), ethics 
application, parental information leaflets & sample processing for the GOSH patients in 
this study. In addition I performed the bronchoalveolar lavage & serum MBL ELISA’s 
on the additional BALs collected at the Royal Brompton Hospital. The neutrophil
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elastase assay was performed by Dr Tom Hilliard, Clinical Research Fellow at the 
Royal Brompton Hospital. Data analysis for all the patients was done by myself.
PICU study
I was responsible for the study design, ethics application, parental information leaflets, 
sample processing and data analysis in this study. In addition Dr Mark Peters 
(Paediatric ICU consultant) and Dr Peter Wilson (Clinical Fellow, PICU) helped with 
patient recruitment and consent. Dr Peter Wilson compiled the database of clinical 
parameters. I performed the EndoCab ELISAs in conjunction with Dr Rob Stephens 
(Clinical Research Fellow, ICH) and the cytokine polymorphisms in conjunction with 
Dr Paul Kotwinski (Clinical Research Fellow, Rayne Institute, UCL). The technique for 
the detection of the IL-10 -1082 (G/A), TNF-a -308 (G/A), ACE and PAI 1 promoter 
polymorphisms had been optimised prior to the onset of this study by Dr Meredith 
Allen (Clinical Research Fellow at ICH) and Dr Paul Kotwinski.
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I acknowledge the help of the nursing and medical clinical staff and the patients and 
their parents/carers in all of these studies.
B) Laboratory work
All other laboratory work presented here is entirely my own. Kind donations of any 
materials or compounds are acknowledged in the relevant section.
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ABSTRACT
From early in life humans come into contact with a wide variety of infectious agents 
including bacteria, fungi and viruses. However, despite the vast array of potential 
pathogens, only a minority have the capacity to cause disease in a human host. This is 
largely due to the efficacy of the human innate and adaptive immune systems. The 
innate immune system consists of a variety of components including mechanical 
barriers, secretions, cells, excreted proteins, and serum proteins including the 
complement components and mannose binding lectin (MBL). MBL is a liver derived, 
acute phase, circulating serum protein that acts as a pattern recognition molecule. It is 
able to bind to a range of sugars presented in particular conformations on the surface of 
microbes and, having bound to its target, it can activate the lectin complement pathway 
and enhance complement-independent opsonophagocytosis. Over the last decade the 
biological importance of MBL has become increasingly apparent as indicated by the 
clinical consequences of the MBL deficient state. This has mainly been addressed by 
looking at the effect that MBL deficiency has on the susceptibility to a wide range of 
infections. More recently, interest has focussed on the role that MBL may play in the 
modulation of inflammation.
It is well recognised that individuals differ in their susceptibility to, and severity of, 
both infectious and non infectious diseases. This raises the question, could the role of 
inherited factors governing host response to infection and inflammation be important? 
The work described in this thesis investigates the role of MBL in two diseases that both 
involve an infective and inflammatory component, namely children with the chronic 
disease cystic fibrosis (CF) and those with acute inflammation/sepsis in intensive care.
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In clinical studies I show that MBL deficiency is associated with worse pulmonary 
function tests in adults with CF and an increased risk of death and/or lung 
transplantation in children with CF. The reasons for this were explored by examining 
MBL binding to bacterial pathogens seen in CF and by examining bronchoalveolar 
lavage (BAL) fluid from children with and without CF. Here I show that MBL can be 
detected in the BALs of children with both acute and chronic respiratory disease but not 
in the controls. In another study of 142 children admitted to paediatric intensive care, I 
demonstrate an association between MBL deficiency and the development of the 
systemic inflammatory response syndrome and an increased severity of sepsis. This 
effect of MBL is independent of age, sex, ethnicity, polymorphisms in the genes for 
TNF-a, IL-6, IL-10, angiotensin converting enzyme (ACE), plasma activator inhibitor 1 
(PAI-1) and levels of antibodies to endotoxin.
The work presented here highlights the importance of MBL in susceptibility to infection 
and may demonstrate a role for MBL in modifying the inflammatory response. These 
data may assist in furthering the understanding of mechanisms in disease pathogenesis 
as well as paving the way for exploratory research into MBL as a potential therapeutic 
agent.
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CHAPTER 1
Introduction
1.1 Mannose-Binding Lectin (MBL) general considerations
In 1968, a child with failure to thrive, diarrhoea and frequent infections, with a serum 
dependent defect in phagocytosis of Baker’s yeast (Saccharomyces cerevisiae) was 
described (Miller et al., 1968). In 1972 this defect was shown to be present in a series of 
children with unexplained frequent infections (mainly bacterial) and could be corrected, 
in vitro, by normal plasma suggesting that the cause was a defective factor rather than 
an inhibitor (Soothill and Harvey, 1976). Independently, a protein that could bind 
mannan particles from Saccharomyces cerevisiae was discovered in rabbit liver and 
termed mannose binding lectin (MBL) (Kawasaki et al., 1978). This was subsequently 
shown to be present in human serum (Kawasaki et al., 1983) and in 1989 Professor 
Turner’s group established that deficiency of MBL was responsible for the opsonic 
immune defect first described in children (Super et al., 1989). The same year the human 
MBL gene (mbl-2) was sequenced independently by two groups (Sastry et al., 
1989;Taylor et al., 1989) and identification of the first structural mutation, causing low 
protein levels, followed two years later (Sumiya et al., 1991).
Mannose binding lectin (MBL) is a liver derived, acute phase, circulating serum protein 
that acts as a pattern recognition molecule and plays a pivotal role in innate immunity. 
This role seems particularly important in the first few minutes after microbial invasion 
and in young children from 6-18 months, a vulnerable age during which passively 
transferred maternal antibody has largely disappeared but the adaptive immune response
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is still immature, hence the coining of the term “ante-antibody” by Ezekowitz 
(Ezekowitz, 1991). MBL has now been found in all mammals and birds studied to date 
(Holmskov et al., 1994) and is estimated to have been present for the last five hundred 
and fifty million years since key elements of the innate immune system were developing 
in early invertebrates (Flajnik, 1998). Two distinct MBL proteins (MBL A and C) are 
found in many mammals such as rats and mice but only one is present in human serum. 
For the rest of this thesis MBL will refer to the human form unless specifically stated.
MBL is able to bind to a range of sugars presented in particular conformations on the 
surface of microbes but not to human proteins or normal cells (Weis and Drickamer, 
1994;Sheriff et al., 1994) and therefore seems to belong to an ancient group of 
molecules important in the recognition of ‘pathogen-associated molecular patterns’ 
(PAMP’s). Having bound to its target it can activate the lectin complement pathway 
(Ohta et al., 1990) and enhance complement-independent opsonophagocytosis 
(Kuhlman et al., 1989;Hartshom et al., 1993;Tenner et al., 1995;Tenner et al., 1995). In 
addition it seems that MBL may play a role in the modulation of inflammation (Jack et 
al., 2001b) and the promotion of apoptosis (Stuart et al., 2006). Over the last seventeen 
years the biological importance o f MBL has become increasingly apparent as indicated 
by the clinical consequences of the MBL deficient state (Super et al., 1989;Garred et al., 
1995;Summerfield et al., 1995;Summerfield et al., 1997;Garred et al., 1999b;Koch et 
al., 2001 ;Fidler et al., 2004;Gordon et al., 2006) (see section 1.6).
1.2 MBL Structure
Lectins are proteins which bind to specific carbohydrate structures, but which are not 
enzymes or immunoglobulins (Barondes, 1988). MBL is a member of a group of lectins 
called the collectins, characterised by both a lectin and a collagenous domain (Malhotra 
et al., 1994b). Other members of the collectin family include the lung surfactant
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proteins SP-A and SP-D in humans and bovine conglutinin and CL-43, all of which 
share similarities in structure. In particular MBL, SP-A and SP-D are large 
macromolecules and on electron microscopy both MBL and SP-A have a bouquet-like 
structure similar to C lq  (Lu, 1997) (Fig 1.1). The basic subunit or monomer of MBL is 
formed from three identical polypeptide chains, each of approximately 32 kDa, that 
associate to form higher molecular weight oligomeric structures that range from dimers 
to hexamers (Turner, 2003), with trimers and tetramers being the most common in 
human serum (Lipscombe et al., 1995;Teillet et al., 2005). Each polypeptide chain 
contains four domains: (i) an N-terminal region comprising 21 amino-acids that is 
cysteine rich and is involved in protein oligomerisation by the formation of intra and 
inter subunit disulphide bonds, (ii) a collagenous domain that forms a classical triple 
helix and contains 59 amino-acids consisting of 20 tandem repeats o f Glycine-Xaa-Yaa 
(except repeat 8 which consists of only Glycine-Glutamine), (iii) an a-helical 
hydrophobic coiled neck region that consists o f 30 amino-acids and is crucial for the 
initiation of oligomerisation and (iv) a 188 amino acid carbohydrate recognition 
domain (CRD). This carboxy terminal CRD, in the presence of calcium, is able to bond 
to the 3- and 4-hydroxyl groups of certain sugars found on the surface of microbes, thus 
MBL acts, effectively, as a universal antibody (Turner, 1996;Garred et al., 2006) (Fig 
1.2). The three sugar binding sites of the CRD of human MBL are separated by a 
distance of 45A (Sheriff et al., 1994;Chang et al., 1994) and are all situated on the same 
face of the molecule giving a relatively flat binding platform for the binding of the 
repeating patterns of sugar groups found on microbial surfaces. Human mannose-type 
sugars are not however displayed at the same density therefore minimizing the chance 
of MBL binding to self proteins (Sheriff et al., 1994). Although the binding of each 
lectin to sugar is of low affinity (approximately 10'3 M) the binding of multiple sites can
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achieve significant functional avidity. The recognition functions of the protein are 
mediated by the lectin domain and effector functions by the collagenous region, 
however it seems that for full functional activity of both parts that high order oligomeric 
structures such as tetramers are required (Yokota et al., 1995).
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Fig 1.1 The collectin family of proteins
MBL, SP-A and SP-D are large macromolecules and on electron microscopy both MBL 
(see next Fig 1.2) and SP-A have a bouquet-like structure similar to C lq  (Lu, 1997). 
(Fig adapted from Prof. Klein with permission).
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Fig 1.2 Mannose-Binding Lectin S tructure
Representation of tetrameric MBL. The N-terminal region is seen at the top of the 
diagram with the C-terminus at the bottom. The CRD’s contain Ca2+ dependent binding 
sites (represented as yellow spots). The four exons of the human MBL-2 gene encode 
for the protein regions indicated. (CRD: carbohydrate recognition domain). Taken from 
Turner, 1996, with permission.
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1.3 MBL Function
1.3.1 MBL binding to micro-organisms
MBL binds to a wide range of micro-organisms that display certain sugars on their 
surface. It has been shown that a specific equatorial orientation of the C3 and C4-OH 
groups of these oligosaccharide ligands is required for MBL binding. This orientation of 
hydroxyl groups is found in mannose, N-acetylglucosamine and glucose; hexoses that 
are present in the cell walls of many infectious agents, but it is interesting to note that 
the configurations of OH groups in galactose and sialic acid, often the penultimate and 
ultimate sugars of self glycoproteins, are not accommodated by the MBL binding site 
(Weis et al., 1992). For human MBL the selectivity o f such sugar binding is as follows: 
N-acetyl-D-glucosamine > mannose > N-acetyl-mannosamine and fucose > glucose 
with sugars such as galactose hardly binding (Holmskov et al., 1994).
Over the last decade, organisms demonstrated to bind to MBL have included yeasts 
such as Candida albicans and Cryptococcus neoformans (Neth et al., 2000;Levitz et al., 
1993), viruses including influenza A (Reading et al., 1997), human immunodeficiency 
virus (HIV) (Ezekowitz et al., 1989;Haurum et al., 1993) and herpes simplex virus 
(Fischer et al., 1994), proteins from the malaria-causing parasite Plasmodium 
falciparum (Klabunde et al., 2002) and a large number of bacteria (Neth et al., 
2000;Townsend et al., 2001;van Emmerik et al., 1994;Davies et al., 2000a). In one of 
the largest of these studies, binding of purified MBL to pathogens was investigated by 
flow cytometry. Diverse Candida species, Aspergillus fumigatus, Staphylococcus 
aureus, and beta-haemolytic group A streptococci exhibited strong binding of MBL, 
whereas Escherichia coli, Klebsiella species, and Haemophilus influenzae type b were 
characterized by heterogeneous binding patterns. In contrast, beta-haemolytic group B 
streptococci, Streptococcus pneumoniae, and Staphylococcus epidermidis showed low
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levels of binding. Bound MBL was able to promote C4 deposition in a concentration- 
dependent manner (Neth et al., 2000) (Fig 1.3).
It is difficult however, from the known biochemical structure of an organism, to make a 
prediction regarding whether or not it will bind to MBL. Two of the most important 
structures that gram-negative bacteria use to assist their invasion of a host and 
subsequent survival are the polysaccharide capsule and endotoxin (lipopolysaccharide 
(LPS) or lipo-oligosaccharide (LOS)). A schematic diagram of LPS is shown in Fig 1.4 
demonstrating that it consists of a lipid A moiety and an inner core which are relatively 
conserved between species and an outer O-antigen (a-oligosaccharide) that is very 
variable and contains a number of different sugars and/or sialic acid. To try and 
determine the relative importance of LPS structure, (specifically the presence or not of a 
terminal sialic acid) and the bacterial capsule in MBL’s binding to an organism, 
experiments using a number of isogenic mutants of Neisseria meningitides and 
Salmonella enterica serovar Typhimurium have been conducted (Jack et al., 
1998;Devyatyarova-Johnson M et al., 2000). The N.meningitides mutants differed in the 
presence or not of a capsule and/or terminal sialyation. The results obtained 
demonstrated that MBL bound poorly to organisms with sialylated LOS; however the 
absence of sialic acid allowed MBL to bind suggesting that sialic acid blocks MBL 
binding to its ligand (Jack et al., 2001a). In addition, the effect of the bacterial capsule 
was minor compared to the effect of LPS sialyation (Jack et al., 2001a) (Fig 1.5). For 
Salmonella the organisms with LPS truncated at various points, revealing different 
terminal sugars and no O-antigen, bound MBL but organisms with O-antigen did not 
bind (Devyatyarova-Johnson M et al., 2000). Binding of MBL was not able to be 
predicted by knowledge of just the terminal sugar and thus it is likely that sugar 
moieties revealed in the 3-dimesional, rather than linear, structure of LPS also play a
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role in determining MBL binding. Differences in MBL binding to another component 
isolated from bacterial cell walls, lipoteichoic acid (LTA), have also been demonstrated 
and bear no obvious correlation to MBL binding to the intact organism (Polotsky et al., 
1996;Jack et al., 2001a). This could suggest that MBL binds differently to bacterial 
components such as LTA depending on whether it interacts with it when soluble in the 
serum or membrane bound on the bacterial cell wall. It must also be remembered that 
conditions used for the binding of purified MBL to bacteria in the laboratory are 
significantly different from those occurring in vivo in the presence of serum which may 
lead to conflicting results. It is known that serum does inhibit MBL binding to some 
degree and that purified MBL will bind carbohydrates on sepharose beads whereas 
MBL in the presence of serum does not (Tan et al., 1996). Possibly serum will only 
inhibit low avidity interactions and therefore “low MBL binding” bacteria will become 
“non-binders” in the presence of serum. Another factor to consider in vivo is the 
presence of different MBL oligomers. It may be that only the higher oligomeric forms 
bind to micro-organisms with poor sugar array patterns but that all forms of MBL may 
bind to organisms with better fitting patterns.
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Fig 1.3 The binding of MBL to different organisms
The binding of purified MBL to pathogens was investigated by flow cytometry. Diverse 
Candida species, Aspergillus fumigatus, Staphylococcus aureus, and beta-haemolytic 
group A streptococci exhibited strong binding of MBL, whereas Escherichia coli, 
Klebsiella species, and Haemophilus influenzae type b were characterized by 
heterogeneous binding patterns. In contrast, beta-haemolytic group B streptococci, 
Streptococcus pneumoniae, and Pseudomonas aeruginosa showed low levels of binding 
(Neth et al., 2000). (Reproduced from Dr O Neth with kind permission).
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Fig 1.4 MBL binding to an organism is dependent upon lipopolysaccharide (LPS) 
structure.
A schematic diagram of LPS is shown demonstrating that it consists of a lipid A moiety 
and an inner core which are relatively conserved between species and an outer O- 
antigen (a-oligosaccharide) that is very variable and contains a number of different 
sugars and/or sialic acid. It can be seen in A) that the absence of sialic acid allows MBL 
to bind but in B) MBL binds poorly to organisms with sialylated LOS (kindly 
reproduced with permission from Prof. Klein).
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Fig 1.5 MBL binding to N.meningitides mutants which differ in the presence or 
not of a capsule and/or term inal sialyation. This flow-cytometric representation 
demonstrates that MBL binds poorly to organisms with sialylated LOS however the 
absence of sialic acid allows MBL to bind suggesting that sialic acid blocks MBL 
binding to its ligand. In addition the effect of the bacterial capsule is minor compared to 
the effect of LPS sialyation (reproduced with permission from Prof.Klein).
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1.3.2 MBL and complement
1.3.2.1 General information on complement
Complement was originally described in the 1890’s as “a factor in serum which 
supplements antibodies in their destruction of bacteria” . Over 30 proteins have now 
been recognised to be involved in the complement system and together they make up 
10% of serum proteins (Jack et al., 2001a). The major functions of complement are help 
in the killing of micro-organisms through opsonisation and preparation for phagocytosis 
and direct killing by the membrane attack complex of the terminal complement 
components. In addition complement plays a role in the activation of other enzymes 
(coagulation cascade) and in inflammation by the release of anaphylatoxins. The 
complement system is an example of a cascade system whereby early components with 
proenzyme activity are activated and subsequently cleave later components in the 
pathway (Fig 1.5). There are three different pathways of complement activation referred 
to as the classical, lectin or alternative pathways (see subsequent sections). These 
pathways all converge to generate an enzyme C3 convertase which activates one of the 
major complement proteins C3. Subsequent to this stage all pathways follow the same 
activation of terminal complement components resulting in the formation of the 
membrane attack complex. Nomenclature of this pathway is sometimes confusing as 
components are numbered in order of discovery and therefore are not always sequential. 
C3 is present in serum at approximately 1.3 mg/ml and is one of the major serum 
proteins. Once cleaved to C3b this can form part of the C5 convertase or alternatively 
act as an opsonin for the organism to which it is attached. C3b can interact with 
complement receptor-1 (CR1) present on phagocytes and can mediate phagocytosis in 
the presence of a second signal. C3b is converted to iC3b in serum by factor I. Although 
no longer active in complement activation, iC3b can bind with high affinity to CR3
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(CD11 b/Cd 18) and also mediate phagocytosis at a rate that is probably more that C3b 
and CR1 (Ross and Densen, 1984).
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Fig 1.6 The three pathways of complement activation.
The classical pathway is activated by interaction of C lq  with immune complexes and 
the lectin pathway by interaction of MBL with sugar arrays on the surface of micro­
organisms which activates MASP’s and cleaves C4 and C2. The alternative pathway is 
activated by microbial components. Complement components are denoted by capital 
letters.
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1.3.2.2 The classical pathway of complement activation
This was the first pathway of complement to be described and is activated primarily by 
the interaction of the C lq  complex with immune complexes containing IgG or IgM. 
This first component of complement, C l, contains three parts, q, r and s, of which C lq 
is the recognition unit that binds to multiple IgG domains or a single pentameric IgM 
domain. C lq has a similar structure to MBL with six globular heads attached to a 
central collagenous structure and forms a complex with two molecules of C ls and two 
of C lr. After the binding of C lq  to its ligand C lr auto-activates and this activates C ls 
which cleaves first C4 and then C2. C4 cleavage produces the components C4b and C4a 
and C2 is cleaved into C2a and C2b. C2a binds to C4b to generate C4b2a which is the 
C3 convertase of the classical pathway.
To ensure control of this cascade and prevention of continued activation a number of 
inhibitory proteins have evolved. The first, C l inhibitor, forms a covalent complex with 
activated C lr  and C ls and releases C lq. The second, a serine protease Factor I, cleaves 
C4b at two sites rapidly stopping its biological activity. Other proteins such as the 
membrane bound complement receptor 1 (CR1) and C4-binding protein (C4bp) 
accelerate the decay of C4b2a. CR1 and other proteins such as membrane cofactor 
protein (MCP) are present on host cells and therefore provide protection against 
complement mediated host damage.
1.3.2.3 The MBL pathway of complement activation
A deficiency in complement activation was the first identifiable immune defect in 
humans who were subsequently shown to have MBL deficiency. Specifically, C3 was 
deposited in lower amounts on yeast surfaces incubated in sera from individuals that 
could not opsonise yeast compared to those who could (Turner et al., 1981). It was then
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shown that MBL could activate the complement system when bound to mannan 
(Kawasaki et al., 1983;Ikeda et al., 1987). Subsequent work has defined the MBL or 
“lectin” pathway of complement activation in much more detail and it is now known 
that MBL in serum is associated with serine proteases, named MBL-associated serine 
proteases (MASP’s), of which 4 have now been described; MASP-1, 2 and 3 and a 
protein with no protease activity named M Apl9 (Matsushita and Fujita, 1992;Thiel et 
al., 1997;Dahl et al., 2001;Takahashi et al., 1999;Stover et al., 1999). The MASP 
proteins are not equally distributed among the different oligomers o f MBL, with 
MApl9 and MASP-1 being associated with lower order oligomers, MASP-2 with 
tetramers and above and MASP-3 being found with the largest oligomers. In serum 
there is 20x more MASP-1 than MBL (most unbound to MBL) (Terai et al., 1997) but it 
seems that it is MASP-2 that is the main initiator of the complement pathway (Thiel et 
al., 1997) with the function o f the other MASP’s being uncertain. MBL (which has no 
catalytic function itself) binding to a target ligand induces a conformational change 
(cleavage of MASP polypeptide chains) causing activation of the MASP enzymes and 
cleavage of C4. The MBL/MASP complex then activates C2 to form C4b2a, an 
identical C3 convertase to that generated by the classical pathway (Fig 1.6). The exact 
nature of the MBL/MASP complex is unclear and the binding site o f MASP to MBL is 
unknown but is in the collagenous region (Fig 1.2). Activated MASP-2 cleaves C4 
twenty times better than activated C ls (Rossi et al., 2001) and MASP-1 can cleave 
complement factors C3 and C2. Mutations in the gene encoding MASP-2 have now also 
been identified (Stengaard-Pedersen et al., 2003;Lozano et al., 2005) and work is 
ongoing to determine the functional significance of these on complement activation and 
subsequent susceptibility to disease. In addition to this lectin pathway being activated 
when MBL binds to a micro-organism it can also bind to other ligands, most
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importantly IgA. Here the carbohydrate recognition domain of MBL binds to polymeric 
but not monomeric IgA with the subsequent activation of complement which may lead 
to a synergistic action of MBL and IgA in antimicrobial defence (Roos et al., 2001).
The regulation of complement activation by MBL/MASP is still unclear. Alpha-2- 
macroglobulin (a2M) is a broad specificity protease inhibitor, abundant in serum, that 
was shown to bind to MASP and inhibit complement activation (Terai et al., 1995) 
although this was subsequently refuted (Petersen et al., 2000). In addition to binding to 
C lr and C ls, Cl-inhibitor also binds to MASP and prevents complement activation and 
is probably the most important regulator of both the MBL and classical complement 
systems (Petersen et al., 2000).
1.3.2.3.1 Ficolins and ficolin activation of the lectin pathway
The ficolins are a group of proteins which, like MBL, bind to pathogen associated 
molecular patterns (PAMP’s), are associated with MASP’s and can activate the lectin 
complement pathway (Matsushita et al., 2000;Matsushita and Fujita, 2001;Matsushita et 
al., 2002;Lynch et al., 2004). Three ficolins are found in humans: L- and M-ficolin, 
which are more than 80% identical and H-ficolin (Matsushita and Fujita, 2001). Like 
MBL, ficolins are composed of subunits of three identical polypeptide chains with a 
collagenous part but in this case fibrinogen-like domains that recognise ligand 
(Matsushita et al., 1996). L- and H- ficolin are synthesised by hepatocytes and secreted 
into the circulation with M-ficolin being mainly on the surface of peripheral blood 
monocytes. Interestingly H-ficolin has recently been observed in bronchoalveolar fluid 
(Matsushita et al., 1996) and M-ficolin in type II lung epithelial cells (Liu et al., 2005) 
suggesting an extracirculatory role. Only one paper has reported low levels of L-ficolin 
being associated with recurrent infections, in this case respiratory infections in children 
(Atkinson et al., 2004). A study of 170 000 people only found deficiency of H-ficolin in
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11 of 13 SLE patients (Inaba et al., 1990) thus it seems that ficolin deficient states are 
not as common or as biologically significant as MBL deficiency.
1.3.2.4 The alternative pathway of complement activation
The central component of complement, C3, is continually activated at low levels by 
cleavage to C3b by serum proteases or by activation to C3i. C3b is then able to form a 
C3 convertase with factor B in the presence of factor D. This C3 convertase, C3bBb, is 
stabilised by the protein properdin. The constant conversion of C3 to active forms could 
potentially result in host damage if it occurs on host cells. To diminish this risk a serum 
protein Factor H and 2 cell membrane proteins Complement receptor-1 and decay 
accelerating factor (DAF) promote the dissociation of the C3bBb convertase. The 
probability of activated C3 being deposited on the surface of a pathogen is much lower 
in this system compared to the more efficient classical and lectin pathways.
1.3.2.5 The terminal (lytic) pathway of complement activation
After cleavage of C3, C3b is incorporated into the C5 convertase C4b3b2a or C3b2Bb 
depending on the source of the C3 convertase (Fig 1.6). Cleavage of C5 yields C5a, a 
potent anaphylatoxin and C5b which helps in the assembly of the membrane attack 
complex(MAC). C5b then sequentially binds to C6, 7 and 8. C9 polymerises to form 
complexes of up to 18 C9 molecules which form a pore like structure and bind to C6, 7 
and 8 to form the C5b6789 MAC and lysis of the target cell. Again this system has 
inbuilt regulatory mechanisms in the form of CR-1, DAF and two inhibitory proteins, 
C8 binding protein and CD59 both of which inhibit the assembly of the MAC.
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1.3.3 MBL and opsonophagocytosis
MBL plays a role in opsonophagocytosis in two ways, by the direct binding to an 
organism i.e. acting as an opsonin and indirectly by complement activation resulting in 
the increased deposition of C3b and iC3b as described above. Phagocytosis of micro­
organisms is known to occur by a number of mechanisms including via distinct cellular 
receptors for different immunoglobulin isotypes (Fc receptors) and complement coated 
organisms (CR 1 and CR 3). In addition the p glucan receptor on monocytes (Czop and 
Austen, 1985) and the mannose receptor (MR) on tissue macrophages directly recognize 
microbial carbohydrate configurations without the need for opsonisation (Kuhlman et 
al., 1989). Circulating monocytes do not express the MR but MBL seems to share 
similar binding characteristics to the MR and thus performs an analogous function in the 
serum. Using Salmonella enterica Montevideo organisms Kuhlman first demonstrated 
in 1989 that both purified and recombinant MBL increased the attachment, uptake and 
killing by phagocytes of organisms expressing a mannose rich polysaccharide 
(Kuhlman et al., 1989).
Much speculation since has centred on putative receptors responsible for mediating 
these effects including cClqR/calreticulin (Malhotra et al., 1990;Ogden et al., 2001), 
C lqRp (Tenner et al., 1995)and CR1 (Klickstein et al., 1997;Ghiran et al., 2000). 
Calreticulin is expressed on the surface of many cells including neutrophils, T- 
lymphocytes, endothelial cells and macrophages. It does not however have a 
transmembrane domain and therefore after binding to the collagenous region of MBL it 
appears to signal through association with CD91 to initiate engulfment of the micro­
organism or apoptotic cell opsonised by MBL. Antibodies to calreticulin inhibit this 
process (Ogden et al., 2001). C lqRp is expressed predominantly on neutrophils, 
monocytes, vascular endothelial cells but is absent in most tissue macrophages (Fonseca
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et al., 2001). Antibodies to ClqRp inhibit both MBL and C lq mediated phagocytosis by 
monocytes (Tenner et al., 1995). Lastly, Complement receptor 1 (CR1) also known as 
CD35 has also been suggested as a cellular receptor for both MBL and C lq. It is still 
unclear whether MBL does infact operate as a direct opsonin for micro-organisms or 
whether it is enhancing other pathways such as complement or immunoglobulin 
receptor mediated opsonophagocytosis as depicted in Fig 1.7. The most recent data 
published suggests that MBL may act by stimulating organism uptake through actin 
cytoskeleton rearrangements in the phagocyte (Jack et al., 2005).
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Fig 1.7 MBL and opsonophagocytosis
It is still unclear whether (A) MBL does infact operate as a direct opsonin for micro­
organisms or whether (B) it is enhancing other pathways such as complement or 
immunoglobulin receptor mediated opsonophagocytosis. (Adapted from Jack & Klein 
with kind permission).
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1.3.4 MBL and inflammation
There is increasing evidence, from disease association studies, that MBL also plays a 
role in the modulation of inflammation and thus contributes to disease severity as well 
as susceptibility (Garred et al., 1999b;Garred et al., 2003;Gordon et al., 2006). To 
further understand the mechanisms by which MBL may be operating a number of in- 
vitro studies have investigated the capacity of MBL to regulate pro and anti­
inflammatory cytokine production (Soell et al., 1995;Chaka et al., 1997;Ghezzi et al., 
1998;Jack et al., 2001b;Sprong et al., 2004).
Soell et al investigated the effect of streptococcal cell wall polysaccharides, formed 
from rhamnose glucose polymers (RGPs), on human peripheral blood monocytes 
(PBMC’s). RGP’s bound to the monocytes and stimulated TNF-a production in a dose 
dependent manner. Anti CD-14 monoclonal antibodies (mAbs) inhibited both RGP 
binding and suppressed TNF-a production from RGP-stimulated monocytes. Further 
analysis found MBL bound to RGPs and also inhibited TNF-a release (through the 
inhibition of RGP binding to CD 14) with an increasing amount o f inhibition occurring 
after incubation of MBL at concentrations of 5, 10 and 20 pg/ml. Concentrations lower 
than 5 pg/ml, i.e. in the clinical deficiency range were not tested. The receptor involved 
in the above interactions remains unknown. The C lq  receptor has been suggested for 
mediating the binding and uptake of RGP-MBL complexes by human monocytes (Soell 
et al., 1995).
Chaka et al subsequently demonstrated that MBL enhanced TNF-a induction by 
PBMC’s after stimulation with Cryptococcus neoformans. Interestingly this occurred at 
MBL concentrations of 0.31 to 1.25 pg/ml, but the effect declined at an MBL 
concentration of 2.5 pg/ml (Chaka et al., 1997).
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Jack et al demonstrated that the addition o f MBL to the ex-vivo blood of MBL-deficient 
donors, after bacterial stimulation with N.meningitidis, influenced the production of 
monocyte-derived inflammatory cytokines in a complex manner. Specifically, high 
concentrations of MBL (>6000ng/ml), such as seen in an acute phase response, 
decreased the production of interleukin-6 (IL-6), interleukin -1(3 (IL-ip) and tumour 
necrosis factor-a (TNF-a) by monocytes, whereas lower concentrations (<1000- 
2000ng/ml), such as seen in MBL homo or heterozygotes, enhanced the production of 
IL-6 and IL-1 (3.
Sprong et al used a different model of stimulating human peripheral blood mononuclear 
cells (PBMC’s) with lipopolysaccharide (LPS) + or LPS- meningococci in a system 
with no exogenous complement. Here only lower concentrations o f MBL were used 
(0.75-2500 ng/mL), different cytokines were assessed (IL-1 (3, IL- 6, IL-10, TNF-a and 
IFN-y) and different results were obtained. The main findings were that MBL (<2500 
ng/mL) significantly augmented IL-1 (3 production after stimulation with both LPS+ and 
LPS- meningococci in a dose dependent fashion and also enhanced IL-10 production by 
LPS- meningococci. In contrast the production of IL- 6, TNF-a and IFN-y were 
unaffected.
1.3.S MBL and apoptosis
The removal of apoptotic cells is essential for the maintenance of a number of 
homeostatic mechanisms in humans, including maintenance of the immune system, 
protection against neoplasia and resolution of inflammation. It has been demonstrated 
that mannose binding lectin (like C lq) can bind to apoptotic cells and enhance 
phagocytosis by macrophages. This process was shown to involve MBL binding, at the
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collagenous region, to the cell surface protein calreticulin (also known as the cClqR). 
As cClqR has no transmembrane domain it in turn is bound to the endocytic receptor 
protein CD91 (also known as the alpha-2-macroglobulin receptor) on the macrophage 
surface and initiates engulfment by macropinocytosis (Ogden et al., 2001). Further work 
has confirmed that MBL binds apoptotic cells via the CRD and that the stage o f 
apoptosis is important. By flow cytometry and fluorescence microscopy, MBL can be 
seen to bind specifically to late apoptotic cells, apoptotic blebs and necrotic cells but not 
to early apoptotic cells and binding did not lead to activation of the lectin pathway. 
MBL may therefore facilitate the uptake o f apoptotic cells by macrophages and promote 
the non inflammatory process of programmed cell death (Nauta et al., 2004). This also 
may contribute to the underlying mechanism by which lack of MBL is associated, in 
clinical studies, with increased inflammation in certain situations (described below).
1.4 MBL genetics
1.4.1 MBL gene structure
There are two human MBL genes of which MBL-1 is a pseudogene and only MBL-2 
encodes the protein product, MBL. MBL-2 has been mapped to the long arm of 
chromosome 10 (qll.2-q21) (Sastry et al., 1989) which is close to the genes for the 
other collectins; SP-A at 10q21 -24 (Bruns et al., 1987) and SP-D at lOq 22.2-23.1 
(Crouch et al., 1993). The gene consists of four exons with an upstream promoter 
region. Exon 1 encodes the amino terminal section comprising the cysteine rich region 
and the first part of the collagenous region. Exon 2 encodes the rest o f the collagenous 
region and exon 3 the “neck” region. The fourth and largest exon encodes the 
carbohydrate recognition domain (see previous Fig 1.2).
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1.4.2 Regulation MBL gene transcription
Examination of the nucleotide sequence upstream of the MBL-2 gene (promoter region) 
revealed several regulatory elements including several features that were characteristic 
of acute phase protein genes such as a heat shock consensus element at -592 base pair 
(bp) and a glucocorticoid-responsive element that may enhance MBL transcription 
(Taylor et al., 1989). MBL was subsequently demonstrated to be a modest acute phase 
protein with serum levels increasing between about 1.5-3 times the “resting” level after 
surgery or during an acute infection (Thiel et al., 1992). Gene transcription is also 
enhanced by interleukin-6 (IL-6) and dexamethasone in human hepatoma cell lines 
(Arai et al., 1993).
1.4.3 Genetic control of MBL serum concentration
MBL serum concentrations differ markedly between individuals and between ethnic 
populations with the median serum concentration in a well Caucasian population being 
approximately 995 ng/ml with an interquartile range of 642-1410 ng/ml. Some variation 
is expected as MBL is an acute phase protein; however the situation is more complex 
than this as levels ranging from undetectable to over 6 000 ng/ml have been 
demonstrated (Garred et al., 1999b). This range is principally due to mutations in the 
structural exon 1 part of the MBL gene although polymorphisms in the promoter region 
also play an important role.
1.4.4 MBL structural gene mutations
Three mutations, all in exon 1, resulting in an amino acid substitution in the MBL 
polypeptide chain have been described. These occur at codons 52, 54 and 57 and are 
known as the D, B and C variants respectively as opposed to A which indicates the wild 
type (normal) gene. The first identified was a G to A base change in codon 54 (GGC to
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GAC) resulting in glycine to aspartic acid substitution in the collagen domain (Sumiya 
et al., 1991) and occurs in approximately 26% of Caucasians (Mead et al., 1997). The 
second mutation described at codon 57 (GGA to GAA) was initially identified in a 
Gambian population, with a prevalence of 58% and results in a glycine to glutamic acid 
substitution (Lipscombe et al., 1992b). The third mutation was identified in 1994 at 
codon 52 resulting in a C to T base change (CGT to TGT) which translates into an 
arginine to cysteine substitution. This allele is only present in approximately 5% of both 
Caucasian and African populations (Madsen et al., 1994). Both the 54 and 57 variants 
result in very low serum levels caused by the replacement of a small glycine residue by 
a large aspartic or glutamic acid leading to disruption to the collagen like domain of 
MBL. In addition, the disulphide bonds of the oligomers are disrupted resulting in the 
formation of unusual two and four polypeptide chains (Wallis and Cheng, 1999). The 
codon 52 mutation may not disrupt the triple helix itself but may just produce extra 
disulphide bonds which prevent the assembly of higher oligomers and thus serum levels 
in individuals with this mutation are not as low as with the 54 and 57 mutation (Fig 1.8). 
Thus MBL deficiency may not in-fact represent a complete lack of MBL in the serum 
but represents the presence of circulating monomeric or oligomeric mutant MBL protein 
with impaired function (Terai et al., 2003). Different detection methods pick up 
different levels of MBL (see Methods section 2.3.1).
These three structural mutations show marked difference in prevalence amongst 
different populations across the globe. The codon 54 mutation is present in Eurasian 
populations whereas the codon 57 mutation is found almost exclusively in sub-Saharan 
Africans. The codon 52 mutation occurs at low levels worldwide (Table 1.1). As the 
mutations seem to be split mainly along African and non-African boundaries it has been 
suggested that these mutations occurred independently after the divergence of these
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populations approximately 150 000 years ago (Lipscombe et al., 1992b). That these 
mutations with a similar phenotypic effect have occurred and persisted at such high 
gene frequencies in such diverse populations is suggestive of a biological advantage in 
some situations (see section 1.6.4).
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Fig 1.8 The effect of MBL genetic polymorphism on the translated protein.
The 54 and 57 variants cause the replacement of a small glycine residue by a large 
aspartic or glutamic acid leading to disruption to the collagen like domain of MBL and 
failure to form higher order oligomers.
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Observed allele frequency
Population Reference Codon
52
Codon
54
Codon 57
UK (Mead et al., 1997) 0.07 0.14 0.02
Denmark (Madsen et al., 1994) 0.05 0.13 0.02
Hong Kong Chinese (Lipscombe et al., 
1992a)
0.01 0.11 0.00
Greenland Eskimos (Madsen et al., 1994) 0.00 0.13 0.00
The Gambia (Lipscombe et al., 
1992b)
0.02 0.00 0.29
Kenya (Madsen et al., 1994) 0.05 0.03 0.23
Xhosa (S.Africa) (Lipscombe et al., 1996) 0.00 0.00 0.27
San Bushmen 
(Namibia)
(Lipscombe et al., 1996) 0.00 0.03 0.07
Papua New Guinea (Lipscombe et al., 1996) 0.00 0.07 0.00
Vanuatu (SW Pacific) (Lipscombe et al., 1996) 0.00 0.01 0.00
Quechua Indians (Peru)
-------------------------------------
(Garred et al., 2006) 0.00 0.80 0.00
Table 1.1 Frequencies of mutant alleles of the MBL-2 gene in various populations.
This shows the marked geographical and ethnically related variation in the prevalence 
of the MBL-2 gene mutations. In some populations such as Vanuatu, mutations are 
extremely rare whilst in others such as The Gambia and the Quechua Indians in Peru 
mutations are extremely common suggesting some kind of selective advantage.
1.4.5 Polymorphisms of the MBL promoter region
There are several polymorphisms within the promoter region of the MBL-2 gene which 
affect serum MBL levels. These are as follows: X/Y (C/G) polymorphism at -221 bp, the 
H/L (G/C) at -550bp and the P/Q polymorphisms at -427 (A/C), -349 (A/G), -336 
(A/G), deletion -329 to -324, -70 (C/T) and +4 (C/T) (Madsen et al., 1995;Madsen et al., 
1998a). Four promoter haplotypes are commonly seen, namely LXP, LYP, LYQ and 
HYP of which HYP is the highest MBL producing haplotype, followed by LYQ and 
then LYP. The LXP haplotype produces the lowest MBL serum levels. The combined 
effect of the structural gene mutations and promoter region polymorphisms affect MBL 
serum concentrations with the influence of the X/Y polymorphism being the most 
profound after the effect of the structural mutation. Due to significant linkage 
disequilibrium between the exon 1 mutations and promoter polymorphisms the 
following haplotypes are linked: LYP and codon 54 mutation, HYP and codon 52, LYQ 
and codon 57 (Madsen et al., 1995;Madsen et al., 1996). A study of Danish Caucasians 
with the normal exon 1 genotype (A/A) demonstrated that those with the promoter HYP 
i.e. HYPA/HYPA haplotype were found to have a serum MBL level six times higher 
than those with the haplotype LXPA/LXPA (means of 2279ng/pl and 346 ng/pl 
respectively) (Madsen et al., 1995). As the X/Y promoter polymorphism has the greatest 
effect on serum level this is the one that is most commonly determined in MBL gene- 
disease association studies.
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1.5 MBL levels in serum and other body fluids
MBL is primarily a serum protein although it has been identified in pleural and ascitic 
fluid, in patients with disease, at mean levels of 690 and 420 ng/ml respectively. Much 
lower levels of 5 and 0.5 ng/ml were found in CSF and urine respectively (Fig 1.9) 
(Terai et al., 1993). At the commencement o f this PhD no one had demonstrated MBL 
in airway secretions such as bronchoalveolar lavage fluid.
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Fig 1.9 MBL levels in serum and other body fluids.
This scattergram, taken from Terai 1993, demonstrates the considerable difference in 
MBL levels in different body fluids. At the commencement of this thesis no studies had 
looked for MBL at the airway surface in humans. (Mean MBL levels shown here are as 
follows: Serum 1600 ng/ml, pleural effusion 690 ng/ml, ascites 420 ng/ml, CSF 5 ng/ml 
urine 0.5 ng/ml)
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1.6 MBL disease associations
1.6.1 MBL and susceptibility to infectious diseases
Over the last two decades the clinical importance of MBL has been increasingly 
highlighted by a number of studies demonstrating the role of MBL deficiency in 
susceptibility to infectious diseases. It now seems evident that MBL also affects the 
severity of the clinical disease (see section 1.6.3).
The first description of low levels of MBL and frequent infections was described in 
1989 (Super et al., 1989) followed in 1991 by a description of 4 family members with 
frequent unexplained infections who were all homozygous for the MBL codon 54 
mutation (Sumiya et al., 1991). In a large cohort of consecutive children admitted to 
hospital, categorised as having infection or not, the prevalence of MBL gene mutations 
in those with infection was almost twice that of children admitted without infection. 
Here both homozygosity and heterozygosity for an MBL mutation was associated with 
an increased susceptibility to infection (Summerfield et al., 1997). Further studies have 
found an association between MBL deficiency and meningococcal disease (Hibberd et 
al., 1999), M ollarefs meningitis (recurrent aseptic meningitis) (Tang et al., 2000), 
unusual and severe infections in adults (Summerfield et al., 1995), susceptibility to 
mycoplasma infection in patients with primary antibody deficiencies (Hamvas et al., 
2005) and most recently in the susceptibility to, but not severity from, the newly 
described severe acute respiratory syndrome (SARS) caused by the novel coronavirus 
(SARS-CoV) (Ip et al., 2005).
1.6.1.1 MBL and respiratory infections
Childhood respiratory infections result in significant morbidity worldwide and bacterial 
respiratory infections are a leading cause of death in the developing world. MBL variant
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alleles have been associated with a number o f respiratory tract infections, although there 
are now some conflicting data published.
Koch’s group followed up 252 children, under the age of two years, weekly for 2 years 
for morbidity surveillance and demonstrated a 2 fold increased relative risk of acute 
respiratory infection in those MBL insufficient children compared to MBL sufficient 
children (Koch et al., 2001). This risk was mainly in children aged 6-17 months and 
thus could suggest that MBL plays an important role in host defence during the period 
of life that maternal antibody is waning and the adaptive response is not yet mature. 
Symptoms and signs detected were broad, ranging from purulent rhinitis to bronchiolitis 
and pneumonia. Causative organisms were not looked for. MBL is known not to bind to 
respiratory syncytial virus (RSV) in vitro and a study looking at 79 infants less than 6 
months of age found no association between MBL variant alleles and RSV incidence or 
disease severity (Kristensen et al., 2003).
Regarding pneumococcal disease, a study of 229 UK patients aged 0-94 years with 
invasive pneumococcal disease demonstrated an overrepresentation of MBL 
homozygotes (but not heterozygotes), in patients compared to controls (odds ratio 2.59). 
This finding was confirmed in a second cohort of patients in a similar geographical area 
(Roy et al., 2002). In a smaller cohort of Danish adults however no association was seen 
(Kronborg et al., 2002)
1.6.1.2 MBL and HIV
Death from HIV/AIDS has now overtaken both tuberculosis and malaria as the most 
common cause of death worldwide from an infectious disease. In 2001, 3.1 million 
deaths were estimated to be from HIV and 42 million people were thought to be HIV 
infected, mainly in Sub-Saharan Africa (Bates et al., 2004). Marked inter-individual
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differences in disease susceptibility and disease phenotype have been noted by 
clinicians for many years. The first study to determine the possible role of MBL was 
that by Garred in which a significantly higher frequency of people homozygous for an 
MBL mutation were found in a cohort infected with HIV compared to a matched 
control group with the same risk taking behaviour (Garred et al., 1997a). This was 
subsequently confirmed in other studies (Garred et al., 1997b;Nielsen et al., 1995) but 
most recently refuted in a Spanish cohort (Garcia-Laorden et al., 2006). A number of 
groups have now reported an increase in mother to child transmission of HIV in the 
presence of MBL polymorphisms (Boniotto et al., 2000;Boniotto et al., 2003;Crovella et 
al., 2005). Regarding disease progression, MBL variant alleles have been associated 
with a slower progression to an AIDS diagnosis and death in adults (Maas et al., 1998) 
but most recently MBL mutations were found to be wtfder-represented in HIV infected 
children who were long term non-progressors (Dzwonek et al., 2006). Differences may 
be due to different geographical cohorts or more likely differences in the ages of the 
individuals, children usually having been infected since birth thus in a developing 
immune system and the adults at a much later date. MBL has been shown to bind to the 
glycosylated glycoprotein gp 120 in the HIV viral coat and possibly inhibits HIV 
infection in vitro (Ezekowitz et al., 1989).
1.6.1.3 MBL and infections in the immunocompromised host
Individuals with primary or secondary immunodeficiencies may rely on components of 
the innate immune system for defence against infection more than the 
immunocompetent host. This has already been discussed with regard to susceptibility to 
mycoplasma infection in patients with primary antibody deficiencies (Hamvas et al.,
2005). A time when the role of MBL may also be crucial is during the period of 
neutropenia that is seen in patients undergoing chemotherapy for malignancy. Two
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initial studies in 2001 demonstrated that this is indeed the case. Neth el al found in 100 
children undergoing chemotherapy that those with MBL variant alleles spent twice as 
many days in hospital with febrile neutropenia compared to wild type individuals (Neth 
et al., 2001). In the same issue of The Lancet, a second study was reported of 54 adults 
undergoing chemotherapy in whom those who developed significant infections had 
significantly lower levels of MBL than those without significant infections (Peterslund 
et al., 2001). A more recent study, however, reported no effect o f MBL on infective 
complications or mortality in adult patients with acute myeloid leukaemia (Bergmann et 
al., 2003).
1.6.2 MBL and disease severity
A number of studies have now highlighted the role that MBL deficiency plays in 
disease severity as well as susceptibility. These include cystic fibrosis (see section 
1.7.2), sepsis (see section 1.8), HIV (see section 1.6.1.2), hepatitis (Yuen et al., 1999), 
recurrent miscarriages (Kilpatrick et al., 1995), Kawasaki’s disease (Biezeveld et al.,
2006), myocardial infarcts in patients with severe atherosclerosis (Madsen et al., 1998b) 
to mention just a few. Further discussion of this is found in chapters 3, 6 and the final 
discussion.
1.6.3 MBL and susceptibility to autoimmune diseases
The aetiology of autoimmune disease is still unclear but is thought to occur in 
“genetically susceptible” individuals with a possible infective trigger. The known 
association with deficiency of the complement component C lq and immune complex 
disease has prompted clinical association studies with MBL. A number of studies and 
meta-analyses have now demonstrated that indeed MBL deficiency and variant alleles 
are associated with both susceptibility to and complications from SLE (Garred et al.,
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1999a;Ohlenschlaeger et al., 2004;Lee et al., 2005) and rheumatoid arthritis (Graudal et 
al., 1998). The mechanism is thought to be lack of removal of immune complexes by 
the classical complement pathway (C lq) and MBL (directly or indirectly).
1.6.4 Advantages of MBL deficiency
The high frequency of variant alleles in some populations (see Table 1.1) suggests that 
MBL deficiency may confer some biological advantage in certain communities, like the 
carriage of sickle cell trait and protection from malaria (Allison, 1954). One hypothesis 
is that MBL deficiency may reduce activation of the complement system and reduce 
host damage due to subsequent release of inflammatory mediators (Lipscombe et al., 
1992b). This is now thought not to be the whole case as MBL deficiency has infact been 
associated with pro-inflammatory states (see chapter 6 ). Secondly, and increasingly 
likely, is the theory that MBL deficiency may contribute to host defence against certain 
intracellular organisms. Bacteria such as leishmania, mycobacteria and legionella use 
C3 opsonisation and C3 receptors on monocytes/macrophages to gain entry into the host 
cell and thus any reduction of complement activation may reduce the risk of infection 
with these intracellular organisms. Evidence in support of this is found in clinical 
studies showing significantly higher MBL levels in patients a) infected with 
Mycobacterium leprae than in healthy controls (Garred et al., 1994)and b) with visceral 
leishmaniasis than healthy controls (Santos et al., 2001). The presence of the MBL C 
allele has also been shown to be protective against pulmonary tuberculosis in Gambian 
adults (Bellamy et al., 1998).
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1.7 Cystic fibrosis
1.7.1 Cystic fibrosis background
Cystic fibrosis is both the most common autosomal recessive disease and the most 
frequent lethal genetic disorder of Caucasians worldwide. 1:25 Caucasians are carriers 
of the defective gene resulting in a CF prevalence of 1:2500 newborns, with more than 
6 , 000 affected patients in the UK.
The disease is due to abnormalities in the CF transmembrane regulator (CFTR) protein, 
a cAMP-activated chloride channel located in the apical membrane of most secretory 
cells. CFTR is primarily a chloride-ion channel but it also inhibits the epithelial sodium 
channel. CF respiratory epithelia (and pancreas, gut, liver and reproductive tract 
epithelia) therefore fail to secrete chloride ions and hyperabsorb sodium ions. Water is 
absorbed with the sodium, resulting in dehydrated, viscous secretions with secondary 
end organ damage, most prominent in the lung where inspissated mucous impairs 
mucociliary clearance resulting in both infection and inflammation. In the sweat glands 
there is a failure of absorption of both chloride and sodium ions resulting in high sweat 
electrolytes.
1.7.2 CF genetics
The gene encoding CFTR protein is located on chromosome 7 and was first identified in 
1989 (Riordan et al., 1989). Over 1,000 mutations have been identified to date. The 
commonest mutation is a deletion of a phenylalanine residue at codon 508 (AF508), 
found on approximately 67% of CF chromosomes. Most clinical laboratories screen for 
31 of the commonest mutations which detects more than 90% of affected Caucasians. 
The CF genotype is not well correlated with phenotype apart from in pancreatic disease 
where, for example, the genotype R117H/ AF508 is associated with pancreatic
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sufficiency and older age of diagnosis compared with AF508 homozygous patients (CF 
consortium, 1993). Screening for CF was initiated nationwide in the UK in 2006.
1.7.3 CF presentation
Clinically the disease causes a wide range of signs and symptoms (see below) and may 
now also be diagnosed by the neonatal screening programme, by the screening of a 
relative of a patient or by antenatal testing in a family with an affected child. The 
commonest presentation in a neonate is with meconium ileus and bowel obstruction. In 
older children it is with failure to thrive and/or recurrent respiratory infections.
• Pulmonary manifestations
Persistent lower airway infection and inflammation with resultant bronchiectasis is the 
main cause of morbidity and mortality in CF. Infection is most commonly with the 
pathogens Staphylococcus aureus and Pseudomonas aeruginosa (80% chronically 
infected by adolescence). Others such as Burkholderia cepacia complex, Haemophilus 
influenzae, Stenotrophomonas maltophilia and atypical mycobacteria also have a 
propensity for the milieu of the CF lung. This manifests clinically as recurrent chest 
infections, persistent sputum production, reduced exercise tolerance and reduced lung 
function.
Whether inflammation follows or precedes infection is a matter of recent controversy 
(Rao and Grigg, 2006). A decade ago Armstrong’s group compared bronchoalveolar 
lavage (BAL) fluid from 46 infants under 6 months old, identified from a neonatal 
screening programme, with 13 controls. Patients were divided into those who had never 
had an infection, those with a definite current infection and those with a possible 
infection. BAL’s were analysed for cell counts, interleukin-8 (IL-8) and neutrophil 
elastase. Those patients without infection had BAL profiles similar to the control
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patients and those with infection had evidence of airway inflammation thus suggesting 
that inflammation follows infection (Armstrong et al., 1997). There is good evidence to 
support the hypothesis that lung damage is due to mediators released by neutrophils, 
e.g. neutrophil elastase, that have migrated to the lung in response to chronic infection 
(Sagel et al., 2001) and that reducing infection attenuates lung inflammation (Ordonez 
et al., 2003). However, more recently the lungs of CF and non-CF fetuses were 
examined and an increased number of macrophages (a major source o f neutrophil 
chemoattractants) were seen prior to birth (Hubeau et al., 2001). Another study found an 
increased number of neutrophils in the BAL’s of young CF infants without clinical or 
microbiological evidence of infection (Rosenfeld et al., 2001). In addition, CF 
monocytes cultured in heterologous serum, produced more tumour necrosis factor- 
alpha (TNF-a) than control monocytes and fresh cultured CF bronchial epithelial cells 
produced more interleukin-6 (IL-6 ) and IL-8 and much less IL-10 than non-CF cells. 
Taken together this suggests that some CF cells may be “primed” to be in a pro- 
inflammatory state compared to non CF cells even prior to infection (Pfeffer et al., 
1993).
• Pancreas
Exocrine pancreatic enzyme insufficiency occurs presenting with steatorrheoa and 
failure to thrive. This is treated by enzyme supplementation (e.g. Creon) and fat soluble 
vitamin supplementation. Endocrine problems i.e. diabetes occurs sometimes in older 
children (8-15%).
• Gastrointestinal tract
Distal intestinal obstruction syndrome (DIOS) and hepatic cirrhosis may occur.
• Upper respiratory tract
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Up to 30% of CF patients have nasal polyps which may be treated with topical steroids 
or surgery. Sinusitis is common, due to obstruction and caused by the same organisms 
as found in the lung.
• Infertility
99% of males are infertile with women having sub-fertility, although many have now 
successfully had children.
1.7.4 CF diagnosis
The “gold standard” is a sweat test where a value of chloride ions (best) or sodium ions 
of >60mEq/l are diagnostic of CF in a patient with a typical history (there are also a 
number of conditions that can give a false positive result). A high level of 
immunoreactive trypsin (IRT) in the serum in the first 2-3 weeks of life is highly 
suggestive of CF and currently used as the CF screening tool (blocked pancreatic ducts 
prevent trypsinogen from reaching the intestines resulting in a build up of the protein in 
the blood). Gene mutations can then be looked for.
1.7.5 CF treatment
The mainstay of therapy remains chest physiotherapy twice daily whilst clinically well 
in addition to during an exacerbation. Prophylactic oral anti-staphylococcal antibiotics 
are used from diagnosis in those under 4 years of age in the UK and most of Europe and 
respiratory infections are treated aggressively, with oral, intravenous and inhaled 
antibiotics, depending on the nature of the organism. Aerolised mucolytics (eg. 
rhDNase) are used to decrease sputum viscosity and aid expectoration. Nutrition is 
optimised and approximately 85% of children need pancreatic and vitamin 
supplementation. Psychosocial support for children and families with CF is also offered.
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Recent attention has focused on mechanisms to reduce inflammation in CF lung disease 
including the use of macrolides, steroids and non-steroidal anti-inflammatory drugs 
(Jaffe and Bush, 2001). Anti-inflammatory treatments may of course abolish the useful 
effects of inflammation if used incorrectly. This has been highlighted by the premature 
stopping of a clinical trial of a leukotriene B4 receptor antagonist in CF patients due to 
an increase in the number of pulmonary infective exacerbations in the treatment group 
(Rao and Grigg, 2006). Further work which may shed light on mechanisms involved in 
the modulation of inflammation in the CF lung is one of the aims of this thesis.
1.7.6 Genetic modifiers of cystic fibrosis (including MBL)
Poor correlation of CF genotype with phenotype has led to large body of work looking 
at the possibility of secondary genes that may modify CF disease progression. 
Discordant phenotypes amongst siblings with the same CFTR mutation brought up in 
the same household with the same environmental influences has further highlighted the 
possibility of modifier genes (Salvatore et al., 2002) (see chapter 3 introduction).
The link between MBL deficiency and CF was first described in 1999 and is also 
described in detail in chapter 3.
1.8 Sepsis and the systemic inflammatory response syndrome (SIRS)
1.8.1 MBL and sepsis
At the start of this project no work had been published, in adults or children, looking at 
the effect of MBL in sepsis or the systemic inflammatory response syndrome (SIRS). 
This topic is discussed in detail in chapter 6 .
1.9 Aims of this Thesis:
The aims of this project were to investigate the role of MBL in two diseases where both 
infection and inflammation are implicated in the pathophysiology.
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The first disease, cystic fibrosis (described in section 1.7), is a multisystem chronic 
disease characterised by a propensity to specific respiratory infections with a marked 
inflammatory response. The second disease is an acute, multisystem, inflammatory 
response to an infectious or non infectious insult, the systemic inflammatory response 
syndrome (SIRS) (see chapters 6 ).
It was hoped that by undertaking studies in these two populations that the role that 
MBL plays in both infection and inflammation may be teased out and the hypothesis 
that MBL plays a role in modulating the inflammatory response, as well as in 
susceptibility to infection, may be tested in primarily a clinical setting.
The specific aims of this thesis are described in each chapter.
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CHAPTER 2
Materials and General Methods
2.1 Reagents and materials
2.1.1 Standard media and solutions
Name Company Product code
Agarose, electrophoresis grade Gibco™ Invitrogen 
Corporation
15510-019
Ammonium persulphate (APS), 
(NH4)2S20 8
Sigma A9164
AmpliTaq Gold DNA polymerase Perwin elmer Applied 
Biosystems
N808-0241
Biotinamidocaproate N- 
hydroxysuccinamide ester
Sigma B2643
Bovine serum albumin, low 
endotoxin
Sigma A2934-100G
Brefeldin A (lOpg/mL) Sigma
Bromphenol blue (3’,3”,5 \5 ”tetra- 
bromophenolsulfonaphthalein),
sodium salt, CiyHyB^OsSNa
Bio-Rad 161-0404
Calcium chloride (dehydrate), 
CaCl2x2H20
Sigma C3881
Cellfix (1% formaldehyde, 0.1% 
sodium azide)
Becton Dickinson 340181
Citric acid, C (OH) C02H 
(CH2C 0 2H)
BDH 10081
Dimethyl sulphoxide (DMSO) BDH 103232
DNA ladder, 1 Kb Gibco™ Invitrogen 
Corporation
15615-024
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2’-Deoxynucleoside 5’-triphosphate 
(dNTP) set lOOmM
Invitrogen stores 10297018
Ethanol, C2H5OH Hayman UNI 170
Ethenediaminetetraacetic acid, di­
sodium salt (EDTA),
C„,H,4N20 8Na:x2H:0
Sigma E5143
Ethidium bromide tablets, 
C2iH2oN3Br
Sigma E2515
FACSflow Becton Dickinson 342003
FACS lysing buffer Becton Dickinson 349202
FACS fix Becton Dickinson
Film, scientific X-OMAT AR Kodak 1651454
Fluoroscein isothiocyanate FITC Sigma F7250
Galactose D-(+) Sigma G0750
Hank’s balanced salt solution with 
and without Ca2 and Mg“’ salts
Gibco™ Invitrogen 
Corporation
24020-091
14025-050
Heparin sodium (10 lU/mL) CP Pharmaceuticals PL4543/0208
Hydrogen peroxide (30% w/w), 
H20 2
Sigma HI 009
lOObp ladder Invitrogen stores 15628019
Leukoperm Serotec Ltd
L-Glutamine 200mM (lOOx), liquid Gibco™ Invitrogen 
Corporation
25030-024
Lipopolysaccharide, E.coli O il  IB: 
4, gel purified
Sigma L4391
Loading dye, 6x Sigma G7654
Magnesium chloride (hexahydrate) 
MgCl2.6H20
Sigma M8266-100G
Mannose D-(+) Sigma M6020
2-mercaptoethanol Sigma M6250
MilliQ water from Millipore Q plus 
purification system
Millipore
Paraformaldehyde (CH20 ) n Sigma P6148
PBS tablets Oxoid BR0014g
PBS (Dulbecco solution) Gibco™ Invitrogen 
Corporation
14190-094
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Protogel, containing acrylamide 
(30% w/v) and bisacrylamide (0.8% 
w/v)
National Diagnostics EC-890
QIAMP DNA extraction kit (250) Qiagen 51106
RPMI 1640 basal medium Gibco™ Invitrogen 
Corporation
22511-026
RPMI 1640 medium with 25mM 
HEPES and lOmM L-glutamine
Gibco™ Invitrogen 
Corporation
52400-041
RPMI 1640 medium without phenol 
red
Gibco™ Invitrogen 
Corporation
32404-014
Skimmed milk Marvel
Sodium azide, NaN3 BDH 10369
Sodium bicarbonate, N aH C03 BDH 10247 4V
di-Sodium borate, N a^O yxlO EbO BDH 10267 4E
Sodium carbonate, Na2C 0 3 BDH 10240
Sodium chloride, NaCl BDH 10241
SDS (sodium dodecyl sulphate 
[Lauryl sulphate])
Sigma L4390
SDS-PAGE standards (biotinylated 
markers)
Bio-Rad 161-0311
SDS-PAGE standards (Rainbow 
markers)
Amersham Pharmacia RPN 756
Sodium hydrogen carbonate, 
N aHC03
BDH 102474V
di-sodium hydrogen 
orthophosphate,
Na2H P04
Sigma S0876-500G
Sodium hydroxide, NaOH BDH 102524X
Streptavidin Horse Radish 
Peroxidase conjugate
Amersham Pharmacia RPN 1231
Sulphuric acid BDH 10249
TEMED (N \N \N ”,N” 
tetramethylethylenediamine)
Sigma 67H0136
3,3’,5,5’-Tetramethylbenzidine 
tablets (TMB)
Sigma T3405
Tris, (hydroxymethyl) 
aminomethane, NH2C(CH2 0 H)3
Sigma T6066
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Tris
([hydroxymethyl]aminomethane) 
Borate EDTA buffer (1 OX)
Sigma T4415
TRIZMA base Sigma T8524
Tween -  20 (polyoxyethylene (20) 
sorbitan monolaurate)
Sigma P1379
Universal heteroduplex generator 
(UHG)
Gift of J.Bidwell and 
N.Wood, Bristol
2.1.2 Equipment
Bio-Rad Mini-Protean II gel electrophoresis 
system with power pack (200V).
Bio-Rad, Hercules, California, USA
Agarose gel electrophoresis apparatus. Northumbria Biologicals
Hybaid PCR machine Hybaid, Oxford, UK
MJ Tetrad DNA engine Thermocycler Applied Biosystems, UK
Thermohybaid Omniultra polycarbonated 
microplates
Hybaid, Oxford, UK
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2.1.3 Buffer solutions
Phosphate buffered saline (PBS), pH 7.3
NaCl 140.0 mM
KC1 2.7 mM
Na2H P04 8.0 mM
KH2P 0 4 1.5 mM
V)
k.
tSi
Prepared by the addition of one PBS tablet to 100 ml MilliQ water
**■
3
X PBS Tween
3
k.
e Prepared as above with the addition of 0.5 % (v/v) Tween-20
O
10 x Transfer Buffer
Tris 48.0 mM
Glycine 39.0 mM
k.
& 3.75 ml 10 % (w/v) SDS added to 11 of 1 x transfer buffer before use
3
CO
V2 SDS-PAGE running buffer
0)k.
O
JSa.
0
Glycine 190.0 mM
k.-*-<CJ
5 Tris 25.0 mM
c
■w
0k. SDS 0.1 % w/v
Cl.
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2 x Sample buffer
Tris 120.0 mM
Glycerol 20.0  % (v/v)
SDS 4.0 % (w/v)
l OxTBE buffer
(Tris-Borate-EDTA buffer)
Tris, 0.9M 0.9M
Boric acid 0.9M
EDTA 20mM
ELISA coating buffer, pH 9.6
N aHC03 35.0 mM
Na2C 0 3 15.0 mM
Citrate / phosphate buffer, pH 5.0
Citric acid (C6HX0 7 .H2 0 ) 0.1 M
Na2H P04 0.2 M
t/i
s .
TMB ELISA substrate buffer
3
09
<
Citrate / phosphate buffer 20.0 ml
£
33
W
TMB tablets 4
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HhO
Wash buffer
im
3
~3u
-aoo
—"©
PBS
BSA
Sodium azide
0.015 % (v/v)
500mls
0.5%
0 .02%
•vo
‘A’ mix
Na2C03 (anhydrous) 
NaHC03
5.8 ml 
10.0 ml
5.3% (w/v) 
4.2% (w/v)
’•ws« Conjugation buffer
o
s'O ‘A’ mix 1 part
«WD
*5* 0.1 M NaCl 9 parts
U
H pH of final mixture 9.5
u.
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2.1.4 Antibodies
Name Company
Anti-human MBL, mouse 
monoclonal IgG clone 131-1
State serum Institute, Copenhagen, Denmark 
A gift from Dr Claus Koch
Mouse IgG 1 negative control Serotec Ltd, Oxford
FITC conjugated anti-human CD 14 
(mouse IgG2a)
Serotec Ltd, Oxford
FITC conjugated isotype control 
(mouse IgG2a)
Serotec Ltd, Oxford
Phycoerythrin (PE) conjugated anti 
human (mouse IgG 1)
TNF-a
IL-6
IL-113
Becton Dickinson, Oxford 
Becton Dickinson, Oxford 
R & D systems
PE conjugated isotype control Becton Dickinson, Oxford
2.1.5 Cytokine Assays
Name Company
TNF-a ELISA kit Bioscience, Cambridge
IL-6 ELISA kit Bioscience, Cambridge
IL-1B ELISA kit Bioscience, Cambridge
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2.2 Clinical Methods
2.2.1 Study design & recruitment
The clinical studies described in this thesis were designed and commenced at the 
beginning of my research and were continued, where appropriate, for the subsequent 
years. I was responsible for patient recruitment at GOSH and Dr J Davies for patients at 
the Royal Brompton Hospital. This involved identifying suitable patients, approaching 
parents and children, discussion of the study, asking for consent for participation in the 
study, allowing time for consideration and returning to obtain written consent. I then 
transferred samples to the laboratory and processed them as described in the relevant 
sections.
2.2.2 Ethical applications and approval
All ethical applications, consent and assent forms, parent and child information leaflets 
for all of the clinical studies at GOSH described here were done in their entirety by 
myself. For the parts of the work undertaken at The Royal Brompton Hospital the 
principle investigator was Dr Jane Davies and ethics applications were done by her. All 
studies were approved by the Ethics Committees prior to their commencement. All 
parents or carers gave informed consent for participation.
2.2.3 Patient data collection
In order to interpret results, detailed and accurate phenotypic data on each patient were 
required. The patient data presented in the following chapters combines clinical and 
laboratory diagnostic results, patient demographic data including age, sex and race, 
microbiological data and for the study of children in PICU (chapter 6 ), daily review of 
the Intensive Care bedside electronic charting system (Care Vue, Hewlett Packard, 
USA). Patient data were anonymized and stored in a password protected excel
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spreadsheet according to the data protection policy of University College London. In 
addition, for the PICU study where a large amount of data were accrued, a purpose 
designed Access Data Base (Microsoft Office’98/XP) was developed for the sole use of 
the small PICU research team which was again password protected.
2.2.4 Blood collection and processing
2-3 mis of whole blood was collected from subjects via an in-situ arterial or venous line 
or by venupuncture, at a time when a clinical sample was being taken to prevent 
additional line sampling or venupuncture procedures. Blood was divided into an 
ethylenediaminetetraacetic acid (EDTA) and a serum collection tube. Whole blood in 
EDTA was stored at -20°C until DNA extraction was performed. Serum samples were 
spun, separated and the serum stored in aliquots at -80°C until analyzed.
2.2.5 Diagnosis of CF
In both GOSH and the Brompton the diagnosis of CF was usually made by a positive 
sweat test and confirmatory genotyping. In some cases babies had been initially 
identified by a high IRT on newborn screening, or after meconium ileus. Borderline 
cases had extended genotyping and/or nasal potential difference performed.
2.2.6 Statistical Analysis
The statistical analysis of data are described separately in the methods section of each 
chapter.
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2.3 Laboratory Methods
2.3.1 MBL Enzyme Linked Immunosorbant Assay (ELISA)
The principle of this ELISA is as follows: microwell plates are coated with a 
monoclonal antibody against the carbohydrate recognition domain of MBL. Bound 
MBL is detected with the same antibody that has been labelled with biotin, followed by 
the addition of horseradish peroxidase (HRP) conjugated to streptavidin and subsequent 
incubation with a colour changing substrate.
2.3.1.1 MBL ELISA used for clinical cohort studies
For all clinical cohorts MBL levels in serum and bronchoalveolar lavage fluid were 
determined by a symmetrical sandwich ELISA using a kit from the State Serum 
Institute, Copenhagen, Denmark according to the manufacturers instructions (Fig 2.1). 
This kit used the same capture and detection antibody, both binding to the carbohydrate 
recognition domain (CRD) of MBL. Patient serum was diluted 1 in 10 to 1 in 200 
depending on the expected value (if known by genotyping). BAL samples were used 
neat or diluted 1 in 2. The standard curve was performed with provided calibrators of 0, 
0.5, 1, 2, 5, 10, 20 and 40 ng/mL. This kit was chosen as it was being used in many 
other clinical cohort studies worldwide allowing exact comparison of levels between 
different research groups. Intraplate variation using the kit was < 4% and interplate 
variability on the same or different days was <7%
2.3.1.2 “In-house” MBL ELISA
To determine serial levels o f MBL in individual patients over time, an “in-house” 
ELISA method was used. This was done as it was more cost effective and provided 
experience of the modification of a previously designed ELISA system. The method 
used was that of a symmetrical sandwich ELISA previously described (Lipscombe et
74
al., 1996) and is depicted in Fig 2.1. At each incubation step a volume of lOOpl was 
used, all reagents were diluted in PBS and each washing step consisted o f three washes 
with PBS-Tween (containing PBS and 0.05% Tween-20 (PBS-T)) using an ELISA plate 
washer unless otherwise stated. Immulon-2 plates were coated with PBS containing 1 
pg/ml anti-MBL (clone 131-1), left for 15-17 hours at +4°C and then washed. Serum 
samples were generally diluted 1/20 orl/200 in PBS and added to appropriate wells. To 
subsequently produce a standard curve from which to calculate MBL levels, standards 
of known values, in doubling dilution were added. These were either those from the SSI 
kits or nine standards from pooled human serum with a known MBL level of 
1600ng/ml, diluted down to 320 ng/ml. The standards in this case were therefore 
320,160, 80, 40, 20, 10, 5, 2.5, 1.25 ng/ml respectively. Additional internal standards of 
known high, intermediate and low MBL sera were also added. All test and standard 
samples were performed in duplicate. At least one well had no sample added to ensure 
that no non specific background binding was occurring. Samples were incubated at 
37°C for one hour, washed and then bound MBL was detected using a biotinylated anti- 
MBL added at 1 pg/ml and incubated for one hour at 37°C. The plates were rewashed 
and 1/1000 dilution of streptavidin horseradish peroxidase (S-HRP) was added prior to 
re-incubation for one hour at 37°C. After washing, the ELISA was developed using 100 
pi of TMB substrate solution. Adding 100 pi 4N H2SO4 stopped the reaction and the 
A450 of each well was read using a Dynatech MRX plate reader (Actema, Aldermaston, 
UK) with the standards plotted as a sigmoid curve (Revelation software).
Prior to using patient samples this system was optimised using various concentrations of 
capture anti-MBL, biotinylated anti-MBL and S-HRP (1/500-1/1000 in different 
combinations) with the above method giving the most reliable and reproducible results.
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2.3.1.3 ELISA validation
For each ELISA method a calibration curve was made by plotting the mean of the 
duplicate optical densities (OD) values for each MBL standard on the y axis with the 
corresponding MBL concentrations in ng/ml on the x axis. The MBL concentration of 
each diluted sample was then determined from its mean OD. The concentration of MBL 
in the undiluted specimen was then calculated by multiplying the result by the dilution 
factor. On each occasion performed, the results were only taken to be valid if the 
following were obtained: (i) an adequate standard curve, (ii) adequate quality control 
and interplate variation, (iii) readings falling within the middle straight part of the 
sigmoid curve and (iv) coefficient o f variation (standard deviation of the replicate 
responses x 100 / mean of the response) between duplicate samples of <10%. If these 
criteria were not satisfied, plates or individual readings respectively, were rejected and 
re run. Acceptable interplate variation was confirmed if the high, medium and low 
“internal” quality control samples were within 10% of their expected value.
In addition during optimisation, intraplate variation of known control samples was 
determined to ensure that coating of plates was even and the ELISA plate reader was 
reading all parts of the plate consistently. Again values differing less than 10% of their 
expected value were accepted. During optimisation a number of problems were 
encountered and rectified. These included variation of laboratory temperature due to air- 
conditioning failure resulting in the overdeveloping of plates (and higher than expected 
MBL values) and the partial failure o f the ELISA plate washer resulting in differential 
washing and high intraplate variation of control samples.
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Both intraplate and interplate variation were slightly higher with the “in-house” method 
compared to the kit ELISA and therefore the “in-house” method was ultimately only 
used for serial measurements on the same patient, ensuring all samples were on the 
same ELISA plate.
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'yf MBL antibody
Plates are precoated with 
primary MBL antibody. The plates 
are ready for use
A  MBL
Diluted samples and calibrators 
are added to each well and incu­
bated
o
Biotinylated MBL antibody
Biotinylated detection antibody is 
added to each well and incuba­
ted
S  Streptavidin - HRP
HRP-conjugated streptavidin is 
added to each well and incuba­
ted
TMB Substrate
Substrate is added to each well. 
Develop for 15 minutes in the 
dark
Stop solution
Stop Solution is added to each 
well. Read plate within 30 min.
Quantitative results are obtained 
by measuring the absorbances of 
the wells at 450 nm
0
1 hour
0
1 
o
Total assay time less 
than 4 hours
Fig 2.1 Schematic overview of SSI MBL ELISA All plates were actually read within 
5 minutes. (Reproduced from SSI information sheet).
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2.3.2 Antibody conjugation procedures
2.3.2.1 Biotinylation of anti-MBL antibody
Aliquots of anti-MBL antibody 131.1 (donated to our laboratory by the SSI) to be 
conjugated were equilibrated with 0.1 M sodium hydrogen carbonate prior to 
biotinylation by washing, spinning and resuspending in NaHC03 in Ultrafree MC 
filters (Millipore, 0.5mls). The reagent for biotinylation, biotinaminocaproate N- 
hydroxysuccinamide ester, was dissolved in dimethyl sulphoxide (DMSO) to produce a 
concentration of 1 mg m l'1, and the antibody was incubated with this solution (75 pi 
ester solution per milligram of antibody) for approximately 5 hours at room 
temperature. Following the incubation period the product was washed three times with 
PBS. The final biotinylated antibody was aliquoted and stored at -70°C. Aliquots were 
defrosted prior to use and stored at +4°C for up to 2 weeks, to prevent freeze-thaw 
disruption, before being discarded.
23.2.2  FITC conjugation of anti-MBL antibody
See chapter 5, section 5.2.6.
2.3.3 MBL Genotyping: heteroduplex method introduction
The heteroduplex method uses PCR to amplify most of exon 1 of the MBL gene. In a 
separate reaction a synthetic DNA based on exon 1, but containing known deletions, 
insertions and/or substitutions near the sites of the three mutations is also amplified 
using the same primers. This synthetic DNA is called Universal Heteroduplex 
Generator (UHG) (kindly donated by Dr. N. Wood, University of Bristol).
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After amplification the two different products are mixed, denatured and allowed to 
anneal slowly. This allows heteroduplexes (between the two different DNA’s) as well 
as homoduplexes to form, of which the former are retarded on a polyacrylamide gel 
with respect to homoduplexes of the same length. As two different heteroduplexes are 
formed for each allele, with differing electrophoretic mobility’s, two bands are seen for 
each allele. Figure 2.2 below is a schematic diagram of the banding pattern seen for 
each of the ten possible genotypes.
Genotyping was performed separately for the exon 1 mutations and the X/Y promoter 
polymorphisms using procedures similar to those previously described (Jack et al., 
1997; Turner et al., 2000).
2.3.3.1 Preparation of DNA samples for genotyping
Samples for genotyping were stored as whole blood in EDTA at -20°C. DNA was 
subsequently extracted from 200 pi of thawed whole blood using the Qiagen Blood 
Amp kit according to the manufacturer’s instructions and the final product resuspended 
in 200 pi of sterile water before being stored at -20°C.
2.3.3.2 PCR amplification of DNA for MBL genotyping
The technique of PCR relies on the fact that DNA can be denatured into single strands 
by heat, and will anneal with primers and nucleotide bases to reform a double strand on 
cooling. Primers complimentary to sections of DNA on either side of the sequence to 
be studied bind to the genomic DNA, and a DNA polymerase adds nucleotides base by 
base between the 2 primers. The polymerase used in this PCR is derived from the 
bacterium Thermus aquaticus (Taq) and is heat stable, thus replenishment of 
polymerase after each cycle o f heating and cooling was not required. PCR enables very
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small amounts of DNA to be increased in quantity until there is sufficient DNA for 
genotyping to be performed.
Separate PCR reactions were performed on the genomic DNA samples, one to amplify 
the region of the gene containing the Exon 1 mutations, and one spanning the region of 
the X/Y promoter polymorphism. Both of these PCRs were also performed for the 
synthetic UHG.
Genomic DNA was PCR-amplified for exon 1 in a 20 pi reaction using 5 pi of aqueous 
DNA (approximately 10 ng p f 1), 0.6 pi each of 50 pM RMBL (5’-
CCAACACGTACCTGGTTCC-3’) and LMBL (5 ’-CTGTGACCTGTGAGGATGC-3’) 
primers (Sigma-Genosys, Pampisford, UK), 2 pi of lOx PCR buffer (provided with 
AmpliTaq Gold enzyme), 2 pi of dNTP mix (2 mM each of dATP, dCTP, dGTP and 
dTTP), 1.2 pi of 25 mM M gC f (provided with AmpliTaq Gold enzyme), 0.2 pi of 
AmpliTaq Gold DNA polymerase (5u p f 1) and sterile water to make the total volume 
up to 20 pi.
PCR reactions for the promoter polymorphisms were carried out in a similar fashion 
to the exon 1 procedure, the only exception being substitution of the exon 1 primers for 
primers for the X/Y promoter; MBLproL (shorty-left, 19 bases) (5’-
CTAAGGAGGGGTTCATCTG-3’) and MBLproR (shorty-right 21 bases) (5’- 
AGGCATAAGCCAGCTGGCAAT-3’), (both Sigma-Genosys, Pampisford, UK).
UHG amplification was carried out in larger volumes of 2000 pi for exon 1 and the 
X/Y promoter with all reagents in the same proportions to the 20 pi genomic reactions
except for the UHG DNA where 27 pi were used.
81
PCR reactions were carried out at 95°C for 15 min, followed by 35 cycles of 95°C for 
45 sec, 56°C for 45 sec and 72°C for 45 sec. These cycles were followed by a final 
extension step of 72°C for 10 min.
The presence of PCR product was confirmed by running 3 pi of product with 1 pi of 
bromophenol blue loading dye on a 2% agarose gel containing 0.5 pg m l'1 ethidium 
bromide in 1 x TBE running buffer for 1 hour. Gels were visualised under UV light.
2.3.3.3 Heteroduplexing and genotyping
Following confirmation of amplification of DNA, 10 pi of UHG PCR product and 5 pi 
of loading dye were added to each genomic DNA sample. Samples were heteroduplexed 
by heating at 95°C for 10 min and then allowing samples to cool to room temperature 
for 20 min.
2.3.3.4 Detection of haplotype on polyacrilamide gel
Fifteen microlitres of heteroduplex product were loaded onto 20% polyacrylamide gels 
and run for 15 hr at 150 V in 1 x TBE buffer at 16°C. Gels were stained in 0.5 pg m l'1 
ethidium bromide in 1 x TBE buffer for 10 min before being visualised under UV light. 
Characteristic and specific bands were obtained for each haplotype (Fig 2.2).
All genotypes and haplotypes were initially identified by me. Any equivocal results 
were repeated. They were then all read by a second independent person who was 
blinded to my diagnosis. 100 % concurrence was seen between both sets of results.
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Fig 2.2 Schematic diagram  showing the banding patterns for each of the possible 
MBL exon 1 genotypes. Homozygotes for wild type or a mutation reveal 2 bands, 
whilst heterozygotes or compound homozygotes demonstrate 4 bands. The apparent size 
in base pairs of each of the bands is shown on the left. The X/Y promoter 
polymorphisms also had a characteristic pattern. (This diagram was kindly provided by 
Dr R. Hamvas).
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CHAPTER 3
The Role of M annose Binding Lectin in Cystic Fibrosis Lung 
Disease
3.1 Introduction
Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder in the 
Caucasian population. Most of the morbidity and mortality relates to lung disease which 
is characterised by chronic bacterial infection, with quite specific pathogens, together 
with a sustained deleterious inflammatory response (see Chapter 1.7). Disease severity 
is highly variable, even amongst individuals with the same CFTR mutation, strongly 
suggesting that other genetic factors may modify the CF phenotype. To date a number 
of candidate modifier genes have been associated with pulmonary disease, including 
TNF-a (Hull and Thomson, 1998), nitric oxide synthase 1 (NOS1) (Texereau et al., 
2004), transforming growth factor beta (TGF-fi) (Arkwright et al., 2000) and surfactant 
protein A I and A2 genes (Choi et al., 2006). Unfortunately many association studies 
have been based on small numbers and consequently multiple studies have given 
conflicting results (Cutting, 2005).
Prior to the commencement of this work, two compelling studies had just reported that 
MBL-2 was a modifier o f lung disease in CF. The first of these by Garred et al 
demonstrated, in 149 Danish patients, that lung function was significantly reduced in 
patients with chronic Pseudomonas aeruginosa infection possessing either one or two 
structural MBL-2 gene mutations (A/O or O/O) compared with normal wild type 
homozygotes (A/A) (Garred et al., 1999b). Patients with variant alleles also had a 
significantly increased risk o f end stage lung disease (death or transplant) compared
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with those who had no mutations. Specifically, the predicted age of survival in those 
carrying variant alleles was reduced by 8 years compared to wild type individuals. In 
addition there was some preliminary evidence that patients were also at risk of acquiring 
the potentially-lethal organism, Burkholderia cepacia, with 7/10 of patients infected 
with B. cepacia carrying an MBL variant allelle. P.aeruginosa carriage was not affected 
per-se by MBL genotype however there was a trend towards carriers of variant alleles 
being younger at the onset of chronic carriage. A second study by Gabolde (Gabolde et 
al., 1999), of 164 French CF patients homozygous for the AF508 mutation, matched 11 
MBL-deficient adults (O/O) with homozygous sufficient controls (A/A). They found a 
reduction in lung function only in adults with two MBL-2 mutations. In addition a trend 
for more 0 /0  than A/A patients to be colonised with P.aeruginosa was demonstrated. 
The same group subsequently also found that CF liver cirrhosis is significantly 
associated with the presence o f MBL mutations (homozygous or compound 
heterozygote) (Gabolde et al., 2001).
Whether the effect of MBL on CF lung disease is seen just in those homozygous (or 
compound heterozygous) for a mutation or in the larger number of MBL heterozygote 
patients as well, would have important implications if MBL replacement therapy were 
to be developed as a treatment for CF. In addition both of these clinical studies focused 
on older children and adults with median ages of 16.2 and 19 years respectively and it 
was unclear whether MBL also acts as a modifier gene in children.
The aim o f this part o f my work was to investigate whether MBL plays a role in CF 
lung disease in a different geographical population (UK) to those previously described 
and to determine if the effect is also seen in children. Two separate hospitals were 
chosen so that the findings in two independent cohorts could be compared. This chapter 
describes the two clinical studies addressing these questions.
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3.2 Methods
3.2.1 Patient Population GOSH & RBH
Children were recruited from the paediatric CF clinic at Great Ormond Street Hospital 
(GOSH) between December 2001 and December 2002 and adults and children from 
respective clinics at the Royal Brompton Hospital (RBH) during 2000 and 2002. After 
informed consent, at the time of a routine blood test, an extra 1-3 ml of blood was taken 
from all patients from whom sufficient could be obtained. This was mainly done at 
annual review when patients were as well as possible apart from 4 children at GOSH, 3 
of whom were admitted for routine elective intravenous antibiotics and one who was 
admitted unwell. Retrospective clinical data were obtained from the CF database, 
patients’ hospital notes, the lung function laboratory and computerised microbiology 
reports. Microbiological data recorded included the age at first isolation of P. 
aeruginosa and B. cepacia complex. S. aureus was not included due to the frequent use 
of prophylactic anti-staphylococcal medication. CFTR genotype was recorded if this 
was available (performed in the DNA Laboratory, Kennedy Galton Centre, Harrow, 
UK). In addition, prospective follow up information on all children from GOSH was 
obtained by myself, from study entry until December 2005. If they had transferred to 
adult clinics or moved to other areas of England I contacted the relevant unit at the end 
of the study in December 2005 to obtain information regarding death/ transplantation 
and/or acquisition of B. cepacia infection.
All clinical information obtained was organised in an excel spreadsheet and 
subsequently transferred into the statistical programmes SPSS (Version 12.00) and/or 
PRISM (GraphPad Prism version 3.00 for Windows, GraphPad Software, San Diego 
California USA) prior to analysis.
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3.2.2 Serial MBL serum measurements
A small number of children from GOSH, who were admitted either acutely or for 
elective intravenous antibiotics, were recruited for serial measurements of MBL. Blood 
samples were obtained whenever a routine clinical sample was taken to avoid 
unneccesary venupuncture or access of central lines.
3.2.3 Ethical Approval
The studies were approved by the Ethics Committees of Great Ormond Street and Royal 
Brompton Hospitals. All parents or carers, and children where old enough, gave 
informed consent for participation.
3.2.4 Lung Function Testing
Forced expiratory volume in the first second (FEVi) and forced vital capacity (FVC) 
were obtained from annual lung function laboratory records. Spirometry was measured 
using Jaeger MasterScreen and Masterscreen Body systems (Viasys Healthcare, 
Germany) following ATS spirometry guidelines. The results are expressed as percent of 
predicted values for age using published reference data (Rosenthal et al., 1993).
For the paediatric cohort at GOSH, FEV] and FVC were obtained for each year from 
age 5-16 where available. For children at the Brompton FEV| and FVC were obtained 
for the following approximate time points: 6-7 years, 8-9 years, 10-11 years, 12-13 
years and 14-16 years. For adults, annual values were recorded, where available, from 
1990-2002.
3.2.5 Sample processing
Preparation and amplification of genomic DNA, and MBL-2 haplotyping were 
performed as previously described (Chapter 2.3.3). MBL serum levels for the whole 
cohort were measured by a symmetrical sandwich ELISA using commercial kits
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(Antibody Shop, Copenhagen, Denmark) according to the manufacturer’s instructions. 
Serial MBL levels on individual patients were performed using the “in house” ELISA 
(section 2.3.1).
3.2.6 Statistical analysis
Data were analysed using SPSS v 12.00 and/or PRISM (GraphPad Prism version 3.00 
for Windows, GraphPad Software, San Diego California USA). Differences in serum 
MBL levels between MBL groups were analysed with the Kruskal Wallis (KW) test. 
Lung fuction test (LFT) data were normally distributed and therefore analysed by one­
way ANOVA and presented as mean +/- 1 SEM. Observed and expected genotype 
frequencies were analysed by the Chi square (x2) test.
3.3 Results
Patient demographics and MBL-2 haplotype results are shown for the GOSH & 
Brompton cohort separately to permit comparison between the 2 cohorts. Data are also 
presented separately for children and adults. Prolonged prospective follow up at GOSH 
enabled survival/transplantation data to be analysed for this group only.
3.3.1 Patient demographics
Great Ormond Street Hospital cohort
122 consecutive children and parents were approached of whom one refused consent 
and one had insufficient blood available for a research sample to be taken. This resulted 
in 120 children with a presumed diagnosis of CF being available to study. A diagnosis 
of CF was made on a clinical history and examination consistent with CF and a positive 
sweat test +/- a known CF genotype or a neonatal screening test with confirmatory 
genotyping or sweat test. During the period of follow up it became clear that two of the 
children did not infact have CF. Both had presented with respiratory infections and 
borderline sweat tests. Neither had a CF mutation detected and both were subsequently 
found to have normal nasal potential differences (Delmarco et al., 1997;Wilschanski et 
al., 2001). On subsequent investigation both had hypogammaglobulinaemia and 
interestingly both were MBL genotype OO, making a diagnosis of minor 
immunodeficiency likely as a cause for their symptoms. These 2 were therefore 
removed from all analyses. O f the remaining 118 cases, 55 (47%) were male and the 
mean age at study entry was 9± 0.4 years. The study group included 3 sibling pairs. 
CFTR genotype data were available on 114 (96.6%) children. 79 (69.3%) were 
homozygous for the AF508 mutation, 29 (25.4%) were compound heterozygotes with 
one copy of AF508 and the remaining 6 (5.3%) possessed 2 other mutations
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(G542X G542X, G551D/R1158X, G 551D/R5560T, Y569D/Y569D, 1461in4/-,
655ID/-). Lung function data were analysed on all patients and also for the AF508 
homozygotes only.
Royal Brompton hospital cohort
Blood samples were available from 298 (57% male) adults aged 29.7±0.5 years. CFTR 
genotype data were available on 269 (90.3%) of these as follows: A/A 48%, A/other 
44.6%, other/other 7.4%. A total of 260 children, (48%) male, with a mean age of 
8.5±0.3 years were included. In 228 (88%) children CFTR data were available as 
follows: A A 58.8%, A/other 34.6% and other/other 6.6%.
3.3.2 Mannose binding lectin genotypes
Great Ormond Street Hospital cohort
Genotype results were available for 113 of the 118 patients. No EDTA blood was 
available for genotyping in 3 individuals and 2 samples failed genotype testing on 3 
attempts, probably due to insufficient amount or poor quality of DNA. These 5 patients 
all had MBL serum results. O f the 118 patients serum was also available for MBL 
determination in 99 patients In 94 cases both MBL serum levels and MBL-2 haplotype 
data were available for correlation. Overall 63/113 (55.7%) had no structural MBL-2 
gene mutation (ie. wild-type and designated conventionally as A/A). 42 (37.2 %) of 
subjects were heterozygous for structural mutations (designated A/O) and 8 (7.1%) were 
either homozygous for one mutation or were compound heterozygotes (both designated 
O/O). This genotype distribution was similar to that observed in the Brompton CF 
cohort (below) and another UK study of healthy subjects (Mead et al., 1997) (p=1.0 
ANOVA), Table 3.1 A. Allele frequencies were as follows; A 0.75, B 0.174, C 0.036, D
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0.040 which were not statistically different (p=0.9 j l )  from those seen in the study by 
Meads et al, Table 3 .IB.
Royal Brompton hospital cohort
Both MBL serum levels and MBL-2 haplotype data were available in 522 cases; in 7 
cases only a genotype was obtained and in 25 only protein levels were available. The 
frequencies of mutations in both exon 1 and the promoter region did not differ between 
adults and children, and were similar to those observed in other studies o f both healthy 
subjects and patients with CF (Garred et al., 1999b). Overall, 61.1% had no structural 
mutations, 35.2% were heterozygous, and 3.8% were either homozygous or compound 
heterozygous (Table 3.1 A). In patients with structural gene mutations, the B allele was 
found on 71% of chromosomes, with the other mutations occurring less frequently (C 
11%, D 18%). The low-expressing X promoter polymorphism was found in association 
with 30.6% of wild-type structural alleles.
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Genotype
Frequency in 
GOSH CF 
population (%)
Frequency in 
Brompton CF 
population (%)
Frequency in UK 
“control” 
population (%)*
A/A 55.7 61.1 59.6
A/O 37.2 35.2 35.8
0 / 0 7.1 3.8 4.6
A/O + 0 / 0 44.3 39 40.4
Table 3.1 A
Allele
Frequency in 
GOSH CF 
population
Frequency in 
UK “control” 
population *
Wild type (A) 0.743 0.775
Codon 52 mutation (D) 0.040 0.066
Codon 54 mutation (B) 0.181 0.144
Codon 57 mutation (C) 0.035 0.015
Table 3.1 B
Table 3.1 The frequencies of (A) MBL genotypes in the GOSH and Brompton 
cohorts and (B) MBL alleles in the GOSH cohort, compared to those in a UK 
“control” population. These frequencies are not significantly different (p=1.0, 
ANOVA for genotype and p=0.9, y l  for allele frequencies) between any of the groups 
studied. *(Mead et al., 1997).
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3.3.3 Relationship of MBL haplotype to serum MBL level
There was a significant correlation between serum MBL level and haplotypes in all 
cohorts (p<0.001 Kruskal Wallis). The highest protein levels were seen in patients with 
wild type structural alleles, and the lowest in individuals homozygous or compound 
heterozygous for structural mutations, and in heterozygotes with the X promoter 
mutation. Data was similar for all cohorts and only the GOSH data are presented in Fig 
3.1.
93
<D><D
PQ
B
<D00
l O O O O n
8000-
6000-
4000-
2000 -
0
o
§o
O oo o
"TTqOo ° ° O o O
O o
o °
o  o  o
o o
ooo
o o o °°o00o
oo°
 o a39@66-
YA/YA YA/XA XA/XA YA/YO XA/YO YO/YO 
n=24 n=22 n=4 n=20 n=17 n=7
Haplotype
Fig 3.1 Relationship between MBL serum level and MBL haplotypes for GOSH 
patients. There was a significant correlation between serum MBL level and MBL 
haplotype (p<0.001 Kruskal Wallis) with wild type genotypes (A/A) having higher 
levels than heterozygotes (A/O) and homozygotes (O/O). The promoter polymorphism 
X/Y also significantly influenced the serum MBL level as shown.
94
3.3.4 Death and transplantation in GOSH cohort
During the period of follow up of the GOSH paediatric cohort (4 years prospectively 
from Dec 2001-Dec 2005), 3 children died, 2 had heart-lung transplants and 1 required a 
liver transplant. MBL variant alleles were significantly overrepresented in these 
patients, (5/6 compared to 42/107 non-transplants/survivors) p=0.03, test. All three 
who died were MBL insufficient with genotypes and serum levels as follows: YO/YO, 
44ng/ml; XA/YO, 74 ng/ml and YA/YO, serum unavailable. One of the two patients 
undergoing heart-lung transplantation was MBL insufficient; XA/YO, 57ng/ml, the 
other sufficient XAXA, 2953 ng/ml and the child requiring liver transplantation was 
also MBL deficient; XA/YO: 94 ng/ml. All deaths and lung transplants were for 
respiratory complications related to CF and the child with the liver transplant had CF 
related liver disease. These data, together with age at death, are shown in Table 3.2. 
Three of these patients who were over the age of 16, died or received a transplant after 
transfer to an adult unit. The children who died or had a transplant were, unsurprisingly, 
some of the oldest children in the cohort. 42 children were over the age of 14 years with 
both LFT/outcome data and a known MBL genotype. Of these older children all 4 who 
died or had a heart/lung transplant possessed an MBL variant allele compared to 14/38 
of those who survived. The effect of MBL genotype on risk of death/transplant 
therefore was even more statistically significant when comparing just the older children 
in the cohort (p=0.015, y2  test).
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Patient
No
MBL
genotype
MBL serum 
level(ng/ml)
Death or 
transplantation
Age at death 
or transplant
(years)
1 O/O 44 Died 14.8
2 XA/O 74 Died 16.1
3 YA/O n/a Died 16.8
4 XA/O 57 HLT 17.1
5 XA/XA 2953 HLT 12.1
6 XA/O 94 Liver transplant 14.2
Table 3.2 Relationship of MBL genotype to death or transplantation in the GOSH 
paediatric cohort. MBL variant alleles are significantly overrepresented in the patients 
who died or received a transplant, p=0.03, y l  test.
HLT= heart lung transplant, n/a= not available
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3.3.5 Lung function tests and MBL genotype 
Great Ormond Street Hospital paediatric cohort
111/118 children had lung function measured on at least one occasion with the other 7 
children being too young to perform the test. As expected in children with CF both 
FEVi and FVC were lower in older children than younger ones (p=0.0004 and 0.0012 
respectively, Kruskal Wallis test) (Fig 3.2). Lung function was therefore analysed 
according to MBL groups for early and late childhood. No gender difference was seen 
in FEVi or FVC at any age analysed (Fig 3.3), and therefore gender was not taken into 
account in further analysis. As MBL haplotype groups were small FEVi and FVC were 
analysed according to MBL genotypes A/A vs A/O vs O/O for the following age 
groups: 7 years, 11 years and the mean FEVi and FVC for ages 5-11 years. Only 4 of 
the OO children were over the age of 12 and therefore FEVi and FVC for the 16 year 
olds and mean FEVi and FVC for 12-16 years was analysed for MBL genotype A/A vs 
A/O and O/O combined. In addition the effect of the X-promotor polymorphism and 
AF508 homozygosity was also determined for each of the above age groups.
No significant difference in lung function was seen between the different MBL groups, 
at any age in childhood (full data not shown) although it was noted at age 5-11 years 
that those with genotype A/O and O/O had slightly higher FEVI and FVCs than those 
in the A/A group, and by age 12-16 this was reversed, (Fig 3.4 and 3.5). No effect of the 
X-promotor polymorphism was seen and limiting analysis to only those with CF 
genotype AF508 / AF508.did not alter any of these findings (therefore data not 
presented). Three sibling pairs were present in this cohort, with two pairs possessing 
different MBL genotypes (both pairs YA/O and O/O, although different MBL 
mutations). In both pairs lung function was worse in the O/O patient than the YA/O
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patient at the same age (pair 1, each year from age 4-11, pair 2, aged 5 only). However, 
factors such as birth order, age at diagnosis and any differences in treatment of these 
siblings are likely to be as influential as MBL genotype in difference in subsequent lung 
function.
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Fig 3.2 A) FEVj and B) FVC according to age in patients with CF.
As expected median FEVi and FVC both significantly reduced as age increased; 
p=0.0004 and 0.0012 respectively by Kruskal Wallis test.
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Fig 3.3 A) FEVi and B) FVC of all ages 5-16 years, according to gender.
There was no significant difference between median FEVi and FVC at ages 5-11, 12-16 
(both not shown) or 5-16 years (shown here) according to gender of patients.
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Fig 3.4 The relationship between MBL genotype and the mean A) FEVi and B) 
FVC for ages 5-11 years.
All 8 of the children with MBL genotype O/O had LFT’s at this age and therefore this 
group, although small, was kept separate for analysis. There was no significant 
difference between MBL wild type individuals and those hetero or homozygous for an 
MBL variant allele, in relation to FEVi and FVC, at this age.
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Fig 3.5 The relationship between MBL genotype and the mean A) FEVI and B) 
FVC for ages 12-16 years.
As only 4 children with MBL genotype O/O had LFTs above the age of 12 and only one 
at age 16 years the O/O genotype was combined with the other MBL deficient group 
A/O for analysis. There was no significant difference between between MBL wild type 
individuals and those with a MBL variant allele in relation to FEVi and FVC at this age.
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Royal Brompton hospital paediatric cohort
191 children were old enough to have lung function measured on at least one occasion 
of whom 186 had an MBL genotype available. As none of the O/O children was over 
the age of 12 years, all comparisons were made for lung function obtained between the 
ages of 7 and 11 years (mean age A/A 9.7, A/O 9.7, O/O 8.6 years, ANOVA p=0.3). 
Results were identical to the GOSH cohort with neither mean FEVi or FVC being 
reduced at this age in children possessing the O/O haplotype (Fig 3.6 ) and there was no 
effect of the X promoter polymorphism (data not shown).
Royal Brompton hospital adult cohort
A mean of 6.1 lung function recordings (range 1 to 13) was available on 273 haplotyped 
adults over a period o f 6.5 years. Mean FEVi was significantly associated with the 
MBL-2 haplotype, the lowest values being observed in individuals possessing two 
structural mutations (ANOVA p<0.05). A similar pattern was seen for mean FVC (Fig 
3.7). Neither parameter was reduced significantly in heterozygotes. No effect was seen 
of the low-expressing X promoter polymorphism on lung function in either the 
homozygous sufficient or heterozygous groups (data not shown).
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Fig 3.6 The relationship between MBL genotype and FEVi and FVC for 186 
children from the Royal Brompton Hospital. No child was over 12 years so the mean 
FEVi and FVC from age 7-11 years was used. There were no significant differences in 
lung function measurements between those with different MBL genotypes.
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Fig 3.7 The relationship between MBL genotype and FEVi and FVC for 273 
adults from the Royal Brompton Hospital. In adults, both FEVi and FVC were 
significantly different across the 3 MBL-2 haplotype groups (ANOVA p<0.05). The 
lowest values were seen in subjects with the O/O haplotype (* p<0.05 vs both other 
groups; # p<0.05 vs A/A subjects). The values in heterozygotes were not significantly 
different from those of wild-type patients.
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3.3.6 Lung function and Serum MBL levels 
Great Ormond Street Hospital paediatric cohort
There was no direct correlation between the MBL serum levels and lung function in the 
GOSH paediatric cohort (p=0.3, Spearman), as expected from the lack of association 
with genotype. However when lung function was compared between groups divided on 
the basis of upper, middle and lower quintiles of MBL serum levels an interesting 
pattern emerged.
Highest FEVi and FVC were observed in the middle quintile group, with patients in 
both upper and lower quintiles demonstrating lower lung function. This was seen at all 
ages. Figs 3.8-3.9 show data for ages 5-11 and 16 years respectively. The effect of 
better lung function in the middle quintile was significant for FVC at age 5-11 years (p= 
0.0157 one way ANOVA) with a trend towards significance being seen for FEVi age 5- 
11 (p=0.079). At age 16 this was not significant, maybe inpart due to smaller numbers, 
FEVi age 16 (p=0.19) and FVC age 16 (p=0.26, all using one way ANOVA). Due to 
different numbers o f patients in each MBL quintile, especially small numbers in the 
older age children, groups were subsequently statistically weighted using the post hoc 
Turkey test. Following weighting the mean FEVi and FVC from ages 5-16 years was 
also significantly higher in the middle quintile group (both p=<0.0001, one way 
ANOVA).
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Fig 3.8 The relationship between serum MBL quintile and mean A) FEVi and B) 
FVC for ages 5-11 years.
Patients with MBL levels in the middle quintile had a trend towards a higher FEVI 
(p=0.079, one way ANOVA) and a significantly higher FVC (p=0.0157, one way 
ANOVA).
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Fig 3.9 The relationship between serum MBL quintile and A) FEVI and B) FVC at 
age 16 years.
Patients with MBL levels in the middle quintile had a trend towards a higher FEVI and 
FVC (p=0.19 and p=0.26 respectively, both by the one way ANOVA test).
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Royal Brompton hospital paediatric cohort
Lung function was not analysed according to serum MBL levels for this cohort.
Royal Brompton hospital adult cohort
Again despite the close relationship between MBL-2 haplotype and MBL protein levels 
in adults, there was no direct correlation between the latter and lung function (p=0.17). 
To explore this discrepancy, lung function was again compared between groups divided 
on the basis of MBL serum level into top, middle and bottom quintiles, where an almost 
identical pattern emerged as in the GOSH paediatric cohort. Highest FEVi and FVC 
were observed in the middle quintile group, with both upper and lower quintiles groups 
demonstrating lower lung function (p<0.05 for FEVI and p=0.02 for FVC) (Davies et 
al., 2004).
3.3.7 Infection with P.aeruginosa & B.cepacia complex
In total 85.8% of GOSH and 85.1% of the Brompton children had experienced at least 
one positive culture for P.aeruginosa. The majority of the adult cohort (86.7%) had had 
repeated positive cultures for P. aeruginosa. There was no significant difference 
between MBL-2 haplotype and age of first P. aeruginosa culture (GOSH median age
3.7 (1.5-6.5) years) in any of the cohorts. Due to limited numbers of non-infected 
individuals further analysis of this effect on the basis of MBL status was not attempted.
Ten children, 3 from GOSH (2.5%) and 7 from the Brompton (2.7%) grew B.cepacia at 
least once each. There was no apparent trend with regard to MBL haplotype (YA/YA 
x4, YA/XA x3, XAXA, YA/YO and XA/YO). 18/298 (6%) adults were infected with 
B.cepacia.
A summary of all data from GOSH patient’s is presented in Table 3.3.
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MBL genotype A/A 
n= 63
A/O & O/O
n=50
p value
Age, mean (SEM) 9.23 (0.58) 9.29 (0.63) n/s
Male sex % (no) 49.2 (31) 48 (24) n/s
Serum MBL level, 
median (range) ng/ml
3995
(867-10000)
328
(30-1833)
<0.0001
MWU
Age at acquisition of pseudomonas 
median (range) years
3.4 (0-15) 4.15(0.2-14.5) n/s
Mean (SEM) of all ages FEVI 78.4 (2.98) 82.2 (3.07) n/s
Mean (SEM) of all ages FVC 82.5 (2.45) 86.8 (3.09) n/s
AF508 / AF508 %(No.) 71.0(44) 72.3 (34) n/s
Deaths/transplants % (No.) 1.5(1) 10(5) 0.03
Table 3.3 Table of GOSH patient demographics and all results relating to MBL 
genotypes A/A vs A/O and O/O. Both MBL serum level and number of deaths or 
transplants were significantly related to MBL genotype. A significantly higher 
percentage of CF patients with MBL variant alleles died or were transplanted (p=0.03,
X2).
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3.3.8 Serial MBL measurements
Serial measurements were performed in 5 children with CF and one with empyema
(Fig 3.11). Three wild type individuals had marked variation in MBL levels with no 
obvious pattern (Fig 3.11 A). None of the MBL insufficient patients with genotype 
XAO (two CF patients and one child with empyema on PICU), mounted an MBL serum 
level above 700ng/ml (Fig 3.11 B). 1 patient with genotype XAXA, fortuitously had an 
initial serum level performed at diagnosis during an admission to PICU with meconium 
ileus. This was 4075 ng/ml. A repeat serum sample one year later when well at annual 
review, revealed a level of 867 ng/ml, also demonstrating the acute phase response of 
MBL is usually small, o f the order o f 3-5 times baseline compared to the large 
increments seen in other acute phase proteins such as C- reactive protein (CRP) (Thiel 
et al., 1992).
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Fig 3.10 Serial MBL levels for patients during hospital stay. Changes in serum MBL 
levels are shown during hospital admission for A) 3 CF patients with MBL sufficiency 
and and B) 2 CF patients and one child with empyema on PICU, all MBL insufficient 
with genotype XAO. None of the heterozygote XAO patients can mount an MBL serum 
level above 700ng/ml. (note scale change in A) and B)). Data points show individual 
measurements on specific days and are therefore only joined up for consecutive days.
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3.4 Discussion
The results of the adult CF patients presented in this chapter represent the largest study 
to date. The data show that the possession of two abnormal structural MBL-2 alleles 
(O/O) is associated with significantly reduced lung function.
Table 3.4 summarises the 7 studies now published on this topic, including the data from 
this chapter (Davies et al., 2004;Davies et al., 2002). Six of these have shown that MBL 
polymorphisms play a modifying role on lung function in CF, the other study (Carlsson 
et al., 2005) found the effect o f MBL only in CF patients colonized with S. aureus. 
Two, (Garred et al., 1999b;Gabolde et al., 1999) (see introduction) were published prior 
to the commencement, and 4 during completion of this work. In 40 Belgian and 72 
Czech CF patients, with a mean age o f 13.4 years, Yarden’s group demonstrated that 
those with an MBL genotype A/O or O/O were significantly more likely to have an 
FEVi % predicted value of less than 90% compared to those A/A patients. This 
remained the case when groups were divided into MBL low producing haplotyes 
(XA/XA, YA/O, X/AO and O/O) and high producers (YA/YA and YA/XA), (Yarden et 
al., 2004). It was subsequently also shown in a small cohort of 47 Italian adult CF 
patients that FEVi was significantly reduced in those with at least one MBL variant 
allele (Trevisiol et al., 2005), and in American CF adults that FEVi was significantly 
reduced in those with at least one MBL variant allele but only in those CF patients 
homozygous for the AF508 mutation (Choi et al., 2006). Lastly, conversely, Carlsson’s 
group found in 112 Sweedish CF patients aged 4-54 that there was no overall 
correlation between MBL deficiency and reduced lung function or need for 
transplantation although in a subgroup of 27 Staphlococcus aureus infected patients this
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association was in fact seen (Carlsson et al., 2005). Only one study specifically analysed 
adults and children separately (Davies et al., 2004).
In the results section of this chapter, data from the two largest and youngest cohorts of 
children to date are also presented. Neither cohort showed a difference in lung function 
between the variant allele and wild type groups. This may reflect that MBL reveals 
itself as a modifyer o f CF lung disease only in older patients with increased disease 
severity. In view of this difference between children and adults, variations between the 
various studies may in part be explained by the differing mix of children and adults 
included in their analyses.
MBL variant alleles were however overrepresented in older GOSH children who died or 
required lung transplantation in line with Garreds original results. One child with a liver 
transplant was also MBL deficient. Taken together these results lend support to the 
hypothesis that MBL does indeed play a role in modifying CF lung (and possibly also 
liver) disease but only in older children and adults with established lung disease.
It can be seen from data presented here, that serum MBL levels were higher in the CF 
children than in published “healthy” controls where the mean of A/A genotype was 
1600ng/ml (Turner, 1996). This could be due to differences in the age of the population 
or more likely reflects the effect that CF chronic lung disease has on serum MBL. To 
further investigate the relationship between MBL level and lung function, both the 
Brompton adult and GOSH paediatric population had lung function analysed according 
to highest, middle and lowest MBL serum quintiles. Unexpectedly a clear and similar 
pattern was seen in both adults and children in that those with serum levels in the lower 
and upper quintiles had reduced lung function compared to those with levels in the 
middle quintile. Low levels of MBL may be due to low production due to gene 
polymorphisms, consumption during disease or reportedly in SLE, due to the binding of
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MBL autoantibodies (Mok et al., 2004). Having genotype data for these cohorts makes 
it clear that the lower serum quintile levels were due to low expressing MBL genotypes. 
Similarly the patients with reduced lung function and MBL serum levels in the upper 
quintile had wild type alleles. It is unclear if the levels in these patients reflect the 
consequence or the cause, of poor pulmonary status. It is tempting to speculate that as 
an acute phase protein, these high levels represent a sustained “acute phase response” in 
those with poor lung function and high expressing genotypes. In support of this 
hypothesis is data from the serial MBL levels performed and presented in this chapter, 
where those patients with high expressing genotypes could increase their MBL levels, to 
many thousand ng/ml, with time.
How MBL is operating in CF is still unclear. Two of the studies (Garred et al., 
1999b;Gabolde et al., 1999) suggested that MBL’s role in the acquisition of 
P.aeruginosa or B.cepacia may be important. However the studies presented here did 
not show an association between MBL genotype and susceptibility to P.aeruginosa or 
B. cepacia (described further in chapter 5) in adults or children. This may suggest that 
MBL is not primarily responsible for protecting CF patients from infection.
MBL plays a complex and incompletely understood role in the inflammatory response 
and a biphasic dose response has been demonstrated in an ex vivo model (Jack et al., 
2001b). Here the addition o f high concentrations of MBL (>6000 ng/ml) to the blood of 
MBL deficient donors decreased the production of proinflammatory cytokines IL-6, IL- 
ip and TNF-a by monocytes in response to infection, whereas low concentrations 
enhanced the production of IL-6 and IL-lp. Cystic fibrosis is known to be a disease 
characterised by marked inflammation as well as infection (Armstrong et al., 1997) and 
it maybe that MBL deficient individuals have a more pronounced deleterious
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inflammatory response in certain conditions such as in patients with CF and/or those in 
intensive care (see chapter 6).
Modifier studies are important in aiding the understanding of disease pathogenesis and 
may influence the development of novel treatments. They must however only be taken 
seriously if repeated studies with large numbers of patients show the same results. The 
work described in this chapter lends substantial weight to the hypothesis that MBL 
plays a modifying role CF lung disease. From this work, and other studies (Table 3.4) 
this seems to occur in older children and adults but not in younger children. This may be 
due to genetic modifiers o f disease being masked by better care nowadays resulting in 
almost normal lung function in early childhood thus the modifying role of MBL does 
not become apparent until later in life.
If MBL does play a role in the modulation of inflammation in lung disease, as well as 
its known effects relating to respiratory infection (Koch et al., 2001), exactly how it 
exerts its effect in the lung is also unknown but it seems probable that getting to the 
airway surface is important. The study described in the next chapter was therefore 
designed to answer the question “Is MBL present at the airway surface?”
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Study 
authors, 
country & 
publication 
year
No of CF 
patients
Mean/ 
median 
age in 
years
MBL
groups
compared
Association of MBL 
genotype and lung 
function
Association of 
MBL genotype 
and bacterial 
pathogens
Garred et al
Denmark
1999
149 16.2
(median)
A/A vs 
A/O + O/O
LFT’s significantly f 
& reduced survival in 
A/O + O/O
t B.cepacia and 
trend towards 
younger age P.a 
in A/O + O/O
Gabolde et al
France
1999
22 19.9
(mean)
A/A vs 
O/O
LFT’s significantly [ 
in O/O
Trend towards f 
P.a carriage in 
O/O
Yarden et al 
Belgium & 
Czech,2004
112 13.4
(mean)
A/A vs 
A/O + O/O
Significantly more 
A/O + O/O had FEV, 
<90%
No association 
with age o f  
acquisition P.a
Davies et al
UK
2004
298
adults,
260
children
29.7 
(mean)
9.7
(mean)
A/A vs 
A/O vs 
O/O
LFT’s & 0 2  
saturation
significantly j in O/O 
adults only. No 
difference in children
No association 
with age o f  
acquisition P.a or 
B.cepacia.
Carlsson et al
Denmark,
2005
112 20.5
(median)
A/A+YA/O
vs
XA/O+O/O
No overall 
association but in 27 
patients with 
S.aureus, XA/O & 
O/O associated with 
1 LFT’s
t P.a in MBL
sufficient pts
Trevisiol et al 
Italy, 2005
47 18.6
(median)
A/A vs 
A/O + O/O
FEVi significantly j 
in A/O + O/O
Significantly 
earlier age o f  
onset o f P.a in 
A/O + O/O
Choi et al
USA
2006
135 33.6
(mean)
A/A vs 
A/O + O/O
FEVi significantly f 
in A/O + O/O in 
those 5F508/5F508 
only
No association 
with P.a
Table 3.4 Results of all published studies in the field of MBL and cystic fibrosis.
Six of the 7 studies found an association between MBL polymorphisms and reduced 
lung function in CF patients. The other study (Carlsson et al, 2005) also found the 
association but only in patients colonized with S. aureus. Differences are seen as to 
whether the effect is seen just in those homozygous, or heterozygous as well, for an 
MBL polymorphism. Only one study (Trevisiol et al 2005) found a significant 
association with MBL polymorphisms and P.a infection. Data from this chapter is 
included (Davies et al, 2004). LFT’s = lung function tests, P.a = P.aeruginosa.
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CHAPTER 4
M annose-binding lectin and airway surface fluid
4.1 Introduction
In chapter 3, data were presented that showed MBL genotype was associated with 
disease phenotype in CF. This concurred with a number of other studies outlined in the 
chapter (Davies et al., 2004;Garred et al., 1999b;Gabolde et al., 1999;Yarden et al., 
2004). MBL is also associated with non-CF lung disease, specifically MBL 
insufficiency is associated with acute respiratory tract infections and pneumococcal 
disease, (Koch et al., 2001;Cedzynski et al., 2004;Roy et al., 2002) (see section 1.6.1.1). 
Taken together it would appear that MBL is important in lung infection/inflammation, 
however it is unclear how MBL exerts its effects in the lung.
The respiratory tract is continually challenged by infective, inflammatory and allergenic 
agents against which it exhibits an array of innate and adaptive defence mechanisms. 
The innate immune system in the lung consists of structural (e.g. mucociliary escalator) 
and cellular (e.g. alveolar macrophage) components together with excreted proteins 
such as defensins, lysozymes, lactoferrin and the hydrophilic surfactant proteins (SP) A 
and D. The latter surfactant proteins, produced by alveolar epithelial cells, have many 
structural and functional similarities with MBL and are also members of the collectin 
family. Specifically all three proteins are macromolecules which contain N-terminal 
collagen-like regions involved in trimerisation and C-type lectin domains (Sastry and 
Ezekowitz, 1993) (see chapter 1, section 1.2). SP A and D, like MBL, bind surface 
carbohydrates on pathogens, enhance phagocytosis and can modify cellular activation 
and the inflammatory response (Clark et al., 2000;Crouch, 1998;van Iwaarden et al.,
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1990;Malhotra et al., 1994a). All three are encoded by genes located on the long arm of 
chromosome 10, between 10q21 -24, suggesting a common ancestral gene (Hansen and 
Holmskov, 1998). Although primarily considered an airway surface protein, SP-D 
mRNA and protein has been identified in human mucosal surfaces as diverse as brain, 
heart, gut, kidney and skin implying that this protein and its function is not restricted to 
the lung (Madsen et al., 2000). Similarly in mice, extra-hepatic expression of MBL has 
now been demonstrated in the lung, kidney and small intestine and from cells of the 
monocyte/macrophage lineage (Uemura et al., 2002;Wagner et al., 2003). Clinical 
evidence of MBLs involvement in lung disease together with MBL’s similarities to SP- 
A and D raises the possibility that MBL might be active on the airway surface in the 
presence of disease. If this is true then it seems plausible that MBL, like the surfactant 
proteins, may be capable of contributing to host defense and/or the modulation of 
inflammation in the lung.
The aim of the work described in this chapter was therefore to determine whether MBL 
is present on the airway surface in either health or disease. To answer this question, 
BAL fluid was analysed for the presence of MBL from a large group of children with 
and without lung disease. One group of children with acute, not chronic, disease was 
specifically recruited to ensure that any effects of chronic disease, such as potential 
MBL breakdown, could be ascertained. Chronic diseases included cystic fibrosis, 
recurrent lower respiratory tract infections (> 2 LRTI with radiological change) and 
primary ciliary dyskinesia. The latter is a rare autosomal recessive condition, caused by 
“dysmotile” cilia and characterized by recurrent lower respiratory tract infections, sinus 
disease and glue ear. To assess the extent of the inflammatory process in the lung, a 
number of markers could have been looked at. However the patients with chronic 
disease were recruited from the Royal Brompton Hospital as part of another study and
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therefore only a single assay, human neutrophil elastase concentration, could be 
performed. This proteolytic enzyme, derived from inflammatory cells has been shown 
to correlate with severity of inflammation (Lengas et al., 1994) and airway obstruction 
in CF (Meyer and Zimmerman, 1993).
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4.2 Methods
4.2.1 Patient Population
Children undergoing an acute or elective bronchoalveolar lavage (BAL) were recruited 
during a 6 month period in 2002 at Great Ormond Street Hospital by myself and a 15 
month period in 2003-4 at the Royal Brompton Hospital by Dr Tom Hilliard 
(Respiratory Research Fellow). They were divided prospectively into the following 6 
groups:
1) Acute Pneumonia or pneumonitis (PP): These children were all ventilated on the 
Paediatric intensive care unit (PICU) at Great Ormond Street Hospital, where a 
diagnosis of pneumonia or pneumonitis was made on the basis of radiological changes 
with a consistent history. Two additional patients with empyema, who did not undergo 
bronchoscopy, had pleural fluid analysed.
2) Cystic fibrosis: These children had been diagnosed by sweat test and/or genotyping 
and were undergoing bronchoscopy and BAL either as a routine investigation at the 
time of diagnosis, for lack of response to antibiotic treatment or for research purposes at 
the time of a general anaesthetic for a surgical procedure.
3) Primary ciliary dyskinesia (PCD): This had been diagnosed on nasal brushing 
samples and these children were undergoing elective bronchoscopy for microbiological 
surveillance.
4) Recurrent lower respiratory tract infections (RLRTIs): These children had at 
least 2 lower respiratory tract infections (LRTIs) and were undergoing elective 
bronchoscopy during a period of clinical stability (i.e. after resolution of acute illness) 
as part of a respiratory work-up.
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5) Acute non-infective conditions (e.g. postoperative, trauma): these ventilated 
children were undergoing non-bronchoscopic BAL for failure to extubate and/or to 
exclude infection. These patients all subsequently had a non-infective diagnosis made 
such as veno-occlusive disease, or failure to extubate due to CNS trauma. In addition 
they all had negative microscopy for organisms, negative bacterial, fungal and 
virological cultures and negative PCRs for a wide panel of respiratory viruses. These 
patients therefore acted as part of a “control” group.
6) Upper airway problems: These patients underwent bronchoscopy for the 
investigation of upper airway (UA) structural problems. Ethical approval had previously 
been obtained to perform BAL on these patients who also formed an important 
“control” group. In none were any adverse effects of the BAL seen.
For most analyses of results these groups were analysed independently but for the 
purposes of discussion, patients from group 1 are referred to as having acute disease, 
groups 2-4 having chronic disease and groups 5 & 6 being the “controls”.
Patient demographic and microbiological/virological data were obtained from the 
routine laboratories at each institution or from the referring hospital. Local Research 
Ethics Committee approval was obtained from Great Ormond Street Hospital and The 
Royal Brompton, Harefield and NHLI Trust. All parents or carers gave informed 
consent and assent was obtained from children where appropriate.
4.2.2 Bronchoalveolar lavage collection and sample processing
BAL was performed with 1-3 aliquots of 1 ml/kg (maximum 30 mis) sterile 0.9% saline 
in either the right middle lobe (bronchoscopic) or aimed at a region of radiographic 
change (non-bronchoscopic). The latter was done by positioning of the child’s head and
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neck to attempt lavage of either right or left side if possible. 15/17 patients on the 
intensive care unit had a non-bronchoscopic BAL performed by a senior 
physiotherapist. The remaining two PICU patients and all the RBH patients had a 
bronchoscopic BAL performed by a Paediatric Respiratory Consultant. BAL fluid 
aliquots were pooled, and provided sufficient was available for required clinical 
investigations, a sample was retained for research. Samples were immediately placed on 
ice and spun at 400g for 10 minutes at 4°C. The supernatant was removed and stored in 
aliquots at -80°C until analysis.
4.2.3 Empyema and sputum collection and sample processing
Two samples of empyema (one from a patient on PICU, the other on the respiratory 
ward) and two samples of expectorated sputum (from two adolescent male CF patients, 
both with severe bronchiectasis and P.aeruginosa infection) were collected into 
specimen pots on ice. All samples were processed in the same manner as the BAL 
samples in section 4.2.2. and MBL levels subsequently determined by ELISA.
4.2.4 Influence of Protease Inhibitors on Resultant MBL levels
In order to determine whether protease inhibition, post BAL collection, was necessary 
to prevent potential MBL degradation, the supernatant from 14 patients was divided and 
treated with or without a cocktail of protease inhibitors (Complete Mini, Roche 
Diagnostics GmbH, Mannheim, Germany). These were added immediately after 
separating the supernatant in accordance with the manufacturer’s instructions. These 14 
patients all had a diagnosis of acute pneumonia/pneumonitis or acute non-infective 
conditions. 7 samples had no MBL detected either with or without PI and no sample had 
MBL detected only in the presence of PI. In the seven with MBL present there was no
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significant difference in the MBL levels with and without PI. Therefore, in the rest of 
the study, samples were not treated with PI.
4.2.5 Blood samples for serum MBL levels & MBL genotyping
1-2 mis of blood were spun, separated and the serum stored in aliquots at -80°C until 
analyzed. In the PICU patients and some CF patients 1-2 mis of whole blood in EDTA 
were also taken for MBL genotyping.
4.2.6 SDS Polyacrylamide gel-electrophoresis and western blotting
SDS Polyacrylamide gel-electrophoresis and western blotting were performed to 
determine whether MBL was present in BAL fluid. 10 % polyacrylamide gels were cast 
using Protogel reagents (National Diagnostics, Hull, UK) in gel casting units 
(Amersham Pharmacia Biotech, Bucks, UK). BAL samples, together with a positive 
(serum of YAYA donor, or MBL “spike” of 5 pg/ml) and negative (bovine serum 
albumin) control, were diluted with an equal volume of 2 x sample buffer containing 4 
% 2-mercaptoethanol (freshly prepared), and heated at 100°C for 5 min. Samples were 
loaded into the gel and electrophoresed at 120 V for 1 hr at room temperature alongside 
a rainbow colour marker and biotinylated broad range size standard (Bio-Rad, Hemel 
Hempstead, UK). To visualise protein bands gels were stained with Coomassie Blue 
stain.
For Western blots, proteins were transferred onto Hybond P nitrocellulose membranes 
(Pharmacia Biotech, Bucks, UK) using a semi-dry transblotter (Trans-Blot, Bio-Rad, 
Hemel Hempstead, UK). Gels were carefully applied to the nitrocellulose membranes 
and sandwiched between 6 pieces of filter paper which, along with the membranes, had 
been pre-soaked in Transbuffer. Transfer was performed by electrophoresis at 12 V for 
40 min ensuring the colour marker was present on the membrane. Transfer was also
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checked by staining with Ponceau S stain. The membranes were then blocked in “block 
solution” of TBS-Tween containing 0.2% I-block™ (Applied Biosystems, CA, USA) 
for 1 hr at room temperature on a shaking platform to prevent binding o f any free 
proteins. Membranes were washed three times for ten minutes in TBS- Tween before 
being probed by biotinylated anti-MBL 1/5000 in block solution for 3 hours at room 
temperature on a roller. After further washing detection was performed with 
Streptavidin-Horseradish peroxidase (Serotec Ltd, Oxford, UK) 1/1000 in block 
solution for 1 hour at room temperature on a roller. After further washing blots were 
developed using ECL chemiluminescent kit (Amersham Int, Little Chalfont, UK) 
according to manufacturers instructions. Proteins were visualised by exposure to X-ray 
film initially for 15 seconds with further longer exposures determined by the results of 
the initial exposure.
The technique used here was a standard procedure optimised by myself to achieve better 
visualization of protein bands. Optimisation involved using different concentrations of 
primary antibody (1/1000-1/10 000), Streptavidin-HRP (1/000-1/10 000) and skimmed 
milk (2-5%). The use of a highly purified casein based blocking reagent, I-block™
0.2% (Applied Biosystems, CA, USA) was finally used as milk contains avidin, which 
binds biotin, so casein based blocking solutions help reduce background.
4.2.7 MBL protein levels by ELISA
MBL levels in BAL fluid, serum and empyema fluid were determined by a symmetrical 
sandwich ELISA (Antibody Shop, Copenhagen, Denmark). Serum was diluted to 1/50- 
1/200, whereas BAL was used neat or 1/2 dilution, with results being corrected for the 
dilution factor. The standard curve was obtained using the ELISA kit standards ranging 
from 0.5-40 ng/ml. Results higher than 6500 ng/ml (serum samples) were repeated with 
further dilutions as appropriate. Levels below 4ng/ml were counted as zero. Samples
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were anonymised ensuring “blinding” to patient diagnoses until the results were 
analysed.
4.2.8 Neutrophil elastase
Neutrophil elastase (NE) was measured in BAL with a colorimetric assay based on NE 
cleaving nitroanilide from a substrate, N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide 
according to manufacturer’s instructions (Sigma Aldrich, St Louis, USA). lOpl sample 
volumes were used and levels were expressed as milliunits (mu)/ml. lmu activity was 
the lowest standard tested and the range of the assay was 20 - 5000 mu/ml, therefore 
any value below 20 mu/ml was taken as zero. This assay was performed by Dr Tom 
Hilliard, Clinical Research Fellow, Royal Brompton Hospital.
4.2.9 Statistical analysis
Differences between multiple groups in both studies were assessed using Kruskal- 
Wallis (KW), Mann Whitney (MW), Chi squared or Wilcoxon signed rank tests as 
appropriate. Spearman and Pearson’s correlations were performed where appropriate. 
As the majority of the data were non-parametrically distributed, results are presented as 
median (range). Analysis was performed using GraphPad Prism version 3.0 for 
Windows, GraphPad Software, San Diego California USA, and SPSS for windows v.9.
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4.3 Results
4.3.1 BAL Patient Demographics
85 children were recruited to this study. Patient demographics and diagnoses are shown 
in Table 4.1. 17 patients had urgent BAL performed whilst ventilated on PICU. The 
remaining 68 BALs were performed electively. Empyema fluid (n=2) and CF sputum 
(n=2) was also evaluated in 4 further children from GOSH. Controls included 3 children 
with upper airway obstruction and 4 with acute non infective “other” diagnoses a) one 
with severe asthma, b) one with pulmonary veno-occlusive disease, and c) two children 
who failed extubation, one after a severe head injury and one with a non-pulmonary 
malignancy. 40/85 (47%) were male and the median age was 5.7 years (1 month -16.8 
years). There were no significant differences in the mean ages (p=0.25, KW) or gender 
proportions (p=0.13, chi-squared) between disease groups.
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Diagnostic group (no.) Malerfemale Age
(% male) Median (range)
Acute pneumonia/ pneumonitis 9 : 4 4
(13) (69) (0.1-16.3)
Cystic fibrosis (37) 13 : 24 7.7
(35) (0.3-16.8)
PCD (6) 2 : 4 9.5
(33) (5.7-14.8)
RLRTI (22) 11:11 5.3
(50) (0.9-15.2)
Acute “other” (4) 2 : 2 8
(50) (0.2-15.1)
Upper airway (3) 3 : 0 7.2
(100) (5.8-7.5)
P value p=0.13 ns p=0.25 ns
Chi squared KW
Table 4.1 Demographic details of 85 patients who had BAL performed.
There was no statistically significant difference in age or sex between the groups. 
PCD=primary ciliary dyskinesia; RLRTI= recurrent lower respiratory tract infections.
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4.3.2 Relationship of MBL haplotype to MBL serum levels
33 patients had MBL genotypes performed, including all those with acute 
pneumonia/pneumonitis and about half o f those with CF or an acute non infective 
illness. In these groups approximately 2/3 had a wild type genotype (A/A) and 1/3 were 
heterozygous for a mutation (A/O). None of these had the O/O genotype. (A/A:A/0 -  
PP 69%: 31%, CF 72%:28%, Acute other n=2, 50%:50%). In the groups who had 
genotypes performed the observed distribution is not significantly different from that 
expected in UK published series (Mead et al., 1997). In 78 children serum was available 
for determination of MBL levels and 27 of these also had whole blood available for 
MBL genotyping. None of these 27 patients possessed the 0 /0  genotype, hence 
comparisons were done between two groups. As previously published (Fidler et al., 
2004;Davies et al., 2002;Garred et al., 1999b), median serum MBL levels were 
significantly different between both genotypes (Fig 4.1 A, p=0.0002, Mann-Whitney) 
and haplotypes (p=0.0063 Kruskal-Wallis, Fig 4.1 B). Levels were not age or sex 
dependent.
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Fig 4.1 Relationship between MBL serum levels and MBL haplotypes. Median 
MBL levels are significantly different between A) MBL genotypes and B) haplotypes in 
27 patients in whom both were available (p=0.0002 Mann Whitney & p=0.0063 
Kruskal-Wallis respectively). Small numbers in the XAXA group (n=2) has resulted in 
median MBL levels being higher than usually seen. There are no patients in this series 
with the O/O genotype.
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4.3.3 Western Blots
Demonstration of MBL in BAL fluid by western blotting was technically difficult due 
to the viscosity of the lavage fluid. After a period of optimization it was possible to 
demonstrate that MBL could be seen in BAL fluid and an example of one Western blot 
is shown in Fig 4.2. However, although Western blotting could have answered the 
question of whether or not MBL was found in BAL fluid, it did not provide quantitative 
data that could be used for comparison between groups. In addition sample volumes 
were limited and it was a more time consuming technique than originally anticipated. 
Thus an MBL ELISA kit (Antibody Shop, Copenhagen, Denmark) was subsequently 
used for all the results shown in this chapter.
4.3.4 Influence of Protease Inhibitors on Resultant MBL levels
No differences were seen in the subgroup of acute samples (n=14), measured by ELISA, 
with or without the addition of protease inhibitors (Fig 4.3; mean (SEM) values: +PI 
15.4 (4 .9) ng/ml; -PI 17.4(5.7) ng/ml; paired t-test p=0.4) and therefore all results 
reported now in this chapter are from untreated BAL. This probably reflects the fact that 
if any protease degradation of MBL occurred, it did so in the lung before BAL 
collection. It is likely that the rapid placement of BAL samples on ice and immediate 
processing limited further MBL breakdown.
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Fig 4.2 Western blot dem onstrating the presence of MBL in BAL fluid
Lanes 1-5 show patient BAL samples (diluted in sample buffer containing 4% 2- 
mercaptoethanol and denatured at 100°C for 5 min). Lanes 1 & 2, 3 & 4 and 5 are three 
different patients without (1, 3 & 5) and with (2 & 4) the addition of protease inhibitors. 
A positive control of high concentration MBL (5pg/ml) and a negative control of bovine 
serum albumin are also demonstrated. Lanes 3 and 4 clearly show a specific band 
(marked by arrows) for MBL (probed by biotinylated anti-MBL) at a size expected for 
denatured MBL (approximately 64,000 Kd). A non specific band is seen in all lanes. A 
biotinylated broad range size standard was included but omitted here for clarity.
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Fig 4.3 Influence of protease inhibitors on MBL levels. No differences were seen in 
the subgroup of samples (n=14), measured by ELISA, with or without the addition of 
protease inhibitors (median (IQR) +PI 8 (0-36)ng/ml and -PI 7 (0-38) ng/ml 
respectively, p= 0.47, Wilcoxon signed rank test) The values of every sample pair +/- 
PI were significantly similar, (effectiveness of pairing p=<0.0001, Spearman rest 0.93).
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4.3.5 MBL levels in BAL, empyema fluid and sputum
MBL was detected in 17 BAL samples overall (20%) and could be found in a 
proportion from each of the groups with pulmonary disease but in no child without 
lower respiratory disease (Figure 4.4). The acute pneumonia/pneumonitis group had a 
significantly greater proportion o f patients with MBL present in the BAL (p=0.0018, y l  
test) and median levels that were significantly higher than those in any of the other 
groups (Figure 4.5; KW p<0.001). For those subjects with MBL detectable in the BAL, 
there was an unexpectedly significant negative correlation with serum MBL measured 
simultaneously (Figure 4.6; Pearson r = -0.72, p=0.002). MBL was present in pleural 
fluid from both patients with empyema (empyema levels 38 ng/ml and 1178 ng/ml, 
genotypes XAO and YAXA respectively) but absent from both CF patients’ sputum 
(Table 4.2).
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Fig 4.4 Proportions of patients with MBL in bronchoalveolar lavage. Proportions of 
patients in the disease groups with MBL detectable in BAL (grey area and % figures) 
differed significantly (p<0.01), highest levels being observed in the acute pneumonia/ 
pneumonitis group. No MBL was present in any of the 7 patients with no respiratory 
disease.
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Fig 4.5 BAL MBL levels and relationship to disease group. Median level of MBL 
was significantly higher in patients with acute pneumonia/ pneumonitis (PP) infection 
than in the other groups (KW p<0.001; * p<0.001 vs chronic respiratory disease, p<0.05 
vs no respiratory infection).
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Fig 4.6 Relationship between MBL in serum and in BAL fluid.
In 16/17 children with MBL present in BAL fluid, serum samples were also available 
for determination of MBL levels. A significant negative correlation between serum and 
BAL MBL levels is apparent (Pearson r = -0.72, p=0.002).
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Patient
No
CF or 
non CF
Empyema 
or Sputum
MBL
(ng/ml)
Serum MBL 
(ng/ml)
MBL
genotype
Organism
cultured
1 Non CF Empyema 1178 4079 YA/XA S. aureus
2 Non CF Empyema 38 271 XA/O Bacteroides
3 CF Sputum 0 7222 YA/YA P.aeruginosa
4 CF Sputum 0 unknown unknown P.aeruginosa
Table 4.2
Relationship of MBL in empyema fluid or sputum to serum MBL levels, MBL 
genotype and organism cultured. Both patients with empyema had MBL detected in 
their empyema aspirates. Neither of the children with CF, P.aeruginosa infection and 
chronic lung disease had MBL detected by ELISA in their sputum.
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4.3.6 Microbiology
Overall a causative organism was found in 30/85 children (35%) (PP:6, CF:12, PCD:3, 
RLRTI:9, acute “other” :0, UA:0). Many children had received antimicrobial treatment 
prior to relevant bacterial and virological cultures being obtained and therefore this 
detection rate was probably falsely low. 29 strains of pathogenic bacteria were isolated 
from BAL fluid from 26 (30%) children (P. aeruginosa n - l \  H. influenzae n=7; S. 
pneumoniae n=6; S. aureus n=6; S. maltophilia n=2; B. catarhalis n=l). Two children 
in the acute PP group had viruses isolated from the BAL: Epstein Barr virus, and 
Influenza A. Two further children in the PP group had organisms isolated from other 
sites, one with varicella pneumonitis and disseminated disease (isolated from skin), the 
other with Group A streptococcal pneumonia and toxic shock (isolated from blood 
culture). None of the children assigned to the ‘acute non-infective’ or upper airway 
groups had positive cultures. Due to small numbers in some of the groups, the 
differences in the proportions o f patients from each group yielding a positive culture did 
not reach significance (PP: 46.2%, CF:32.4%, PCD:50%, RLRTI:40.9%, acute 
“other” :0%, UA:0%; p=0.36), although children with airway disease were significantly 
more likely than those in the control groups to have a positive culture (38% vs 0%, 
p=0.041). Neither those in whom bacteria were isolated, nor the combined bacteria/ 
virus isolated group had a greater likelihood of MBL being present in their BAL nor 
higher median BAL MBL levels. The two empyema fluid samples grew Bacteroides 
fragilis and S. aureus (empyema MBL levels 38 ng/ml and 1178 ng/ml respectively).
These data, together with MBL in BAL data is summarised in table 4.3.
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Diagnostic group 
(n)
No (%) with 
MBL detected 
in BAL
BAL MBL level 
ng/ml;
median (range)
No (%) with 
positive 
microbiology/ 
virology (n=30)
Acute pneumonia/ 
pneumonitis (13)
8 (61.5) 14(0-44) 6 (46.2)
Cystic fibrosis (37) 3(8.1) 0(0-17) 12 (32.4)
PCD (6) 1 (16.6) 0 (0-9) 3(50)
RLRTI (22) 5 (22.7) 0(0-14) 9 (40.9)
Acute “other” (4) 0 (0 ) 0 (0-0) 0 (0)
Upper airway (3) 0 (0 ) 0 (0-0) 0 (0)
P value p=0.0018
Chi squared
p= 0.0005 
KW
p=0.36 ns 
Chi squared
Table 4.3 Details of 85 patients who had BAL performed. Significantly more 
patients in the acute pneumonia/pneumonitis group had MBL detected in BAL fluid and 
at significantly higher levels than other groups. There was no statistically significant 
difference in age, sex or those with a positive culture of an organism between the 
groups. PCD=primary ciliary dyskinesia; RLRTI= recurrent lower respiratory tract 
infections.
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4.3.7 Neutrophil elastase (NE)
Levels of airway inflammation as determined by neutrophil elastase (NE) differed 
significantly between groups (p<0.001 KW, Fig 4.7A). Median levels were high in the 
acute PP (285[0-4044] mu/ml), CF (211 [0-5005] mu/ml) and PCD (134[0-3502] mu/ml) 
groups, with no differences between them. Significantly lower levels were observed in 
both the RLRTI (27.7[0-1297] mu/ml; p<0.01 vs acute PP and CF) and no respiratory 
infection (control) groups (32.3[0-579.8] mu/ml; p<0.05 vs CF). For the group as a 
whole, levels of BAL MBL did not correlate significantly with NE, although for the 
subgroup with detectable MBL (n=17), there was a positive correlation (Fig 4.7B, 
r=0.52; p<0.05). This relationship was held up in the acute pneumonia/pneumonitis 
group with detectable MBL (n=8; r=0.73; p<0.05) but numbers were not sufficient to 
further analyse this relationship in other disease subgroups.
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Fig 4.7 Relationship of BAL neutrophil elastase levels to clinical groups and BAL 
MBL levels A) NE levels were significantly higher (log fold) in the PP, CF and PCD 
groups compared to RLRTI and controls (p=0.001, Kruskal-Wallis). B) In the cohort 
with MBL detected in the BAL (n=17), there was a significant positive correlation of 
BAL MBL with concentration o f neutrophil elastase (r=0.52; p=0.027, Spearman).
(PP=acute pneumonia/pneumonitis, controls=acute “other” and upper airway patients).
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4.4 Discussion:
The work described in this chapter is the first large human study to attempt to measure 
MBL at the airway surface and demonstrates that, whilst the protein is undetectable in 
normal health, it is present in a variety of lung disease states in children.
This led to the hypothesis that some of the links reported of MBL-deficiency and lung 
disease might relate to the fact that MBL is able to play a role in local host defence. 
Children with acute pneumonia/ pneumonitis were most likely to have MBL detected in 
the BAL and had the highest concentrations; intermediate levels were observed in more 
chronic disease states and the protein was not detectable in any child from the control 
groups. When present, concentrations of MBL correlated with those of neutrophil 
elastase, a marker of local inflammation.
Low levels or absence of MBL in chronic disease may be due to reduced leakage or 
secretion into the airways or increased breakdown of the protein once there. The latter 
would seem more likely in the patients with CF and PCD for two reasons. Firstly the 
degree of inflammation, as assessed by the surrogate marker of inflammation neutrophil 
elastase, is likely to correlate with epithelial leak and was similar in both the acute and 
chronic CF and PCD groups. It is known that these groups have a marked 
infective/inflammatory component most of the time and therefore at the time of BAL. In 
contrast almost all the children with recurrent lower respiratory tract infections were 
relatively well at the time o f the BAL which may explain the finding of near control 
levels of NE in these patients. This subgroup may well therefore have had reduced 
leakage or secretion of MBL into the airway compared to those with acute 
pneumonia/pneumonitis. Secondly, both CF and PCD BAL contain high levels of 
proteolytic enzymes (Armstrong et al., 1997), which have been shown to degrade the
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structurally similar proteins SP-A and D (Griese et al., 2004;Rubio et al., 2004). In 
further support of protein breakdown, Garred et al reported rapid disappearance of MBL 
when normal human serum was mixed with CF sputum (Garred et al., 1999b) and in the 
two CF sputum samples tested here no MBL was detected.
Although several publications have reported increased susceptibility to, or severity of, 
respiratory disease in patients with MBL-deficiency (Koch et al., 2001;Cedzynski et al., 
2004;Roy et al., 2002;Garred et al., 1999b;Gabolde et al., 1999;Davies et al., 
2004;Carlsson et al., 2005) the question of whether or not MBL can reach, and 
subsequently act at the airway surface has not been extensively explored. One previous 
murine study reported that MBL was absent in the bronchoalveolar lavage (BAL) fluid 
of healthy mice, but detectable after intratracheal instillation of influenza A virus 
(Reading et al., 1997). In parallel to the human cohort described in this chapter, Dr Jane 
Davies and colleagues developed a system to explore acute pulmonary infection in a 
murine model, and demonstrated that MBL was undetectable in BAL fluid in the 
healthy airway or after instillation o f PBS, but appeared as early as 4 hours after 
infection with B. cenocepacia (personal communication). No human study had been 
published at the time o f undertaking this work although subsequently Gomi et al have 
also shown, in a small adult cohort, that MBL can be found in BAL fluid in the presence 
of respiratory disease (n=5) but not in healthy controls (n=5) (Gomi et al., 2004). Levels 
determined by ELISA (11-78 ng/ml) were found to be very similar to those reported 
here.
Although the work described here demonstrates an important finding, namely that MBL 
can be detected in BAL fluid in disease but not health, there are a number of limitations 
to this work. This is inevitable, since lower airway sampling can only ethically be 
performed in children when indicated clinically or at the time of another procedure, and
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cannot be scheduled electively for research. Firstly the numbers of patients in the 
control groups were small, and had a variety of different conditions. These small 
numbers reduced power for some of the statistical comparisons. However, obtaining 
lavage samples from healthy paediatric lungs is difficult, both logistically and ethically 
and this is a common limitation of such studies. Secondly the study was not designed to 
fully explore the mechanisms by which MBL appears at the airway surface. These 
include passive leak through damaged epithelia, active secretion, local production or a 
combination of these. With levels o f BAL MBL correlating with inflammation, as 
evidenced by neutrophil elastase, passive leak may be involved although local 
production has also been inferred by finding MBL-A mRNA in the mouse lung 
(Uemura et al., 2002). Determination o f expression levels in respiratory epithelial cells 
in the context of disease and health could aid further understanding of this. In addition 
only MBL and NE were measured in bronchoalveolar lavage fluid and maybe the 
measurement of further inflammatory markers (such as IL-8), MBL breakdown 
products and the ratio o f total BAL:serum protein levels may have helped give an 
insight into the underlying pathophysiology of the appearance of MBL in the lung.
To try and investigate the possible mechanism further, BAL MBL levels were 
correlated with serum MBL levels and unexpectedly there was a significant inverse 
relationship between them. In fact the 2 patients with the highest MBL levels in BAL 
fluid (44 & 44 ng/ml) were 2 children with acute pneumonia/pneumonitis who had the 
lowest serum MBL levels (294 & 422 ng/ml). If MBL level in BAL fluid merely 
reflects passive leakage from high serum levels then a positive correlation would have 
been expected. As the converse was seen, active secretion could be involved as well or 
if passive leak is the mechanism it must also be related to disease severity and damage 
to the integrity of the epithelium. One possibility is that more severe disease may be
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seen in those with lowest MBL serum levels thus accounting for the inverse relationship 
seen here. Unfortunately numbers here are too small to correlate MBL levels in BAL 
and serum with paediatric disease severity scores.
It is also unclear whether the oligomeric structure of the MBL found in BAL from MBL 
deficient or sufficient patients differs, as it does in the serum (Dean et al., 
2005;Lipscombe et al., 1995). Further work with non-reduced, gradient gel 
electrophoresis of MBL from BAL fluid would be needed to determine this.
Lastly, limitations of this study also include the fact that it was not designed to address 
the question of whether MBL present in the BAL fluid is actually functional in host 
defence. However, the data presented here provide two possible pieces of evidence that 
it is. It has been estimated that MBL levels required for complement activation are 
likely to be in the region o f 300-400 ng/ml (Valdimarsson et al., 1998;Neth et al., 2000), 
whereas the levels that were detected in these BAL samples reached a maximum of 44 
ng/ml. However, based on reports using markers to calculate the dilution of epithelial 
lining fluid (ELF) by instilled saline during BAL (Restrick et al., 1995), levels in the 
ELF are likely to be 1-2 logs higher than this, therefore within the range for function. 
Furthermore, very high levels were measured in the empyema fluid of a patient with 
Staphylococcus aureus, an organism known to be bound by MBL (Neth et al., 2000). 
Further determination o f MBL binding to detected respiratory pathogens found in these 
BAL’s may tease out further mechanisms by which MBL may be operating in the lung.
In addition to MBL’s role in the clearance of microbes there is increasing evidence of 
an immunomodulatory effect o f MBL (Jack et al., 2001b;Sprong et al., 2004). It has 
previously been considered whether this may account for the link between MBL- 
deficiency and CF disease severity (Davies et al., 2004), as it has been shown that MBL 
binds very poorly to the major CF respiratory pathogen, Pseudomonas aeruginosa
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(Davies et al., 2000a). Further work looking at MBL binding to one of the most serious 
bacteria found in CF lungs, Burkholderia cepacia, is presented in the following chapter.
In conclusion, MBL, a protein similar in structure and function to the collectins more 
conventionally associated with the lung, SP-A and D, may contribute to lung host 
defence by acting locally at the airway surface.
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CHAPTER 5
The Effect o f M BL status on the susceptibility of cystic 
fibrosis patients to Burkholderia cepacia complex (Bcc) 
infection
5.1 Introduction
Burkholderia cepacia complex (Bcc) comprises a group of closely related gram 
negative bacteria that are important opportunistic pathogens in patients with cystic 
fibrosis (CF). Infection with these organisms is associated with increased morbidity and 
mortality (Muhdi et al., 1996;Isles et al., 1984) especially after lung transplantation (De 
Soyza et al., 2001). In a proportion o f patients, a fulminating illness, the “cepacia 
syndrome” occurs. This is characterised by high temperature, respiratory failure and 
septicaemia and carries a high mortality (Isles et al., 1984). Clinical concerns also relate 
to the high transmissibility o f some o f these organisms and their antibiotic multi­
resistance.
Recent taxonomic techniques have revealed that the Bcc comprises a number of distinct 
genomic species each known as a genomovar, with genomovars I-IX having now been 
characterised and assigned names (Baldwin et al., 2005;LiPuma, 2005) (Table 5.1). 
Most clinically relevant species belong to the first 5 genomovars with the most common 
isolate from CF patients being B.cenocepacia (G III) (LiPuma et al., 2001;LiPuma, 
2005) of which the Electophoretic type (ET) 12 strain is one of the most virulent & 
transmissible and has been associated with transatlantic outbreaks. Infection with
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different Bcc species affects outcome with mortality being significantly higher in those 
infected with B.cenocepacia than B. multivorans (Jones et al., 2004). Predominance of 
certain strains in CF patients indicates a differential capacity for human infection. This 
may in part be influenced by differences in host immunity.
It was reported by Garred et al, in a small CF cohort, that MBL variant alleles were 
significantly more frequent in patients with Bcc infection (7 out of 10 patients), (Garred 
et al., 1999b). This appeared to be confirmed in a preliminary analysis of 13 patients 
from the Royal Brompton Hospital with Bcc infection in whom an overrepresentation of 
variant alleles was seen compared to population data from both healthy Caucasian 
controls and CF patients (8/13, 62%) (Davies et al., 2000b). It was subsequently shown 
that MBL binds to Bcc clinical isolates and activates complement, to a significantly 
greater extent than it does to the commonest CF pathogen, Pseudomonas aeruginosa 
(Davies et al., 2000a).
These data led to the hypotheses that a) MBL-deficient patients are at risk from Bcc 
infection and b) MBL-deficient patients may be at higher risk of acquiring certain 
strains of Bcc because the binding o f MBL to Bcc may differ between genomovars.
The specific aims of the work described in this chapter were therefore
A) to determine if MBL binding is
(i) present in further Bcc pathogens isolated from patients with CF and
(ii) genomovar related
B) To confirm the hypothesis that patients with MBL variant alleles were predisposed to 
Bcc infection by looking at a larger cohort of patients than previously studied.
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Genomovar
designation
Bcc Species Approximate % *
I B. cepacia 3
II B. multivorans 40
III B. cenocepacia 45
IV B. stahilis <1
V B. vietnamiensis 6
VI B.dolosa 4
VII B.ambifaria 1
VIII B.anthina <1
IX B.pyrrocinia <1
Indeterminate 1
Table 5.1 Species name and genomovar designation of Burkholderia cepacia 
complex (Bcc) organisms. * Approximate % of infection amongst >1200 Bcc infected 
CF patients in the USA. Adapted from LiPuma 2005.
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5.2 Methods
A) MBL binding to Burkholderia cepacia complex
5.2.1 Bacterial Isolates
Twelve freeze dried isolates from the reference panel of Bcc genomovars I-V were 
obtained (BCCM/LMG Bacterial Collection, Gent, Belgium) (Table 5.2). Thirteen 
patient sputum samples were obtained from Dr Jane Davies at the RBH. These included 
12 adults and one child with Bcc from the CF clinic. Genotypic identification o f these 
organisms was unknown, however pulsed field gel electrophoresis of these isolates 
showed at least 5 different strains were present (personal communication, Dr Jane 
Davies).
5.2.2 Preparation and Growth of Organisms
Freeze dried isolates were reconstituted in sterile brain heart broth (Oxoid, 
Buckinghamshire, UK) transferred to Bcc selective agar (Oxoid, Buckinghamshire, 
UK) and subcultured twice prior to use as per manufacturer’s instructions. Patient 
samples were incubated on Bcc selective agar at 37°C and subcultured once prior to 
experimental use. Bacteria were cultured as described by Bridson (The Oxoid manual, 
7th ed., Oxoid, Buckinghamshire, United Kingdom). Experiments were commenced 16- 
18 hours post subculture to obtain organisms in the stationary phase of growth.
5.2.3 Quantification of Burkolderia cepacia organisms in Hanks’ balanced salt 
solution (HBSS++) at an Optical Density (OD) of 1
Quantification of Bcc bacterial concentration was performed by the method described 
by Miles & Misra (Miles et al., 1932). Briefly a solution of Bcc bacteria (grown as 
described in section 5.2.2) in HBBS++ was adjusted to an OD of 1 (540nm). lOOpl of 
this solution was taken and serially logio diluted a further 7 times with HBBS++. 4 x
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lOpl drops of each of the 8 dilutions were plated out on to BCC agar and colonies 
counted at 24 hours, from which total colony forming units (CFUs)/ml were estimated.
5.2.4 Determination of bacterial growth characteristics
Previous experiments by other researchers on MBL binding to different organisms were 
conducted approximately 16-18 hours after subculture of the organism, in the stationary 
phase of growth (Neth et al., 2000;Devyatyarova-Johnson M et al., 2000). To confirm 
that Bcc organisms were in this phase, one strain, 18870, known on preliminary 
investigation to be a high MBL binder, was grown in broth and on solid agar at 37 °C. 
150pl of Bcc 18870 at OD of 1 (540nm) was added to 2850pl of brain heart broth (1/20 
dilution). At regular time points the OD of an aliquot of broth was measured. In addition 
samples were taken from broth at the same times, serially log diluted (as described in 
section 5.2.3) and 4 x 10pl drops transferred onto quadrants of agar plates. Plates were 
read at 24 hours. Lag, log and stationary phases were determined.
5.2.5 Purification of MBL
MBL was purified from human, ethanol-fractionated plasma paste by the method of 
Kilpatrick (Kilpatrick, 2001) modified to include positive affinity removal of human 
immunoglobulin. Essentially, the sample was twice passed through mannan-agarose 
columns to isolate the protein, and the product was then passed through an anti­
immunoglobulin column as a safeguard against immunoglobulin contamination. Briefly, 
500 g of frozen ethanol-fractionated human plasma paste (donated by C. Dash, Blood 
Products Laboratory, Elstree, United Kingdom) was purified by ammonium sulfate 
precipitation to give 42% saturation. After dialysis the solution was applied to a 
mannan-agarose (Sigma, Poole, United Kingdom) column (5-ml packed volume; 
Pharmacia Biotech, Uppsala, Sweden) and the calcium-dependent proteins were eluted
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with 0.01 M EDTA. The first EDTA eluate was recalcified to 0.05 M CaCl2, reapplied 
to the same mannan-agarose column, and eluted with 0.1 M mannose. The concentration 
of MBL was determined by enzyme-linked immunosorbent assay, and sample purity 
was verified by nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
using a 3 to 10% polyacrylamide gradient gel and silver staining. MBL prepared in this 
manner is known to be noncovalently associated with MASP. This was kindly 
performed and donated by Dr Marina Johnston at ICH.
5.2.6 FITC conjugation of anti-MBL antibody
Conjugation was performed using a well established method in our laboratory. The 
storage buffer of a 1-mg/ml solution of monoclonal anti-MBL antibody (clone 131-1; 
State Serum Institute, Copenhagen, Denmark) was exchanged for conjugation buffer 
(see conjugation buffer in methods) using a centrifuge ultrafiltration device (Ultrafree 
MC; Millipore, Watford, United Kingdom) according to the manufacturer's instructions. 
To this a solution of fluorescein isothiocyanate (FITC; 1 mg/ml in conjugation buffer) 
was added (0.3 ml/ml of antibody solution), and the resulting mixture was incubated at 
room temperature for 3.5 h. The buffer was exchanged for phosphate-buffered saline 
(PBS) using an ultrafiltration membrane. Unconjugated FITC was removed by 
continuous washing with PBS until the buffer ran clear. The conjugated antibody was 
aliquoted and stored at 70°C until use. Antibody concentration (a) and efficiency of 
coupling (b) were determined by measuring absorbance at 280nm (protein) and 495nm 
(FITC) and using the following equations.
a) Antibody concentration = OD280nm-(OD495nm x 0.35) / 1.35mg/m
b) Efficiency of coupling = O D 2 8 0 n m  /  O D 4 9 5 n m
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A coupling efficiency ratio of 0.5 -  1.0 indicates good coupling whilst a ratio o f less 
than 0.5 indicates a poor conjugation. In this study the OD280nm was 0.580 and OD495nm 
was 0.686 giving a final antibody concentration of 0.25mg/ml and a coupling efficiency 
ratio of 0.85 demonstrating good conjugation.
Efficacy was tested using the MBL binding assay (see section 5.2.7) with an organism 
known to bind MBL. Fig 5.1 shows that approximately 90% of the organisms were 
positive for FITC with the new conjugated antibody compared to both an old antibody 
that had undergone multiple freeze/thaws and a control for background fluorescence 
(where the same FITC anti-MBL antibody, but no MBL, was used). This control also 
demonstrated that unbound FITC had been washed off during the conjugation process. 
FITC conjugation was therefore confirmed and this antibody was used in all subsequent 
experiments.
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Fig 5.1 Comparison of “new” and “old” FITC conjugated anti-MBL antibody:
Newly prepared FITC conjugated anti-MBL antibody was compared with a previous 
“old” antibody in an experiment binding MBL to an organism known to bind MBL. 
FITC conjugation was therefore confirmed.
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5.2.7 Assay for MBL binding to microorganisms
The binding of MBL to all bacteria was determined by a flow cytometric procedure as 
described previously (Jack et al., 1998). A 50-pl aliquot of organism suspension at OD 
1 (540nm) was centrifuged at 8300g for 5 minutes and the pellet was resuspended in 
HBBS++ containing 5pg/ml MBL or no MBL for a negative control. Suspensions were 
incubated at 37°C for 30 min and then respun at 8300g for 5 minutes. The supernatant 
was removed and the cell pellet was washed with 200pl HBBS++ before resuspension 
in 25pl of HBBS++ containing 10 pg/ml of FITC-conjugated anti-MBL antibody. This 
mixture was incubated at 37°C for 30 min before centrifugation at 8300g for 5 minutes. 
The supernatant was removed and the pellet washed with 200pl HBBS++ before 
resuspension in 150pl of PBS. The samples were fixed by the addition o f 150pl of 
FACS fix for flow cytometry. Organisms were identified on the basis o f size and 
granularity. Data were evaluated both as percentage of positive organisms and median 
fluorescent intensity (MFI).
5.2.8 Influence of MBL concentration on binding
To determine the concentration dependence of binding, 4 strains identified as high (3) 
and low (1) binders, were incubated with MBL at concentrations ranging from zero to 
10 pg/ml. Concentrations were chosen to reflect both MBL deficiency, normal levels 
for a Caucasian population (approximately 1.6 pg/ml (Turner, 1996) and higher levels 
seen in an acute phase response (up to lOpg/ml).
5.2.9 MBL inhibition studies
To confirm that the binding of MBL was due to an interaction of the C-type lectin 
domain with bacterial sugars, competition experiments were performed using EDTA (a 
calcium chelater and known antagonist of MBL), a monosaccharide A-acetly-D-
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glucosamine known to bind MBL and a sugar, galactose, known not to compete with 
MBL binding (Devyatyarova-Johnson M et al., 2000). In each case either 0.5 M EDTA, 
0.25M A-acetly-D-glucosamine or 1 M galactose were added to the organism 
suspension for 10 minutes prior to the addition of MBL in a method described 
previously by Neth et al (Neth et al., 2000). The organisms used were BCC 18870 
(GIV) and BCC 16656 (GUI).
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B) The influence o f  MBL variant alleles on the acquisition o f  BCC in a clinical 
cohort ofpatients with cystic fibrosis
5.2.10 Population of CF patients with Bcc
MBL genotypes were known for the 13 patients from the RBH whose sputum isolates 
of Bcc were used in the MBL binding experiments (section 5.2.2 and 5.2.7) (Davies et 
al., 2000b). In addition I determined the MBL haplotypes on a further 38 patients 
colonized with Bcc from 3 other UK collaborating centers in Cambridge, Leeds and 
Belfast (samples kindly provided by Prof D Bilton, Dr S Conway and Prof S Elbom). 
Patient samples in the latter cases were anonymous, identified only by number, and 
therefore no further clinical data are available. Whole blood samples were provided and 
DNA extraction and MBL haplotypes were performed as described in chapter 2.
5.2.11 Evaluation of data and statistical analyses
MBL binding was determined by flow cytometry. Differences between MBL binding to 
different organisms were analysed by a Kruskal-Wallis test. In each case, comparisons 
were made with the background fluorescence in the absence of MBL (negative control) 
which was set at 2% by previous convention. Allele frequencies were estimated by gene 
counting. The goodness o f fit between observed and expected allele frequency was 
statistically tested using a y l  test.
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5.3 Results
A) MBL binding to Bcc
5.3.1 Quantification of Burkolderia cepacia complex organisms in Hanks’ balanced 
salt solution (HBSS++) at an Optical Density (OD) of 1
Organisms were quantified using the method of Miles & Misra. A suspension of Bcc in 
HBBS* at an OD of 1 (540 nm) equated to approximately 1.5x 109 CFU/ml. This is of 
the same order of magnitude as other similarly sized gram negative organisms (Ison et 
al., 1995).
5.3.2 Bacterial Growth Properties
When grown in broth the time course was as seen in Fig 5.2A. A lag (approx 0-4 hours), 
log (approx 4-12 hours) and stationary phase (approx 12-20 hours) can be determined. 
The no of CFU grown when samples were taken from the broth and plated onto agar is 
shown in Fig 5.2B. Again the organisms seem to be in stationary phase around 16-18 
hours. This confirms a similar growth time course o f Bcc to other bacteria previously 
used in MBL binding experiments.
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Fig 5.2. A) Growth of BCC 18870 (G IV) in brain heart broth. Turbidity of broth 
was measured by measuring the optical density (OD) at 540 nm. B) No of CFU of BCC 
18870. Samples were taken from broth at times shown, serially log diluted and 4 x lOpl 
drops transferred onto quadrants of agar plates using the methods of Miles and Misra. 
Plates were read at 24 hours.
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5.3.3 Influence of MBL concentration on binding
With organisms that bound high levels o f MBL (Fig 5.3 A,B,C) binding increased 
rapidly from low concentrations to a plateau o f maximal binding between 2.5 pg/ml and 
5 pg/ml. The one low binder did not bind MBL at any concentration. 5pg/ml of MBL 
was therefore chosen for the subsequent experiments.
5.3.4 MBL binding inhibition studies:
MBL binding to both Bcc 18870 and 16656 was markedly reduced in the presence of 
EDTA, demonstrating the divalent-cation (calcium) dependent nature of the observed 
interactions. In addition W acetyl-D-glucosamine inhibited binding of MBL due to 
competitive binding. The addition o f galactose in the same experiments had no effect on 
MBL binding (Fig 5.4).
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Fig 5.3. The binding of MBL to Burkholderia cepacia organisms is dependent on MBL 
concentration. Bcc organisms A) 18826, B) 16656 (both G III), C) 18870 (G IV) and D) 2161 
(G I) are shown. A, B & C bind strongly at physiological concentrations of MBL, with binding 
increasing rapidly from low concentrations to a plateau of maximal binding at about 2.5pg/ml. 
Bcc 2161 (D) did not bind MBL at any concentration.
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Fig 5.4. Specificity of MBL binding to two Bcc strains 18870 & 16656.
Binding of MBL to Bcc organisms 18870 and 16656 is inhibited by preincubation with 
EDTA & yV-acetylglucosamine but not by galactose.
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5.3.5 MBL binding to Bcc organisms isolated from CF patients
MBL binding was demonstrated to the majority of the clinical isolates (11/13) with two 
of the organisms showing minimal binding (no’s 11 and 12) (Fig 5.5). Both of the ET 
12 strains (no’s 9 and 10) bound MBL.
The source of the organisms was from a population in which there was an 
overrepresentation of MBL structural alleles (8/13, 62%) (Davies et al., 2000b) and low 
MBL serum levels (9/12 (75%) <1000ng/nl). However the patients own serum level did 
not affect whether they were infected with an organism that bound or did not bind 
MBL; Pearson’s coefficient of linear correlation r = 0.2, p=0.5 (Table 5.2 & Fig 5.6).
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Fig 5.5 MBL binding to 13 Bcc strains isolated from CF patients. Data are 
expressed as percentage o f organisms positive for FITC (samples incubated with MBL 
and FITC-anti MBL antibody). Each organism was compared to its own control 
(incubated with FITC-anti MBL antibody alone). Each control was set at 2% so only 
one (C) is shown for clarity. Mean MBL binding 66%; range 2-98%). * are ET12 
strains.
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Patient
number
MBL
Genotype
MBL
Serum level
MBL binding (% 
positive) to 
patient’s Bcc 
isolate
ET 12 strain
Y/N
1 XAO <100 77 N
2 XAO 450 69 N
3 OO <50 52 N
4 XAO <100 97 N
5 YAYA 1877 83 N
6 YAO <100 99 N
7 YAYA 5555 99 N
8 YAO 180 73 N
9 YAXA No serum 75 Y
10 YAYA 2872 66 Y
11 YAXA 738 6 N
12 YAO 702 2 N
13 YAO 244 66 N
Table 5.2 Relationship of patient MBL genotype, MBL serum level, presence or 
not of Bcc ET12 strain and MBL (5 pg/ml) binding to patients own Bcc isolate.
In this series of 13 cases the binding of purified MBL (5 pg/ml) to the patients own 
clinical isolate of Bcc was determined by flow cytometry.
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Fig 5.6 Relationship between MBL binding to patients own strain of Bcc and 
patients serum MBL level. 12/13 patients had serum available. 9/12 had serum levels 
< lOOOng/ml. An MBL concentration of 5pg/ml was used in the binding experiments. 
There was no correlation between patients own serum level and whether they were 
infected by an organism that bound or did not bind MBL (Pearson’s r = 0.2, p=0.5).
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5.3.6 MBL binding to different BCC genomovars
To investigate if a specific Bcc genomovar influenced MBL binding, 12 strains from 
genomovars (GI-V) were examined. The most common genomovar to cause severe 
clinical disease in the UK is B. cenocepacia, G III, (previously known as B.cepacia). A 
larger number of reference isolates from this group were therefore chosen (Table 5.3).
Fig 5.7 demonstrates that 3 isolates showed significantly higher binding to MBL than 
other organism (p=0.0034, Kruskal-Wallis). 2 were from G III (16656 & 18826) and 
one from G IV (18870). One showed low binding (BC 2161; G l). Interestingly the 
ET12 strain (16656) showed the highest binding.
Genomovar Species name Identification Number & Source of Isolate
I B. cepacia 1222 (onion), 2161 (soil)
II B. multivorans 18822 (CF), 13010 (CF)
III B. cenocepacia 18826 (CF), 
16654 (CF),
16656 (CF ET 12 strain), 
18832 (UTI)
IV B. stabilis 14294 (CF), 18870 (CF)
V B. vietnamiensis 10929 (soil), 18836 (CGD)
Table 5.3 Genomovars and strains of Burkholderia cepacia used in the MBL 
binding experiments.
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Fig 5.7 MBL binding to known strains of different genomovars of Bcc.
Data are expressed as percentage of organisms positive for FITC (samples incubated 
with MBL and FITC-anti MBL antibody). Each organism was compared to its own 
control (incubated with FITC-anti MBL antibody alone). Each control was set at 2%. 
Each column represents the mean of at least three experiments, error bars show one 
standard deviation. Binding to different organisms was significantly different; p=0.0034 
Kruskal-Wallis test.
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5.3.7 Relationship between MBL variant alleles and Bcc acquisition
In total, blood samples were obtained from 51 non selected CF patients who developed 
chronic infection with Bcc organisms. Although in the first cohort (CF centre 1, Table 
5.4) there was an overrepresentation of MBL alleles in those with Bcc infection (62%) 
this was not reflected in the other cohorts (CF centres 2-4, Table 5.4). Overall 45% were 
found to have a polymorphism, 41% were heterozygotes and 4% homozygotes for a 
variant allele (Table 5.4) which is not different from published MBL variant allele 
frequencies (Mead et al., 1997). Genotype & allele frequencies are shown in Table 5.5.
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CF
Centre
No of
patient
samples
No (%) MBL 
heterozygotes
(A/O)
No (%) MBL 
Homozygotes 
( 0 /0 )
Total no (%)MBL 
polymorphisms
(A/O + 0 /0 )
1 13 7 (54%) 1 (8%) 8 (62%)
2 21 8 (38%) 1 (5%) 9 (43%)
3 11 4 (36%) 0 (0%) 4 (36%)
4 6 2 (33%) 0 (0%) 2 (33%)
Total 51 21 (41%) 2 (4%) 23 (45%)
Table 5.4 Analysis of MBL variant alleles in 51 patients with cystic fibrosis and 
Bcc infection. These patients were recruited from 4 UK regional CF centers. Patients 
from centers 2-4 were completely anonymous and therefore no further data are 
available.
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Genotype Frequency in Bcc 
patient
population (%)
Frequency in UK 
“control” 
population (%)*
Frequency in UK 
CF population 
(% )#
A/A 55 59.6 61.1
A/O 41 35.8 35.2
O/O 4.0 4.6 3.8
A/O + O/O 45 40.4 39
Table 5.5 A
Allele Frequency in Bcc 
patient population
Frequency in UK 
“control” population *
Wild type (A) 0.755 0.775
Codon 52 mutation (D) 0.040 0.066
Codon 54 mutation (B) 0.166 0.144
Codon 57 mutation (C) 0.040 0.015
Table 5.5 B
Table 5.5 shows genotype (A) and allele (B) frequencies for the 51 patients with 
Burkholderia cepacia complex infection. These frequencies are not significantly 
different from those published in a UK well “control” population and in our UK CF 
population (p=0.94 Chi-square). *(Mead et al., 1997), #(Davies et al., 2004) and chapter 
3.
172
5.4 Discussion
Infection with Bcc usually occurs in patients with cystic fibrosis who are already 
colonized with Pseudomonas aeruginosa and have background lung disease. Why only 
a small proportion of patients acquire this organism and why some have a more severe 
clinical course is unknown. Both bacterial factors and the host response are thought to 
play a role. Certainly the propensity for the acquisition of B. cenocepacia and 
B.multivorans by CF patients would suggest some differences in virulence factors 
between genomovars that are of particular importance in the CF lung. The way that Bcc 
organisms are handled by parts o f the innate immune system, such as MBL, were 
thought to be important following the effect seen of MBL variant alleles on acquisition 
of Bcc in CF patients in preliminary small cohorts (Garred et al., 1999b;Davies et al., 
2000b).
In two small previous studies by Garred (n=10) (Garred et al., 1999b) and Davies 
(n=13) (Davies et al., 2000b) an association between Bcc infection and MBL genotype 
was observed. In the study presented here 51 patients with cepacia (including the 13 
patients from the RBH (Davies et al., 2000b)) were genotyped for MBL 
polymorphisms. There was no significant difference in the overall number of variant 
alleles in this cohort compared to published data from a prospectively recruited UK 
population of children being followed up for the ALSPAC study (Mead et al., 1997) and 
the large UK CF population presented in chapter 3 (Davies et al., 2004) (p=0.94, chi- 
square). The observed genotype frequencies of the Bcc group as a whole were not 
significantly different from those expected as calculated by the Flardy Weinberg 
equilibrium equation.
From the work presented in this chapter, MBL deficiency does not seem to predispose 
CF patients to Bcc infection. This is consistent with the finding that despite worse lung
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disease, MBL deficient CF patients are also not at increased risk o f acquisition of P. 
aeruginosa, as shown in Chapter 3 and also by Garred et al (Garred et al., 1999b;Davies 
et al., 2004). Taken together, these findings may suggest that complement mediated 
clearance of bacteria is not sufficient to prevent infection with these two organisms. 
However MBL could be operating in a number of ways. Although not sufficient to 
prevent colonization, MBL could still limit infection or reduce bacteria within the lungs. 
Indeed a recent report highlights a case of chronic Bcc infection in an MBL deficient 
non CF individual (Whitehouse et al., 2005). In the cohort presented here insufficient 
clinical or microbiological data were available to analyse this aspect further. However 
as the capacity of Bcc to bind MBL is likely to be a prerequisite for any MBL mediated 
antimicrobial activity, its capacity to bind to the organism was explored.
11/13 (85%) of the clinical isolates of Bcc showed significant binding to MBL. Bcc 
have been subdivided into genomovars on the basis of physical and genotypic 
characteristics. To investigate if  these bacterial properties were important in 
determining MBL binding, 12 Bcc reference strains representing 5 different 
genomovars were examined. No clear pattern emerged of MBL binding to the specific 
genomovars found commonly in CF. Only 2/4 G III, and 1/2 G IV organisms bound 
MBL but interestingly binding was highest to the genomovar III ET12 strain. Binding 
of organisms to MBL showed similar MBL concentration dependence and inhibition as 
seen with another gram negative organism, Salmonella serovar Typhimurium 
(Devyatyarova-Johnson M et al., 2000).
Bcc organisms are known to have multiple virulence factors including bacterial 
haemolysins (Hutchison et al., 1998), proteases (Kooi et al., 1994) and siderophores 
(McKenney and Allison, 1995). Lipopolysaccharide (LPS) from Bcc organisms is 
particularly pro-inflammatory and has been shown to elicit a nine fold higher release of
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cytokines from leukocytes compared to that o f P. aeruginosa (Shaw et al., 1995). 
Genomovar specific pro-inflammatory cytokine (TNF-a & IL-1(3) production has been 
looked at in vitro and shown varying biological activity within and between 
genomovars that was probably related more to components of LPS than to genomovar. 
Interestingly significantly more GUI isolates (including BCC LMG 16656 & 18826) 
elicited above average TNF-a production (De Soyza et al., 2004). MBL binding to 
organisms is also known to be influenced by LPS structure (Devyatyarova-Johnson M 
et al., 2000;Jack et al., 1995). As genomovars are not defined by LPS, it is perhaps not 
surprising that MBL binding does not occur in a genomovar specific pattern.
In spite of the mixed binding pattern o f the reference strains, 11 of the 13 clinical strains 
did bind MBL. Although it appears unlikely that MBL is affecting Bcc acquisition it is 
possible that it can modulate the host’s inflammatory response to this and other bacteria. 
The next chapter investigates how MBL can affect the development of systemic 
inflammation in response to an acute infectious or non-infectious insult.
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CHAPTER 6
The role of MBL in Inflam m ation
6.1 Introduction
Multiple organ failure resulting from systemic inflammation remains the predominant 
cause of morbidity and mortality on intensive care, irrespective of the initial illness or 
insult precipitating admission (Vincent, 1996;Marshall, 2001). Individuals differ 
considerably in their response to an infectious or traumatic insult which could be 
explained by polymorphisms o f the genes encoding proteins involved in this response. 
Seminal work by Sorensen et al (Sorensen et al., 1988) showed that death from 
infection of a biological parent under the age of 50 years, conferred a 5.8 fold increased 
risk of dying on the offspring. In this study the genetic contribution to this risk was 
more than seen in cardiovascular disease or cancer. Exactly which genes are involved 
are as yet unknown but are likely to include those involved in innate immunity, 
coagulation and inflammatory pathways (Sutherland and Russell, 2005). In children, 
mortality is low and therefore markers of morbidity such as severity of illness, multi­
organ failure and the systemic response to an insult, the systemic inflammatory response 
syndrome (SIRS), must be examined.
The work described in this thesis so far has demonstrated that MBL can bind to 
organisms (chapter 5), can be found in extra-vascular sites (chapter 4) and can modulate 
disease severity (chapter 3). It was therefore hypothesised that MBL is also involved in 
the modulation of inflammation. This hypothesis largely arose from work by Jack et al 
which showed, in an ex vivo whole blood model, that the addition of MBL to the blood 
of MBL-deficient donors influenced the production of monocyte-derived inflammatory
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cytokines after bacterial stimulation. Specifically, high concentrations of MBL 
(>6000ng/ml), such as seen in an acute phase response, decreased the production of 
interleukin-6 (IL-6), interleukin - lp  (IL-1J3) and tumour necrosis factor-a (TNF-a) by 
monocytes in response to meningococci, whereas lower concentrations (<1000- 
2000ng/ml), as seen in MBL homo or heterozygotes, enhanced the production of IL-6 
and IL-lp (Jack et al., 2001b) (See section 1.3.4).
In this chapter, the role that MBL may play in a clinical setting in which inflammation 
occurs in both the presence and absence o f infection was examined. To do this a study 
was designed to look at the association o f MBL haplotypes and serum levels with the 
development of both sepsis and/or SIRS in admissions to a PICU (part A). In addition 
experiments were performed to explore ex-vivo cytokine responses to bacteria in the 
presence or absence of MBL (part B).
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6.2 Methods
A) The effect of MBL on the systemic inflammatory response syndrome (SIRS) 
and sepsis in paediatric intensive care patients
6.2.1 Patient Selection
Consecutive admissions to the tertiary multi-disciplinary PICU at Great Ormond Street 
Hospital were recruited to this study over a 10 month period in 2002. Inclusion criteria 
were: age between birth and 17 years; presence of at least one organ system failure for > 
12 hours (or death within the first 12 hours). Organ failure was defined as follows; 
respiratory failure: the need for assisted ventilation (mask CPAP or intubation), 
cardiovascular failure: the need for inotropes following > 40ml/kg/day of resuscitation 
fluid, renal failure: the need for dialysis or haemofiltration, central nervous system 
failure: a Glasgow coma scale (GCS) o f < than 8/15. The following exclusions were 
applied: presence o f multiple congenital abnormalities; known congenital
immunodeficiency; known central neurological or neuromuscular disease (all 
considered to represent major risk factors for ICU admission resulting from infection); 
persistent pulmonary hypertension o f the newborn, weight < 2.2 kg, informed consent 
not available; suspected non-accidental injury; repeat PICU admission during the study 
period; lack of intravenous or intra-arterial access and anticipated short stay of <24 
hours (eg high dependency patients or those ventilated briefly and routinely post 
operatively) on the PICU.
On enrolment, cases were assigned to one of two groups according to the principal 
reason for ICU admission as documented for audit purposes by ICU physicians not 
involved in the study. The groups were: 1) infection (presumed or proven), 2) non­
infection (trauma, post operative or ‘other’). The primary outcome measure within each
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group was the development or not o f SIRS within 48 hours of admission by age- 
adjusted criteria.
Infection was defined as ‘proven’ if a causative organism was isolated and ‘presumed’ 
in those with a history and examination consistent with an infection e.g. fever, cough 
and coryza combined with chest x-ray changes consistent with pneumonia. Diagnoses 
of SIRS, sepsis and septic shock were made according to 1992 ACCP/SCCM guidelines 
modified for age (Bone et al., 1992;Hayden et al., 1993). In brief, SIRS was determined 
by the presence of >2 of the following: central temperature >38.0°C or < 36.0°C, white 
cell count > 12x 109/l or <4xl09/l and a heart rate (beats per minute, bpm) outside age 
specific ranges (newborn to 3 months: 95-145 bpm, 3-12 months 110-175 bpm, l-<3 
years 105-170 bpm, >3-<7 years, 80-140 bpm, >7-<10 years 70-120 bpm, >10 years 60- 
100 bpm). Respiratory rate was not included as a diagnostic criterion because of the 
very high proportion of cases receiving mechanical ventilation. Cases meeting these 
criteria for SIRS with ‘proven’ or ‘presumed’ infection were classified as ‘Sepsis’. 
Septic shock was diagnosed in cases o f sepsis who were hypotensive, defined against 
age specific values for mean blood pressure (newborn to 3 months: 40-60 mmHg, >3- 
<6 months 45-75 mmHg, >6 - <12 months 50-90 mmHg, >l-<3 years 50-100 mmHg, 
>3-<7 years, 50-100 mmHg, >7-<10 years 60-90 mmHg, >10 years 65-95 mmHg) after 
fluid resuscitation, requiring treatment with inotropic and/or vasopressor therapy (> 
dopamine 5pg/kg/min, any dose o f epinephrine, norepinephrine or vasopressin).
An electronic patient charting system (Care Vue, Hewlett Packard) was in use on PICU 
in which clinical and laboratory parameters were recorded on at least an hourly basis. 
For study patients these values were reviewed regularly by a PICU consultant (Dr Mark 
Peters) or senior clinical fellow (Dr Peter Wilson) and maximum and minimum 
ventilator and physiological parameters for each 24-hour period were recorded.
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Microbiological, biochemical and haematological information was recorded from the 
laboratories at GOSH and the referring hospital if available. A severity of illness score, 
the Paediatric Index o f Mortality (PIM) which estimates the risk of death from the 
severity of physiological disturbance, was assessed on first contact with the PICU team 
(Shann et al., 1997). Another severity of illness score; the sequential organ failure 
assessment (SOFA) score, was also calculated (section 6.2.8). All clinical information 
obtained was organised into a designated, password secured, access database and 
subsequently transferred into the statistical programmes SPSS (Version 12.00) and/or 
PRISM (GraphPad Prism version 3.00 for Windows, GraphPad Software, San Diego 
California USA) prior to analysis.
6.2.2 Consent & recruitment
I or one of my colleagues, a PICU consultant (Dr Mark Peters) or a senior clinical 
fellow (Dr Peter Wilson) reviewed all paediatric and neonatal intensive care admissions 
almost every day that the study was running to identify possible patients for inclusion. 
All of the initial patient recruitment and consent was done by myself or one o f these 
doctors, however I was subsequently unaware of the patients final diagnosis or whether 
or not they developed SIRS.
6.2.3 Ethical Approval
The study was approved in advance by the Ethics Committee of Great Ormond Street 
Hospital. All parents or carers gave informed consent for participation.
6.2.4 Blood sample processing
2-3 mis of whole blood was collected, at a time of a clinical sample being taken and 
divided into an EDTA and serum collection tube. Samples were taken within 48 hours, 
(usually within 8 hours) of admission. Whole blood in EDTA was stored at -20°C until
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DNA extraction was performed. Serum samples were spun, separated and the serum 
stored in aliquots at -80°C until analyzed.
6.2.5 Mannose binding lectin genotyping and serum analysis
Preparation and amplification of genomic DNA, and MBL-2 haplotyping were 
performed as previously described (Section 2.3.3). MBL serum levels were measured by 
a symmetrical sandwich ELISA using commercial kits (Antibody Shop, Copenhagen, 
Denmark) according to the manufacturer’s instructions. Serial MBL serum levels were 
performed using the “in house” ELISA (Section 2.3.1).
The investigator performing the MBL genotype and serum levels (KF) was blinded to 
the diagnosis of SIRS/non SIRS. Likewise the clinician (PW) who acquired the clinical 
data did so before the results were analysed and was therefore also blinded to the 
outcome.
6.2.6 CRP measurement
This procedure was performed by staff in the Biochemistry Department at GOSH by an 
enzymatic sandwich immunoassay (Vitros CRP).
6.2.7 Serial MBL serum measurements
A small number of children were recruited for serial measurements of serum MBL. 
Blood samples were obtained, daily where possible, whenever a routine clinical sample 
was taken to avoid unnecessary venupuncture or access of central lines.
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6.2.8 Severity of illness scores
In children mortality is low and therefore markers of morbidity such as severity of 
illness are required for studies such as these. To help determine a patients’ outcome at 
the beginning of, or during, an illness a number of scoring systems have been devised to 
stratify patients into high or low risk groups. These include the paediatric index of 
mortality (PIM), from which a risk o f mortality can be calculated and the Sequential 
Organ Failure Assessment (SOFA) score which is calculated daily to determine 
progression or resolution of multiorgan failure. Both involve complex mathematical 
equations to translate physiological data into a score. Table 6.1 demonstrates the 
physiological parameters required to calculate these scores.
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Parameters used to calculate the risk 
of mortality or to describe the 
severity of illness. Yes=V
PIM SOFA
Elective admission <
Underlying condition v1
C
en
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al
ne
rv
ou
s
sy
st
em
Response of pupils to bright light V
Glasgow coma scale V
l 
....
 
■ 
--J
R
es
pi
ra
to
ry Mechanical ventilation V V
Fi02 (%) / Pa02 (mmHg) V V
PaC02
C
ar
di
ov
as
cu
la
r Heart Rate
Systolic Blood Pressure (mmHg) V V
Base excess (mmHg) 
(arterial or capillary blood)
V
Use of inotropes V
H
em
at
ol
og
ic
al
White blood cell count
Platelet count V
INR or prothrombin time
R
en
al Creatinine V
ua>>
'3
SGOT
Bilirubin V
Table 6.1 Parameters used to calculate the PIM and SOFA scores. These scores are 
based on the severity of physiological disturbance. The PIM score also uses information 
on whether or not the patient is an elective admission and/or has an underlying 
condition. All describe morbidity. PIM = paediatric index of mortality, SOFA = 
sequential organ failure assessment.
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B) The effect of MBL on the production of cytokines by monocytes
6.2.9 Meningococcal strains
Two strains of serogroup B meningococci were used in this study, B1940 and H44/76 
(B: 15:P 1.7,16:) (Holten, 1979). Both are encapsulated and express the L3 immunotype. 
In addition, two galE mutants each derived from the respective parent strains were used. 
The galE strains were made by homologous recombination using a chloramphenicol 
resistance cassette inserted in the galE gene, which encodes the enzyme UDP-4 
galactose epimerase (Hammerschmidt et al., 1994). The resulting mutants are 
encapsulated but express a truncated LOS exposing a terminal glucose that lacks the 
lacto-neotetraose moiety of the alpha chain and cannot be sialylated. The mutants are 
piliated and express outer membrane proteins opa and opc (Hammerschmidt 1994). 
Prior to use, bacteria were heat inactivated at 56 °C for 30 minutes. All of these killed 
organisms were kindly provided by Dr Garth Dixon, Clinical Scientist, ICH.
6.2.10 Mannose binding lectin
MBL was purified from human plasma (as described in chapter 5.2.5) and used at the 
concentrations stated.
6.2.11 To determine MBL binding to wild type meningococci and the gal E isogenic 
mutant
To confirm that MBL did indeed bind these meningococcal organisms, as demonstrated 
in many previous reports (Jack et al., 1995), binding experiments were performed as 
described in chapter 5.2.7. In the experiment performed here 50jul of 1 x 109/1 of 
organism suspension (approximately 5 x 107 organisms) was incubated with 5|ug/ml of 
MBL.
6.2.12 Whole blood collection
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The required amount of whole blood was collected from laboratory volunteers (usually 
approx 20 mis) via a single venupuncture. Samples were placed immediately into sterile 
5ml bijous containing preservative free heparin (final concentration 10 U/ml). To avoid 
ex vivo activation, all blood samples were processed immediately. MBL deficient 
donors were used for the relevant experiments.
6.2.13 Assay for intracellular monocyte cytokine production
Whole blood culture
Whole blood from persons known to have little or no serum MBL was placed in a vial 
containing anti-coagulant. This was initially heparin sodium (final concentration 
lOiu/ml) and in subsequent experiments sodium citrate (final concentration 0.76% 
wt/vol). Brefeldin A (Sigma, Steinheim, Germany) was added to a final concentration 
of lOgg/mL. Brefeldin A interferes with the export o f proteins from the Golgi apparatus 
and causes the intracellular retention o f proteins that would normally be secreted 
(Misumi et al., 1986). 500pL o f blood was aliquoted into polypropylene tubes, and 
purified MBL (final concentration 0-8pg/mL) was added. The blood was then diluted 
with an equal volume of RPMI 1640 medium containing unlabelled meningococci to a 
final concentration of 5 * 106 organisms/mL or only medium (unstimulated control). 
Blood was incubated for 3 hours at 37°C with 5% CO2.
Monocyte Surface Staining
Aliquots of the whole blood mixture (200pL) were taken after 3 h and incubated with 
5pL of FITC conjugated monoclonal anti-CD 14 antibody (IgG2a, Serotec) (final 
concentration of 5pg/ml) or 5pL of an isotype control, for 30 min at room temperature 
in the dark. The erythrocytes were subsequently lysedby the addition of 2 mLs of FACS 
lysing buffer (Becton Dickenson, San Jose, USA) for 10 min. The remaining cells were
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pelleted by centrifuging at 350g for 5 minutes, the supernatant was decanted and cells 
washed in 2 mLs of “wash buffer” of phosphate buffered solution (PBS) containing 
0.5% Bovine Serum Albumin (BSA, Sigma, Steinheim, Germany) and 0.02% sodium 
azide (BDH, Poole, England) and repelleted by centrifugation at 350g for 5 minutes.
Cell membrane permeabilisation and intracellular cytokine staining
After surface staining and washing the cells were fixed by pellet resuspension in 200pl 
of 4% wt/vol paraformaldehyde in PBS for 10 minutes at room temperature. The 
samples were centrifuged, and the cell pellet was rewashed with “wash buffer” and 
recentrifugation. Cells were resuspended in 50pL of Leucoperm (Serotec Ltd, Oxford, 
England) followed by repeat washing. This permeabilisation step was critical to allow 
the cytokine specific monoclonal antibodies to penetrate the cell membrane, cytosol and 
endoplasmic reticulum.
The production of intracellular cytokines was assayed as per manufacturer's instructions 
using phycoerythrin (PE) conjugated mouse anti-human monoclonal antibodies to IL-6, 
TNF-a (Becton Dickinson), or IL -ip  (R&D Systems). In brief 5pL of anti-cytokine 
antibody or 0.5pL of the isotype control were added to the cell suspension, and the 
mixture was incubated at room temperature for 30 min in the dark. Samples were then 
washed twice with wash buffer before resuspension in 400pL of Cellfix (BD) for flow 
cytometry. For each antibody an isotype matched control was used to control for non­
specific binding. To conserve fluorescence, samples were protected from the light and 
stored at 4°C until analysed. Jack et al had previously shown by flow cytometry that the 
concentration of citrate used in this whole-blood model did not influence the binding of 
MBL (Jack et al., 1998).
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6.2.14 Cytokine ELISAs
During the same whole blood experiments extra aliquots were set up in an identical 
manner and supernatant was removed after 3 hours of stimulation and stored for later 
cytokine anlaysis. ELISAs were performed for IL lp, IL-6 and TNF-a, according to 
manufacturer’s instructions.
6.2.15 Flow cytometry
Flow cytometry allowed identification of monocytes from whole blood samples based 
on the cell size and granularity, in addition to the presence of fluorescence labeled 
monoclonal antibody to CD 14. Prior to experiments being undertaken, the positions of 
cells were confirmed using the whole blood method but staining the cells with 
monoclonal antibodies to CD 14 (monocyte marker), CD l ib  (neutrophil marker) and 
CD3 (lymphocyte marker) (data not shown).
6.2.16 FACS analysis
Flow cytometric analysis was performed on a FACSCalibur and analysed using 
CellQuest software (Becton Dickenson UK Ltd, Oxford, UK). Laser excitation was at 
488nm and data were collected on FITC fluorescence at 525nm and PE fluorescence at 
575nm. Forward and side scatter measurements were made with gain settings in linear 
mode and the monocyte population could be easily identified. Accuracy of the gate was 
confirmed by staining with a FITC conjugated antibody against the surface antigen 
CD 14. Only cells that were both o f the correct size and granularity, and stained with 
CD 14* monoclonal antibody were collected for analysis. 5000 gated events were 
collected for analysis.
187
6.2.17 Confirmation of cytokine detection after whole blood stimulation with LPS
To ensure that the “system” worked and for acquisition of the technique, the experiment 
was initially performed using neisserial lipopolysaccharide at 1 and 50 ng/ml as the 
stimulus (kind gift from Jenner vaccine laboratory, Compton, Berkshire; extracted from 
serogroup B strain 44/76 by phenol chloroform extraction followed by purification). 
Antibodies to CD 14, TNFa, IL-6 and IL-ip were used as above. Isotype controls for 
each cytokine were included. Unstimulated and stimulated CD14+ cells were analysed 
for each cytokine. The amount of cytokine produced from the stimulated cells were 
compared to both the unstimulated cells and to background fluorescence from non 
specific binding ie the isotype control.
6.2.18 Statistical analysis
Data were analysed using SPSS v 12.00 and/or PRISM (GraphPad Prism version 3.00 
for Windows, GraphPad Software, San Diego California USA). Observed and expected 
genotype frequencies were analysed by the Chi square (%2) test. Differences between 
MBL serum levels were analyzed with the Mann-Whitney U test (for 2 groups) and the 
Kruskal-Wallis test (3 or more groups). Comparisons of the proportions of different 
MBL genotypes between clinical groups were performed using Chi square test. To 
determine the independence o f any association detected, logistic regression techniques 
were used to determine the impact o f the covariates MBL genotype, age, sex and 
ethnicity on the development o f SIRS (or sepsis). Similarly MBL serum levels (rather 
than genotype) were analysed. Relationship o f PIM and SOFA score to SIRS, sepsis and 
mortality was also assessed by logistic regression techniques.
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6.3 Results
A) The effect of MBL on the systemic inflammatory response syndrome (SIRS) 
and sepsis in paediatric intensive care
6.3.1 Patient Demographics
After informed consent 147 cases were available for study. Three had no blood 
available and 2 were actually repeat admissions for which only the first admission was 
included for analysis. 142 patients were therefore available for full analysis of MBL 
genotype of whom 139 also had serum available for MBL serum levels & CRP. Ninety 
(63%) of the cases were male and the median age was 25.5 months (2.1 years).
Patient diagnoses were as follows: 1) Infection n=69 (48.6%), of whom 19 (27.5%) had 
localised infection only, 24 (34.8%) had sepsis and 26 (37.7%) had septic shock; 2) 
Non-infectious etiology n=73 (51.4%) including head injury trauma n=33; post surgical 
n=34; other n=6 (2 necrotising enterocolitis; 1 acute exacerbation SLE; 1 acute 
demyelinating encephalomyelitis(ADEM); 1 drowning and 1 with drug related Stevens 
Johnsons’ syndrome). These were sub divided into those with, n=83 (58.5%) and 
without n=59 (41.5%) SIRS, irrespective o f the aetiology. 134 of the 142 children were 
ventilated for >12 hours and 2 others were ventilated but died within 12 hours of 
admission. The remaining 6 were not ventilated but had at least one organ failure. The 
characteristics of the patients studied in relation to MBL exon 1 polymorphisms are 
shown in Table 6.2
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All Cases 
n=142
Wild type 
AA
n=91
Hetero/homozygous 
variant A/O, O/O
n=51
P  value
Male, no. (%) 90 (63%) 59 (65%) 31 (61%) 0.63 y2
Age, median (IQR), 25.5 32 19 0.2 MW
(months) (7.5-121) (10.5-127) (7-103)
Caucasian: 
non Caucasian
99:43 60:31 39:12 0.19x2
Table 6.2 Characteristics of patients studied and M BL-2  exon 1 genotype.
There were no significant differences in patient age, sex or ethnicity between those with 
wild type (A/A) and variant (A/O, O/O) MBL alleles.
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6.3.2 Mannose binding lectin genotypes
MBL genotype and haplotypes were successfully performed on all 142 patients. In 
addition haplotypes were performed on the 2 repeat admissions, excluded from analysis, 
to allow 2 “internal controls” . In both of these cases the haplotype was the same, as 
expected, on both occasions.
Overall 91/142 (64.1%) had no structural MBL-2 gene mutation (ie. wild-type and 
designated conventionally as A/A). 49 (34.5 %) of subjects were heterozygous for 
structural mutations (designated A/O) and 2 (1.4%) were either homozygous for one 
mutation or were compound heterozygotes (both designated O/O). Overall allele 
frequencies were as follows; wildtype (A) 0.813, codon 54 (variant B) 0.085, codon 57 
(variant C) 0.042 and 52 (variant D) 0.060. This distribution was in Hardy-Weinberg 
equilibrium and did not differ significantly from those published in a population of UK 
“well” children (Mead et al., 1997). This was despite the difference in the ethnic mix of 
the 2 groups with Meads study having a non-Caucasian component of 2.4% and mine, 
for this study period, a self stated non-Caucasian component of 30% (Table 6.3).
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Genotype
Frequency in 
PICU population
n=142 (%)
Frequency in UK 
“control” 
population (%)*
A/A 64.1 59.6
A/O 34.5 35.8
O/O 1.4 4.6
A/O + O/O 35.9 40.4
A)
Allele
Frequency in 
PICU population
n=142
Frequency in UK 
“control” 
population *
Wild type (A) 0.813 0.775
Codon 52 mutation (D) 0.060 0.066
Codon 54 mutation (B) 0.085 0.144
Codon 57 mutation (C) 0.042 0.015
B)
Table 6.3 Expected and observed distribution of MBL genotype (A) and allele (B) 
frequencies. The frequencies in the study population were not significantly different to 
those from a published UK control population *(Mead et al., 1997)
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6.3.3 Relationship of MBL haplotype to serum MBL level
As expected, there was a significant correlation between serum MBL level and MBL 
genotype and haplotype (p<0.001 Kruskal Wallis). The highest protein levels were seen 
in patients with wild type structural alleles, and the lowest in individuals homozygous 
or compound heterozygous for structural mutations, and in heterozygotes with the X 
promoter mutation (Fig 6.1). MBL levels were higher in patients heterozygous for the D 
mutation compared to the the B and C variants. This finding has now also been 
demonstrated in the largest study to date in children followed up for the Avon 
Longitudinal Study of Parents and Children (ALSPAC) (personal communication Prof. 
M. Turner).
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Figure 6.1 Relationship between serum MBL levels and A) MBL-2 exon 1 genotype 
and B) MBL haplotype including X and Y promoter polymorphisms n=139. Serum 
levels in both cases are significantly related to genotype and haplotype (Kruskal-Wallis 
P<0.0001 for both).
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Haplotype
Figure 6.2 Relationship of serum MBL level to MBL haplotype for 139 children on 
PICU. Heterozygotes (A/O) have been further divided into those with a mutation at 
codon 52(D) and those with mutations at codon 54(B) and 57(C). Serum levels are 
significantly related to haplotype (Kruskal-Wallis PO.OOOl). Bars represent median 
levels. 0=B+C+D
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6.3.4 Relationship of MBL to age, gender, ethnic origin and C-reactive protein 
levels.
The data demonstrated in Fig 6.3 shows no correlation between age and serum MBL 
(Spearman linear correlation coefficient 0.02, p=0.83) but does demonstrates that even 
young babies can generate MBL levels of up to 9000 ng/ml in this clinical situation.
Ethnicity is an important determinant of MBL serum levels due to the difference in 
frequency of MBL gene mutations in various populations world wide (Turner, 1996). 
Overall in this PICU cohort there was no difference in MBL serum levels or proportions 
of variant genotypes between those stated  Caucasian and non-Caucasian children (Fig 
6.4). There was also no relationship o f MBL serum levels to gender (data not shown).
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Figure 6.3 Relationship of serum MBL to age (n=139). There was no linear 
correlation between age and serum MBL (Spearman correlation coefficient 0.02, 
p=0.83). This data also demonstrates that even young babies can generate MBL levels 
of up to 9000 ng/ml in certain circumstances such as when in intensive care.
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Figure 6.4 Relationship between serum MBL level and stated ethnicity in PICU 
patients (n=139).
No significant difference was seen in serum MBL levels of Caucasians and all non- 
Caucasian patients.
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6.3.5 MBL variant alleles and low serum levels are associated with the 
development of SIRS
Fig. 6.5 shows both MBL serum levels and the proportion of cases with MBL-2 exon 1 
mutations, by infective or non-infective reason for admission to PICU. MBL levels 
were significantly lower in those children admitted with infection (p<0.028, Mann- 
Whitney) and a trend was apparent between the proportion of children with a variant 
allele in whom infection had precipitated PICU admission compared to those without 
infection (43.5% vs.28.8%) (p=0.06 Chi squared, OR 1.9, 95% Cl 0.95-2.02).
Analysis of the development o f SIRS revealed significantly lower MBL serum levels 
(p<0.0001 Mann- Whitney) and a significantly higher proportion of variant alleles 
(p=0.0003 Chi squared OR 4.1, 95% Cl 1.9-8.9, Fig. 6.6) in those children who 
developed SIRS compared to those who did not. This relationship remained after age, 
sex and ethnicity were accounted for. Further analyses of subgroups revealed that in 
both the ‘non-infection’ (Fig 6.7 A) and ‘infection’ sub-groups (Fig 6.7 B) the 
significantly increased odds o f developing SIRS in association with an MBL variant 
allele remained (p=0.019 Chi sq, OR 3.49, 95% Cl 1.19-10.1 and p=0.02 Chi sq, OR 
4.06, 95% Cl 1.18-14 respectively). Within both subgroups serum MBL levels were 
again significantly lower in those who developed SIRS than those who did not (without 
infection p=0.05, Mann- Whitney U and with infection p=0.0014, Mann- Whitney U)
(Fig. 6.8 A&B).
As expected SIRS occurred more frequently in haplotypes associated with reduced 
MBL levels. Only 2 children were homozygous for an MBL-2 exon 1 polymorphism, 
one D/D (52/52) and one B/C (52/57), both of whom developed SIRS. Interestingly 
13/15 (87%) of patients heterozygous for an MBL exon 1 mutation associated with a
199
low expression promotor (XA/YO) developed SIRS and the risk of SIRS decreased with 
increasing prevalence of the A and Y alleles (p=0.0079, Chi squared, Table 6.4).
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Fig. 6.5 Relationship of MBL serum level (A) and MBL-2 exon 1 genotype (B) to 
whether or not infection precipitated admission to PICU, n=142. A) MBL levels 
were significantly lower in those children admitted with infection (p<0.028, Mann- 
Whitney). Individual and median values are shown. B) A higher proportion of children 
with MBL variant alleles were admitted with infection although this did not reach 
significance (p=0.06 %2, OR 1.9, 95% Cl 0.95-2.02).
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Fig. 6.6 Relationship of MBL serum level (A) and MBL-2 exon 1 genotype (B) to 
the early development of SIRS in children requiring intensive care, n=142. A)
MBL levels are significantly lower in children who developed SIRS (p<0.0001, Mann- 
Whitney). Individual and median values are shown. B) A significantly higher proportion 
of children with MBL variant alleles developed SIRS (p=0.003 OR 4.1, 95% Cl 1.9- 
8.9).
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Fig. 6.7 Proportion of children who developed SIRS according to an admission 
diagnosis of non infection or infection. In both patient groups the presence of an MBL 
variant allele was still associated with the development of SIRS A) p=0.019 chi sq, OR 
3.49, 95% Cl 1.19-10.1 and B) p=0.02 chi sq, OR 4.06, 95% Cl 1.18-14.
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Fig. 6.8 MBL serum levels in children who developed SIRS according to admission 
diagnosis of infection or non infection. In both children admitted without and with 
infection MBL serum levels were lower in those patients who developed SIRS 
compared to those who did not develop SIRS (p=0.05 and p=0.0014, Mann-Whitney U, 
respectively).
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Haplotype SIRS n=83 Non SIRS n=59 Total n=142
YA/YA 21 (42%) 29 (58%) 50
YA/XA 18 (53%) 16 (47%) 34
XA/XA 3 (50%) 3 (50%) 6
YA/YO 25 (74%) 9 (26%) 34
XA/YO 13 (87%) 2 (13%) 15
YO/YO 2 (100%) 0 (0%) 2
Failed promotor genotype 1 1
Table 6.4 Relationship of the development of SIRS to MBL short haplotype.
A significant correlation is seen between the increasing prevalence of A and Y alleles 
and the decreasing incidence o f SIRS (p=0.0079, Chi squared)
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6.3.6 MBL variant alleles and low serum levels are associated with an increasing 
severity of sepsis
Median serum MBL levels decreased significantly with increasing severity of infection 
(p=0.005 Kruskal-Wallis) (Figure 6.9 A). This was even more striking in the first 100 
patients analysed (Fidler et al., 2004).
In the whole cohort a significant association was seen between the severity of the 
systemic response to infection and the presence of an MBL variant allele (localized 
infection 4/19 vs. sepsis 14/24 vs. septic shock 12/26) (p=0.047, chi squared, Figure 6.9
B). When sepsis and septic shock are combined, as in some papers (Gordon et al., 2006) 
and compared to localized infection this significance increases (4/19 Vs 26/50 p=0.02 
chi squared). In the first 100 patients analysed this relationship was again more striking 
(localized infection 2/15 vs. sepsis 10/19 vs. septic shock 12/16) (p=0.002 chi squared) 
(Fidler et al., 2004).
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Figure 6.9 Relationship of MBL serum level (A) and M BL-2  exon 1 genotype (B) 
to the severity of infection (n=142). A) MBL levels are significantly lower in those 
children admitted with sepsis and septic shock than those with infection alone (p=0.005 
Kruskal-Wallis). Individual and median values are shown. B) A higher proportion of 
children with MBL variant alleles developed sepsis or septic shock (p=0.047 %2).
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6.3.7 The Relationship of MBL and C-reactive protein levels.
A weak inverse linear relationship was seen between CRP and MBL serum levels 
(Spearman r = -0.1747, p= 0.041) and a weakly positive linear relationship between 
serum CRP and the highest SOFA score (Spearman r =0.306, p= 0.0003), Figure 6.10. 
This may reflect that, in this cohort, patients with more severe sepsis and SIRS (and 
hence higher CRP levels) are more likely to be MBL deficient.
6.3.8 MBL and association with mortality and severity of illness in PICU patients
Lower levels of serum MBL were associated with higher on admission PIM scores 
(r-1.6, p=0.06, Spearman) and maximum SOFA scores (r-0.23, p=0.0078, Spearman) 
(Fig 6.11). Mortality for this cohort was 9% which was typical for this unit and 
considerably lower, as expected, than in adult intensive care studies (Simpson et al., 
2005). Fatality rates were similar in the MBL sufficient and insufficient individuals. 
From Fig 6.12 it can be seen that those who died seemed to have low levels of MBL 
(due to polymorphisms) or higher than normal levels (>2500 ng/ml) probably reflecting 
an acute response to their illness. Only two patients who died had a “normal” MBL 
level. Eight of the 13 children who died were admitted with an infectious aetiology (1 
enteroviral meningitis infection, 2 sepsis, 5 septic shock) and 5 without (3 head injuries, 
1 post operative, 1 drowning). Analysis of MBL levels and survival within the 
“infectious” and “non-infectious” groups did not reveal any significant differences 
either.
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Fig 6.10 The relationship of C-reactive protein to A) serum MBL and B) highest 
SOFA score in PICU patients. A weak but significant inverse linear relationship is 
seen between serum CRP and MBL levels (Spearman r = -0.20, p= 0.019). A weak but 
positive linear relationship is seen between serum CRP and the highest SOFA score for 
the patient (Spearman r =0.306, p= 0.0003).This may reflect that in this cohort patients 
with the higher CRP’s are those with MBL deficiency and more severe disease.
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Fig 6.11 The relationship of serum MBL levels with PIM and SOFA scores
A weak inverse correlation between serum MBL and paediatric risk of mortality (PIM) 
and sequential organ failure assessment (SOFA) scores was apparent. Lower levels of 
serum MBL were associated with higher on admission PIM scores (r-1.6, p=0.06, 
Spearman) and maximum SOFA scores (r-0.23, p=0.0078, Spearman).
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Fig 6.12 Serum MBL level in patients who died and in those who survived n=139.
There was no significant difference between these groups (p=0.48, Mann-Whitney test) 
although the number o f patients who died is small n=13 (9%). The bold line 
demonstrates the median MBL level for each group.
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6.3.9 The effect of MBL on the prevalence of the infecting microorganism
A wide spectrum of micro-organisms cause infection in intensive care patients. In this 
series of 69 children with an infectious insult precipitating admission the following 
organisms were thought to be causative; gram positive bacteria: 15 (21.7%), gram 
negative bacteria: 23 (33%), viruses 12 (17.4%), mycoplasma 2 (2.9%), fungi 0. No 
organism was isolated in 17 (24.6%) cases, probably due to the prior administration of 
antibiotics. Further identification of these organisms is shown in Table 6.5. Overall a 
trend was seen towards a causative organism being identified in those with an MBL 
variant allele although this did not reach significance (p=0.07 y l  test). No association 
was seen with specific class of microorganism and MBL deficiency.
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Infecting
Microorganim
Number (%) of Cases 
n=69
Disease caused
Group A 
streptococcus
1 (1.4%) Sepsis
Group B 
streptococcus
3 (4.3%) Meningitis 1, sepsis 1, 
mixed 1
Viridans
streptococcus
2 (2.9%) Sepsis
Pneumococcus 4(5.8% ) Meningitis 1, sepsis 1, 
mixed 2
Staphylococcus
aureus
2(2.9% ) (1 MRSA) Sepsis
Staphlococcus
epidermidis
1 (1.4%) Sepsis
“other” gram positive 
organisms
2 (2.9%)
(1 enterococcus,l 
bacillus)
Sepsis
Nisseria menigitidis 6 (8.7%) Sepsis 5, meningitis 1
Pseudomonas 3 (4.3%) Pneumonia 2, sepsis 1
Ecsherichae coli 2 (2.9%) Sepsis
Klebsiella 3 (4.3%) Sepsis
Haemophilus
influenzae
5 (7.2%) (2 type b) Epiglotitis 1, meningitis 1, 
sepsis 1, tracheitis 1, mixed 
1
“other” gram negative 
rods
4 (5.8%) Sepsis 3, pneumonia 1
Respiratory syncitial 
virus (RSV)
6 (8.7%) Bronchiolitis 3, 
bronchiolitis and sepsis 3
Enterovirus 4 (5.8%) Meningitis 1, myocarditis 3
Herpes simplex virus 1 (1.4%) Encephalitis
Epstein Barr Virus 1 (1.4%) Pneumonitis
Mycoplasma
pneumoniae
2 (2.9%) Pneumonia
Fungi 0 (0%)
No organism isolated 17(24.6% ) Infection 7, sepsis 10
Table 6.5 Table of disease causing organisms isolated from 69/142 cases admitted
with infection to PICU. The spectrum of diseases is shown.
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6.3.10 Serial serum MBL measurements
Serial measurements were performed in 11 children on PICU (Fig 6.13). Nine wild type 
individuals had marked variation in MBL levels with no obvious pattern seen in those 
who did or did not develop SIRS. The one child with genotype YA/O had the D (52) 
mutation associated with higher levels than normal for a heterozygote and interestingly 
although his levels were mainly insufficient he did generate a level of approximately 
2000 ng/ml on admission.
Only one patient was MBL insufficient with genotype XA/O. Like the children shown 
in chapter 3 (section 3.3.8) this child also did not raise his MBL level into the normal 
range despite having a substantial insult ie SIRS. Maximal increase in serum MBL are 
shown in Fig 6.14 where increases are similar, in order of magnitude, to those 
previously published (Thiel et al., 1992).
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Fig 6.13 Serial MBL levels in patients on PICU.
Data are shown for those with MBL genotype A) YAYA, B) YAXA and C) combined 
XAXA, YAO and XAO in patients with and without SIRS. In this small sample no 
significant relationship is seen between MBL genotype, the presence or not of SIRS and 
the ability to mount an acute phase response, however those with low producing 
genotypes produce lower, or no (XAO patient, graph C) responses.
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Fig 6.14 Relationship between MBL group and maximum increase in serum MBL 
level. Numbers are too small to comment on the relationship between genotype and 
maximum increment in serum MBL levels. The one child with genotype YA/O had the 
D (52) mutation associated with higher levels than normal for a heterozygote.
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B) The effect of MBL on the production of cytokines by monocytes :
6.3.11 Confirmation of cytokine detection after whole blood stimulation with LPS
Fig 6.15 demonstrates the positions o f lymphocytes, monocytes and other cells (mainly 
neutrophils) on forward and side scatter plots by FACS analysis. The monocytes were 
also identified by being the only group o f cells to be CD 14 positive (Fig 6.16). 
Demonstration that the “system” works is shown in Fig 6.17 with the production of 
TNF-a by CD 14 positive monocytes in stimulated but not unstimulated cells. IgGl PE 
controls are shown in both the stimulated and unstimulated experiments. Further 
demonstration of this is shown in Fig 6.18 where the stimulation of whole blood with 
both 1 and 50 ng of LPS resulted in significant IL lp  production by CD 14+ monocyte 
cells. The pattern of TNFa and IL-6 production was almost identical (data not shown).
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Figure 6.15 Flow cytometric profile of whole blood after lysis of red blood cells.
Anticoagulated whole blood was incubated with the appropriate monoclonal antibodies 
before lysis of red blood cells and fixation of remaining cells. The sample was then 
passed through the flow cytometer where each particle was assessed and plotted 
according to its size (forward scatter) and granularity (side scatter). Monocytes were 
recognisable as the smaller population of cells located between granulocytes and 
lymphocytes.
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Fig 6.16 Identification of monocytes as the only cells to be positive for CD14.
A) shows the flow cytometric profile o f whole blood (after lysis of red blood cells) with 
gates around each cell population. B) shows the same cells in histogram format and 
demonstrates that only the gated monocytes are CD 14 positive.
Fig 6.17 Production of TNF by monocytes after stimulation with LPS
Flow cytometer gain settings were adjusted to ensure that the negative controls were 
shown in the lower part o f the quadrant. A and B are unstimulated cells, C and D are 
stimulated with LPS. Cells positive for both CD 14 (FITC) and TNFa (PE) are clearly 
seen in the upper right quadrant (D). Staining of cells is specific for the cytokine, in this 
case TNFa, as can be seen with the PE isotype control (unstimulated A, stimulated C).
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Fig 6.18 The influence of lipopolysaccharide (LPS) on CD14+ monocyte production
of ILl-p. Whole blood was cultured with either 1 or 50 ng/ml of LPS in the presence of 
brefeldin A for 4 hours at 37°C with 5% C02. The unstimulated control was incubated 
with culture medium and brefeldin only. CD 14 surface staining followed by 
intracellular ILl-p cytokine staining was performed and cells analysed by FACS. The 
presence of LPS at both concentrations resulted in a significant production of ILl-p 
compared to the control sample. By convention 2% of the control population were 
deemed positive for the PE flurochrome (background fluorescence).
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6.3.12 The influence of MBL on IL ip , TNFa and IL-6 production by monocytes 
from an MBL deficient donor
Having demonstrated that cytokine production could be readily assessed following LPS 
stimulation in whole blood, the effect of MBL could be explored. Experiments were 
performed with an MBL deficient donor and blood stimulated with wild type and an 
isogenic mutant of N. meningitides (cpD-). Fig 6.19 A and B demonstrates that both 
of these organisms stimulate cytokine production. The introduction of MBL into the 
system alone did not induce cytokine production (ie MBL was not contaminated by eg 
LPS). The addition of MBL at 5 different concentrations (0,2,4,6 and 8 pg/ml) did not 
show any consistent effect, by FACS analysis (Fig 6.19) or ELISA (Fig 6.20), of MBL 
on the 3 cytokines, IL1(3, IL-6 and TNFa., investigated.
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Fig 6.19 The influence of MBL on ILlp, TNFa and IL-6 production by monocytes 
from an MBL deficient donor: analysis by flow cytometry. No significant difference 
was seen in cytokine production in the presence of varying concentrations of MBL.
MFI = median fluorescent intensity
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Fig 6.20 The influence of MBL on ILlp, TNFa and IL-6 production by monocytes 
from an MBL deficient donor: analysis by ELISA. No clear pattern of the effect of 
MBL was seen for either the wild type or gal E mutant of H4476.
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6.3.13 Changes made to the “cytokine system”
Looking more closely at the experiments published by Jack et al and my own revealed a 
number of differences in our systems. Essentially Jack et al had used different 
organisms and their respective mutants (TV. meningitidis B 1940 instead of Type B 
H44/76), different MBL donors with different polymorphisms and different 
anticoagulants (citrate as opposed to heparin used here). Previously published work has 
demonstrated that bacterial survival is markedly increased in citrated blood compared to 
heparinised blood, although this was mainly for the Type A meningococcus (Ison et al., 
1995).
In order to determine if any of these factors contributed to the difference in findings 
from that reported by Jack et al, experiments were repeated using a different MBL 
deficient donor, citrate as the anticoagulant and N.meningitidis B 1940. Prior to 
performing these experiments MBL was shown to bind to both the wild type and 
isogenic mutant of H77/46 and B1940 (Fig 6.21) and showed that indeed B1940 bound 
more MBL than the H44/76 organism. In this latter experiment three concentrations of 
MBL (0,1,8 pg/ml) were used and 2 cytokines assessed; IL ip  and IL-6 (Figure 6.22).
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Fig 6.21 MBL binding to the wild type and gal E isogenic mutant of meningococci H 7746 and B 1940.
The top two histograms are wild type organisms and the bottom two are the gal E isogenic mutants. The percentage of cells positive 
for FITC are shown in red. By convention the negative control in each case, i.e. without MBL, was set at 2%. The histograms 
demonstate that MBL binds more to the gal E than WT for each organism and that indeed B1940 does bind MBL more than H7644.
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Fig 6.22 The influence of MBL on A) ILip and B) IL-6 production by monocytes 
after stimulation with a different organism, B1960 meninogcoccus. Whole blood 
was preincubated with or without MBL and then stimulated with either WT B1940 
meningococcus or an isogenic mutant, gal E. There was no significant increase in 
median fluorescent intensity (MFI) of the unstimulated cells with MBL compared to 
those without MBL. The addition of lpg/mL MBL showed a small increase in ILlp and 
IL-6 which was abrogated by 8pg/mL MBL. This was seen in the wild type organism 
only.
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6.4 Discussion
Data from this chapter, the only study to date looking at the effect of MBL in critically 
ill children, demonstrates that MBL genetic polymorphisms and reduced serum levels 
are associated with the development o f the severe inflammatory response syndrome 
(SIRS) and a more severe systemic response to infection within 48 hours of presentation 
to PICU.
Specifically the development o f SIRS was independent of the patient’s underlying 
condition, age, sex or ethnicity although the association was strongest in those with an 
infective aetiology. The importance o f MBL genotype in the development of SIRS is 
underlined by the observation that possession of the wildtype MBL haplotype is 
associated with an approximate 50% reduction in the risk of SIRS with 42% of those 
with genotype YA/YA developing SIRS compared to 100% of those with genotype 
O/O.
It is known that there is an effect o f age on MBL serum levels in health. Levels increase 
from 500 ng/ml at 25 weeks gestation to normal adult levels by 20 weeks post full-term 
(Lau et al., 1995) and then seem to stay approximately the same from the 2nd until the 
4th decade when a decline commences (Ip et al., 2004). In disease states the effect of age 
on MBL serum levels is not known and therefore this data also provides evidence that 
even young babies can generate MBL levels of up to 9000 ng/ml in certain 
circumstances such as critical illness. No sex differences in MBL levels have been 
described. MBL variant alleles are known to occur at different frequencies in different 
populations (see Introduction section 1.4.4) but surprisingly non-caucasians (self stated) 
were not overrepresented in those with MBL variant alleles. Despite the high non- 
Caucasian component (30%) o f this cohort, due to the central London location and 
overseas referral patterns, ethnicity was not found to be associated with development of
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SIRS or severity o f sepsis suggesting no other ethnicity related factor was a 
confounding variable in the link between MBL deficiency and SIRS.
Whilst this present study was under review for publication (Fidler et al., 2004), Garred 
and colleagues in Denmark published a similar study on the role of MBL in critical 
illness in adults (Garred and Madsen, 2004). 272 adult Danish Caucasian intensive care 
patients with SIRS were compared to a control group of 190 blood donors and 60 
hospital staff. The frequency of MBL variants in both groups was similar. However, 
there were significantly more MBL variant alleles in the infection-related reason for 
admission group when compared to the non-infectious reasons for admission. The 
severity of sepsis was linearly related to the frequency o f MBL variant alleles (and 
inversely related to serum MBL levels) and the risk o f mortality rose with the number of 
MBL variant alleles, homozygotes had a 2.3 relative risk (C.I. 1.19-4.48) for in-hospital 
death compared to wild-type. Considering the differences in the patients studied, there 
is remarkable concordance between the essential findings presented here and those of 
the Danish group. Both studies show an increasing over-representation of variant MBL 
alleles with increased severity o f sepsis, although the ratio of WT/variant alleles is more 
dramatic in children. The results presented in this chapter show a strong relationship 
between MBL variants and the development of SIRS in the first 48 hours on ICU. These 
findings contrast with the Danish study in which MBL variants occurred with the same 
frequency amongst SIRS patients admitted to the ICU and healthy controls. Several 
possible explanations exist for these differences. This study is capturing the risk of 
developing early SIRS whilst fully supported on intensive care -  which will include 
more cases than those with established SIRS on admission. The difference might also 
reflect the stringent criteria applied for a diagnosis of SIRS (with exclusion of the 
respiratory rate as a criterion), or differences between the control populations in the two
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studies (here ICU cases without SIRS and in the Danish study healthy blood donors and 
laboratory staff). A remaining possibility is that these findings may reflect differences 
in the pathogenesis o f critical illness between children and adults. One example of this 
is the high proportion o f critically ill children who have no major pre-existing morbidity 
- a situation that will have been refined by our exclusion criteria. In contrast, the adult 
study reflects a typical pattern with the majority of cases having very significant pre­
morbidity. There may also be differences in the referral patterns to ICU between 
children and adults with children being admitted earlier in the course of their illness. 
Finally, perhaps children and adults also differ in the contribution of the various 
mechanisms leading to organ dysfunction in SIRS. For example, MBL deficiency is 
known to be protective against ischaemia-reperfusion injury which may play a greater 
role in adults (Jordan et al., 2001). The Danish study also demonstrated an increased 
risk of death with MBL variants and SIRS. This could not be directly investigated in the 
paediatric cohort because o f the low numbers of deaths.
In 2005 Sutherland and collegues also confirmed the association between MBL 
deficiency (and other innate immunity polymorphisms in CD 14, and Toll Like Receptor 
-2) and an increased prevalence o f positive blood cultures and sepsis in a cohort of adult 
Caucasian patients admitted to a mixed intensive care unit (Sutherland et al., 2005). In 
this study no association was seen with septic shock or risk of death. Again, differences 
in case mix may be important. Lastly 174 white adult patients with severe sepsis or 
septic shock were recruited in a prospective multicenter study across eight intensive 
care units in the South o f England, UK. Genotype and haplotype frequencies were 
compared between normal population controls and patients, and between survivors and 
nonsurvivors. MBL polymorphisms (A/O or O/O) were significantly more common in
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the patients with severe sepsis and septic shock than in normal healthy adults (54.6% vs. 
39.7%, P = 0.001) (Gordon et al., 2006).
All of these studies lend support to the findings presented in this chapter that MBL 
deficiency does indeed increase the risk o f SIRS or severe sepsis in paediatric patients 
admitted to intensive care.
A key question is whether MBL deficiency modulates the initial insult, the subsequent 
response to this insult or both. For example MBL deficiency seems to increase 
susceptibility to infection (Summerfield et al., 1997) but could also alter the host’s 
response to micro-organisms and/or microbial products, potentially increasing the 
severity of illness. MBL deficiency could also have an effect on the development of 
SIRS remote from the primary insult. A central observation from this study points 
towards the latter as the likely explanation as a similar effect exists in trauma and post­
operative cases when the role of MBL in opsonophagocytosis would appear to be of 
little consequence compared to the infection cases.
The reason for the observed effect o f MBL on the development of SIRS remains 
unclear. It is thought that the principal role o f MBL is to activate complement and this 
can occur even in the presence o f an otherwise intact complement system (Brandtzaeg 
et al., 1996). The role o f complement in critically ill patients is complex. Complement 
activation invariably occurs in patients with sepsis and following major surgery. For 
example, Brandtzaeg and colleagues have demonstrated marked complement activation 
in patients with meningococcal sepsis (Brandtzaeg et al., 1996). There are numerous 
pathways by which complement activation can lead to enhanced inflammation and 
therefore one might postulate that in fact a low MBL level may actually be beneficial as 
it may reduce inflammation and the development of SIRS. However a novel mechanism 
by which MBL could influence the development of SIRS is through a direct effect on
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pro-inflammatory cytokine production. In a human whole blood model, high levels of 
MBL were observed to inhibit TN Fa, IL-6 and IL -ip  release from monocytes (Jack et 
al., 2001b). It is assumed that in this case MBL is operating through a receptor 
expressed, but as yet unidentified, on monocytes. MBL levels in patients presented in 
this chapter and those observed in the Danish study, were in a range which has been 
shown to inhibit cytokine production in vitro (Jack et al., 2001b).
Sprong et al have recently shown that low levels of binding, below the detection limits 
of conventional flow cytometric techniques, were still sufficient to modulate the 
inflammatory response. This involved a different model whereby human peripheral 
blood mononuclear cells (PBM C’s) were stimulated with lipopolysaccahride (LPS) + or 
LPS- meningococci in a system with no exogenous complement. Here only lower 
concentrations o f MBL were used (0.75-2500 ng/ml), different cytokines were assessed 
(IL-ip, IL- 6, IL-10, TNF-a and IFN-y) and different results were obtained. The main 
findings were that MBL (<2500 ng/ml) significantly augmented IL-1 p production after 
stimulation with both LPS+ and LPS- meningococci in a dose dependent fashion and 
also enhanced IL-10 production by LPS- meningococci. In contrast the production of 
IL- 6, TNF-a and IFN-y was unaffected. Thus, even in the presence of pathogens to 
which the protein is thought to bind poorly, there may be a significant effect on 
inflammation, an often integral part o f the disease process.
Whatever the mechanism underlying the influence of MBL on the severity of sepsis and 
the development of SIRS, this observation could prove to be clinically important. 
Firstly, considerable effort is currently being invested in analyses of risk stratification to 
identify patients likely to have the most severe patterns of illness. As this study 
indicates, it is possible to evaluate the host MBL status by partial genotyping (i.e. 
structural gene variants alone, Fig 6.1 A), extended genotyping (to include the X/Y
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promoter variant, Fig 6 .IB) or by phenotypic assays of MBL protein levels (Fig 6.9). 
All three approaches showed remarkable concordance, therefore a simple serum test 
may provide an indicator o f susceptibility to the development of SIRS. MBL is 
currently being prepared for clinical use and has been used in one patient with Cystic 
Fibrosis and end stage lung disease (Garred et al., 2002). We need to understand more 
clearly the costs and benefits o f such therapy during specific episodes of critical illness 
but this study raises the possibility that judicious use of MBL in MBL deficient patients 
may lead to a reduction in the number that develop SIRS or severe sepsis/ septic shock.
This study provides data that contributes to the insight into the pathogenesis of SIRS & 
sepsis and may provide a novel therapeutic avenue for the treatment of critically ill 
children.
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CHAPTER 7
The effect of cytokine polym orphism s and endotoxin  
antibodies on the role o f M BL in inflammation
7.1 Introduction
Work presented in the previous chapter (chapter 6) has demonstrated the association 
between MBL deficiency, at both a genotypic and phenotypic level, with the 
development of SIRS and an increased severity of sepsis.
Gene association studies have to be regarded with caution due to a multitude of false 
positive associations (Sutherland & Russell 2005). These include linkage disequilibrium 
with an unknown candidate gene and confounding variables such as ethnic differences 
in both genotype frequencies and disease prevalence such that they are linked 
independently of the polymorphism. Despite these limitations, genetic associations that 
are found in large numbers and are repeatable in different situations are likely to provide 
clinicians with potential tools for the early assessment of risk in specific patient groups. 
This may allow more accurate prognosis, early intervention and treatment of high risk 
individuals and better analysis of risk benefit effects for low risk patients.
Genetic Polymorphisms
Over the last decade many studies have found associations between polymorphisms in 
genes that control levels o f proteins in the innate immune system, and susceptibility to, 
and severity of, critical illness. However results from these studies are complex. It is 
likely that it is the combined effect of many of these polymorphisms that will ultimately
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determine the host’s response to an inflammatory challenge. Additionally the actual 
serum level of a protein or cytokine, and the timing of various responses at different 
points in the illness, may well be critical (Waage et al. 1989). This is highlighted in a 
recent study where the A allele o f the IL-10 -1082 promoter polymorphisms was 
associated with susceptibility to severe sepsis, but once sepsis was established then 
presence of the G allele was associated with higher IL-10 levels and mortality 
(Stanilova et al., 2006).
Analysis of this published literature identified a number of key serum factors that may 
play a role in an individual’s susceptibility to the development of SIRS and severe 
sepsis. These include polymorphisms in the tumour necrosis factor alpha (TNF-a), 
interleukin-6 (IL-6), interleukin 10 (IL-10), angiotensin converting enzyme (ACE) and 
plasma activator inhibitor 1 (PA l-1) genes as well as antibodies to endotoxin.
Tumour necrosis factor- alpha
TNF-a is an important cytokine associated with the development of systemic 
inflammation. High circulating levels have been associated with greater mortality rates 
in sepsis (Damas et al. 1989;Debets et al. 1989;Nadel et al. 1996). The gene encoding 
TNF-a is found within the MHC on chromosome 6. A polymorphism at position -308 in 
the promoter region of this gene has been identified, in which a G in the common allele 
is substituted for an A in the uncommon allele (found in approximately 30% of the 
Caucasian population). Although there are some conflicting studies, it seems overall, 
that the A allele is associated with higher constitutive and inducible TNF-a levels. This 
may be associated with adverse outcomes (Holmes et al., 2003) (Nadel, et al., 1996).
Interleukin-6
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IL-6 is another pro-inflammatory cytokine with a short systemic half life, levels of 
which are also regulated by a number of factors, the most important of which is a 
polymorphism at position -174 in the promoter region where a single nucleotide G is 
substituted for a C. Higher levels o f IL-6 have been associated with severity of sepsis 
and levels above 1000 pg/ml have been associated with increased mortality (Damas et 
al., 1992). Conflict in the literature relates to which allele causes the highest levels of 
IL-6, which may be age or disease related. In newborns the CC genotype was associated 
with higher IL-6 levels but no effect was seen in healthy patients (Kilpinen et al., 2001). 
In adults with abdominal aortic aneurysms, again the CC genotype was associated with 
higher levels (Jones et al., 2001). However other studies looking at patients post-cardiac 
bypass have found higher levels associated with the GG genotype (Burzotta et al., 2001) 
and in the patient group most similar to that described in this chapter (post-operative 
children on cardiac intensive care at GOSH) the GG genotype was associated with 
highest IL-6 levels (Allen M.L. personal communication).
Interleukin-10
IL-10 is an anti-inflammatory cytokine, levels of which may be critical in the 
modulation of the pro-inflammatory / anti-inflammatory balance. An excess of IL-10 
however has been reported to induce immunosuppression in patients with sepsis, 
inflammation or post- cardiac surgery (Allen et al., 2006; Gomez-Jimenez et al., 1995; 
Lyons et al., 1997). Inter-individual differences in IL-10 levels are thought to be due to 
a number of polymorphisms in the promoter region of the IL-10 gene which is found on 
chromosome 1. These include nucleotide substitutions at positions -1082 (A/G), -819 
(C/T) and -592 (C/A) of which -1082 has been the one most associated with severity of 
infection (Schaaf et al. 2003;Shu et al. 2003) and therefore chosen for study here.
Plasminogen Activator Inhibitor-1
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Plasminogen Activator Inhibitor 1 (PAI-1) is released from endothelial and liver cells 
and inhibits plasminogen activators thus inhibiting fibrinolysis. High levels of PAI-1 
thus result in a pro-thrombotic tendency, which may be detrimental in certain conditions 
such as sepsis and SIRS which may also have a pro-thrombotic potential. A 
polymorphism in the promoter region o f PAI-1, involving an insertion or deletion of a 
guanine (G) base, has been described where possession of the 4 G allele results in 6 
times the production of PAI-1. The 4 G allele has been associated with severity of 
disease outcome in severely injured patients (Menges et al. 2001) and in sepsis, 
specifically meningococcal sepsis (Haralambous et al. 2003; Komelisse et al. 1996; 
Menges et al., 2001).
Angiotensin converting enzyme
Increased activity o f the renin-angiotensin systems in human tissue drives a pro- 
inflammatory response (Weber et al. 2003). In such systems angiotensin converting 
enzyme (ACE) is not only an important enzyme for the generation of angiotensin II 
from angiotensin I but also degrades bradykinin. Both these molecules have been shown 
to have many cellular effects (Marshall et al. 2002). ACE inhibitors reduce the IL-6 
response after coronary artery bypass graft surgery (CABG) and myocardial cell 
dysfunction (cardiac failure) (AIRE Study Investigators 1993) and are one of the ways 
in which this medication could be operating. It could be postulated therefore that low 
ACE levels could also confer an anti-inflammatory state. ACE is encoded by one of two 
variants of the ACE gene. One carries an insertion of 287 base pairs and is termed “I”, 
the other does not and is called “D”. The longer I allele is associated with lower enzyme 
activity which is beneficial in a number of circumstances. A number of studies have 
shown that presence of the I allele is associated with enhanced endurance performance 
to intense exercise (Woods, et al., 2000) and enhanced mechanical efficiency in trained
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muscle (Montgomery et al., 1997). The high expressing DD genotype however has been 
associated with a number o f adverse outcomes. Marshall et al found that patients on 
ITU with the DD genotype were significantly more likely to develop ARDS compared 
to those without DD and this genotype was significantly associated with mortality in the 
ARDS group (Marshall et al., 2002). The DD genotype has also been associated with a 
higher Paediatric Risk o f mortality (PIM) score, higher Glasgow Meningococcal 
Septicaemia Prognostic Score (GMSPS) and severity of illness in a paediatric cohort 
with meningococcal disease (Harding et al., 2002).
Endotoxin
Endotoxin, found in the outer membrane of gram-negative bacteria, is an important 
trigger of SIRS. With co-factors including CD 14 and lipopolysaccharide binding protein 
(LBP), endotoxin binds to Toll-like receptor 4 (TLR-4), one of a family of 
transmembrane proteins expressed on key cells including macrophages, endothelial cells 
and neutrophils. TLR-4 recognises ‘pathogen-associated molecular patterns’ a key event 
in the innate immune response (Stephens & Mythen 2000). TLR-4 stimulation initiates 
a complex series o f intra-cellular signalling events (involving MyD88, IRAK, TRAF6, 
and NF-kB) resulting in the production o f pro-inflammatory mediators including 
cytokines and adhesion molecules. Experimentally endotoxin can initiate a systemic 
inflammatory response and is found in large quantities in the colonized human gut 
(Suffredini et al., 1999). Critically ill patients, as well as those undergoing surgery, may 
be exposed to endotoxin from leakage into the systemic circulation via an impaired 
gastrointestinal barrier, gram-negative infection or as a result o f bowel manipulation 
during surgery.
All adult humans have antibodies directed against the core of endotoxin (EndoCAb) 
although observed levels vary within populations by more than eighty-fold (Stephens &
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My then 2000). IgG EndoCAb is present at birth, and is probably maternal in origin 
(trans-placentally acquired). IgM EndoCAb is almost absent in the first month but 
increases to approximately adult levels by a year (Oppenheim et al., 1994). In adults, 
higher pre-operative levels of IgM EndoCAb are associated with a good outcome 
following surgery, whilst higher IgG EndoCAb levels have been linked to survival in 
sepsis (Bennett-Guerrero et al., 2001b; Bennett-Guerrero et al., 2001a; Goldie et al., 
1995; Strutz et al., 1999). It is not known if  this is a causal association with EndoCAb 
acting to modulate systemic inflammation, or if  high EndoCAb titres are simply a 
consequence of a favourable immune state in patients at risk o f systemic inflammation.
The aims of this part of my work were:
1) to investigate whether children who develop SIRS or severe sepsis in their initial 
period on ICU have lower levels o f antibodies to endotoxin core,
2) to determine whether polymorphisms in one of the genes for TNF-a, IL-6, IL-10, 
angiotensin converting enzyme (ACE) and plasma activator inhibitor 1 (PAI-1) may 
also play a role in the development o f SIRS and
3) to determine if the association observed in chapter 6 that MBL-2 polymorphisms are 
associated with the development o f SIRS and/or sepsis is confounded or influenced by 
these other key polymorphisms and/or antibodies to endotoxin core?
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7.2 Methods
7.2.1 Patient Selection
These patients are the same as those in the previous chapter- see section 6.2.1
7.2.2 Consent & recruitment, ethical approval, blood sample processing
These patients are the same as those in the previous chapter- see section 6.2.2-6.2.5.
Blood serum samples were initially divided thus allowing a second sample for EndoCab 
analysis which had had remained frozen or had at most one thaw/refreeze.
7.2.3 EndoCAb ELISA
Polystyrene microplates (pre-coated with an equimolar mixture of incomplete core, 
rough, mutant endotoxins from each o f four species of gram-negative bacteria 
complexed with polymyxin B were used to measure IgM and IgG EndoCAb 
concentrations using an enzyme-linked immunosorbent assay described previously 
(Barclay & Scott 1987). An eight-point standard curve was constructed using doubling 
dilutions of a pooled-serum calibrated in EndoCAb median units, where 100 is the 
median value for 1,000 healthy adults’ immunoglobulin G or immunoglobulin M, 
respectively. Test and control samples were diluted 1:200 with dilution buffer and 100 
pL of each sample to be assayed added in duplicate to the pre-coated plate and 
incubated for 1 h at 37°C. After washing 3 times with wash buffer (sodium chloride, 
0.138 M; phosphate, 0.01 M; pH 7.4 containing 0.10% [v/v] polyoxyethylene sorbitan 
monolaurate), 100 pL o f a diluted alkaline phosphatase conjugated goat antihuman IgG 
or IgM antibody (Sigma-Aldrich Chemical Co; Poole, UK) was added to each well. 
After incubation for 1 h at 37°C the plates were washed three times with wash buffer 
then once with distilled water, and blotted dry. Substrate (180 pL per well), comprising
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1 mg/mL disodium p-nitrophenyl phosphate dissolved in 1 M Diethanolamine buffer 
with 0.5mM magnesium chloride, was added and the plate incubated at room 
temperature in the dark for 20-30 minutes. The reaction was stopped with 50pL per well 
of 2M Sodium hydroxide and read at 405-nm wavelength with an automated plate 
reader (Dynatech MRX, Virginia, USA). Results from the whole plate were rejected and 
repeated if predetermined characteristics were not met, specifically if  the optical density 
reading was not on a specific part of the standard curve or if the coefficient of variation 
between readings was greater than 10%.
7.2.4 Polymerase chain reaction (PCR) of e genes for TNF-a, IL-6, IL-10, ACE and 
PAI-1
7.2.4.1 Preparation of DNA
DNA was extracted previously as part of the MBL study (see chapter 2.3.3.1). To 
minimize the risk o f contamination of stock DNA and facilitate a high throughput, 
arrays were created o f two 96 well plates, each well containing 25pl/well. Each array 
was clearly labelled and had a corresponding grid sheet listing samples by study number 
within an 8x12 grid (Fig 7.1).
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1 2 3 4 5 6 7 8 9 10 11 12
A 1 9 17 25 33 41 49 57 65 73 81 89
B 2 10 18 26 34 42 50 58 66 74 82 90
C 3 11 19 27 35 43 51 59 67 75 83 91
D 4 12 20 28 36 44 52 60 68 76 84 92
E 5 13 21 29 37 45 53 61 69 77 85 l’(
F 6 14 22 30 38 46 54 62 70 78 86 Blank
G 7 15 23 31 39 47 55 63 71 79 87 Blank
H 8 16 24 32 40 48 56 64 72 80 88 Blank
Fig 7.1 An example of a standard array grid sheet. Each plate contained at least 3 
blanks (negative controls) and space for a positive control (PC). 2 array plates were 
made for the 142 patients. Each number corresponded to an individual patient.
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7.2.4.2 Preparation of samples for PCR
Working arrays were defrosted and centrifuged at 1450g for 1 minute. This minimised 
DNA loss or cross-well contamination on removal of the array lid. Two microlitres of 
each DNA sample was removed and transferred into a 96-well polycarbonated PCR 
plate using a multichannel Finnipipette. Positive and negative controls were used in 
each array to ensure accuracy. Extreme care was taken to ensure that samples were 
placed in the identical orientation as in the original array. Loaded PCR plates were then 
centrifuged at 160g for 1 minute to ensure the DNA was at the bottom of each well, 
before drying on a Thermal Cycler block at 80°C for 10 minutes.
Polymerase chain reactions were performed in a total volume o f 20pl. Each reaction 
was prepared on ice and contained lx  concentration o f polmix (50mM KC1, lOmM 
Tris-HCl (pH 8.3), 0.2mM dATP, dGTP, dTTP and dCTP), 1.5-2.5mM MgCl2, 600- 
lOOOpmol of forward and reverse primers, and 25-30 units o f Taq polymerase. The 
concentration of each had been optimised prior to the initiation of this work.
The PCR mix was added to each well o f the PCR plate using an automatic repeating 
dispenser. Each sample was overlaid with 20pl of paraffin oil to prevent evaporation. 
PCR amplification was performed on an MJ Tetrad DNA engine Thermocycler, using 
cycle conditions specific to each PCR. Presence of product was confirmed on a 2% 
agarose gel stained with ethidium bromide. PCR cycle conditions for each 
polymorphism are shown in Table 7.1. Primer pairs to amplify the appropriate region of 
interest were obtained from the literature and were kindly provided by Dr Paul 
Kotwinski (shown in Table 7.2).
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Polymorphism Step 1 
denature
Step 2 Step 3 Step 4 No. of 
cycles 
(steps 2-4)
Termination
step
IL-6 -174 95°C 95°C 50°C 72°C 35 cycles 72°C
G/C 4 min 40 sec 30 sec 1.5 min 5 min
IL-10 -1082 95°C 95°C 59.8°C 72°C 30 cycles 72°C
G/A 5 min 45 sec 45 sec 45 sec 10 min
TNF-a -308 95°C 95°C 57°C 72°C 30 cycles 72°C
G/A 5 min 45 sec 45 sec 45 sec 10 min
ACE 95°C 95°C 54 °C 72°C 35 cycles 72°C
D/I 5 min 45 sec 45 sec 30 sec 5 min
PAI 1 -675 95°C 95°C 60 °C 72°C 30 cycles 72°C
4G/5G 5 min 30 sec 30 sec 30 sec 2 min
Table 7.1 PCR cycle conditions for each polymorphism
PCR’s for each of the 5 polymorphisms were carried out separately.
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Polymorphism Oligonucleotide Sequence 5 ’-3’ 
(Forward / Reverse)
IL-6 -174 
G/C
5’-TGA CTT CAG CTT TAC TCT TGT-3’ 
5’-CTG ATT GGA AAC CTT ATT A AG-3’
IL-10 -1082 
G/A
5’-AAT CCA AGA CAA CAC TAC TAA GGC-3’ 
5’-CTG GAT AGG AGG TCC CTT AC-3’
TNF-a -308 
G/A
5'-GGC CAC TGA CTG ATT TGT GTG T-3' 
5'-CAA AAG AAA TGG AGG CAA TAG GTT-3'
ACE
D/I
5’- CAT CCT TTC TCC CAT TTC TC-3 
5’- ATT TCA GAG CTG GAA TAA A AT T-3’
PAI 1 -675 
4G/5G
5 ’CAC AGAGAGAGTCTGGCCACGT 
5 ’CCAAC AGAGGACTCTTGGTCT
Table 7.2 Primer pairs for amplification of DNA
Forward and reverse primers are detailed for each of the polymorphisms detected.
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7.2.4.3 Restriction Enzyme Digest
Restriction enzymes are enzymes derived from bacteria that will cleave double stranded 
DNA at a particular sequence. The restriction enzyme is sensitive even to a single base 
change in the recognition sequence, and thus can be used to detect point mutations and 
single base polymorphisms. A single base change, such as those seen in the promoter 
polymorphisms studied, eliminate or create a cutting site for the restriction enzyme.
Following generation of the PCR product, a restriction enzyme digest mix was made 
containing sufficient enzyme to digest the PCR product. 8-10pl o f PCR product was 
added to 5 pi of digest mix in a 96-well microtiter plate, and the plate centrifuged at 
21 Og for 1 minute. The PCR/digest mix was incubated for a minimum of 4 hours at a 
temperature appropriate for the specific enzyme used (Table 7.3).
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Polymorphism Restriction
Enzyme
Manufacturer Temperature 
of digest
Fragments
generated
(base pairs =bp)
IL-6 -174 G/C Nla III New England 
Biolabs
37°C G -  190 bp 
C -  143 /4 7  bp
IL-10 -1082 
G/A
EcoNl New England 
Biolabs
37°C G - 253 /9 7 /2 7  bp 
A -  280 / 97 bp
TNF-a -308 
G/A
Ncol 1 New England 
Biolabs
37°C G - 2 1 0 /2 3 /2 0  bp 
A -  233 / 20 bp
ACE
D/I
Bsl 1 New England 
Biolabs
37°C I 65bp 
D 85bp
PAI 1 -675 
4G/5G
Bsl 1 New England 
Biolabs
55 °C -675 4G uncut 
98bp
-675 5G cuts to 
77+22bp
Table 7.3 Details of Restriction Digests
The details of the specific restriction enzyme and optimal temperature for digest are 
outlined for each cytokine polymorphism. The size of fragments generated are 
tabulated in the last column.
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7.2.5 Microtitre Array Diagonal Gel Electrophoresis (MADGE)
Following PCR and restriction digest, identification o f various polymorphisms was 
conducted. Detection of the promoter polymorphism for IL-6 -174 (G/C) had been 
previously established using Microtitre Array Diagonal Gel Electrophoresis (MADGE) 
by the Cardiovascular Genetic laboratory at The Rayne Institute, University College 
London (Brull et al. 2001;Fishman et al. 1998). This technique had then been optimised 
and extended for the detection o f the IL-10 -1082 (G/A), TNF-a -308 (G/A), ACE and 
PAI 1 promoter polymorphisms prior to the onset o f this study (see acknowledgements 
section).
Using a 96 diagonal well polyacrylamide gel, with a horizontal current allowed 96 
sample to be run on the same gel. For example for IL-10 -1082 the following procedure 
was performed (as shown in Fig 7.2 & 7.3). Following digestion with EcoNl overnight 
at 37°C, 5pl of the PCR product was added to 2pl of formamide dye and loaded onto a 
7.5% polyacrylamide gel. The gel was electrophoresed at 100V to separate digest 
products and visualised using UVP Gel Documentation System. The digestion enzyme 
EcoNl cuts the PCR product 3 times if guanine is present at the -308 position, but only 
twice if there has been a base change to adenine. Other polymorphisms were run in a 
similar manner.
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GG -  3 fragments 
253/97 /27  bp
G A - 4 fragments 
280 /253 /97 /27
A A -2  fragments 
280/97 bp
Fig. 7.2 M icrotitre A rray  Diagonal Gel Electrophoresis (MADGE) for IL-10 (- 
1082 G/A) prom oter polym orphism . Following digestion with EcoNl overnight at 
37°C, 5pl of the PCR product was added to 2pl of formamide dye and loaded onto a 
7.5% polyacrylamide gel. The gel was electrophoresed at 100V to separate digest 
products and visualised using UVP Gel Documentation System. The digestion enzyme 
EcoNl cuts the PCR product 3 times if guanine is present at the -308 position, but only 
twice if there has been a base change to adenine. (Gel reproduced with permission from 
Dr Meredith Allen).
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The investigators performing the MBL genotype and serum levels, the cytokine 
genotypes and the EndoCAb ELISAs were blinded to the diagnosis of SIRS/non SIRS. 
Likewise the clinician who acquired the clinical data did so before the results were 
analysed and was therefore also blinded to the outcome.
7.2.6 Statistical analysis
Comparisons of the proportions o f different MBL, TNF-a, IL-6 and IL-10, PAI 1 and 
ACE genotypes between clinical groups were performed using Chi square tests. 
Multiple and binary logistic regression were used to investigate the association of SIRS 
and sepsis with MBL serum level & MBL genotype after adjustment for TNF-a, IL-6, 
IL-10, PAI 1 and ACE genotypes and differences in age, sex and ethnicity.
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7.3 Results
7.3.1 The effect of MBL on the development of SIRS is not affected by endotoxin 
immunity
ELISA s for IgM and IgG endotoxin core antibodies (EndoCab) were performed on all 
139 serum samples. 71/139 samples were from children admitted without infection and 
68/139 from children with infection. Patient demographics were the same as shown for 
MBL (section 6.3.1). In the unselected cases (n=139), there was a non-significant trend 
towards lower IgG EndoCAb levels in those patients who had early SIRS, but this did 
not reach significance; (SIRS median: 99 MU/ml, IQR 44-198 vs Non-SIRS 119 
MU/ml, 59-229; p=0.215). There was no difference in the IgM levels between the two 
groups (87 MU/ml, 44-152 vs 86 MU/ml, 45-189 p=0.588).
In those children without infection, IgG EndoCAb levels were significantly lower in 
those children developing SIRS (p=0.009 Mann-Whitney U) but there was no difference 
in IgM EndoCAb levels between the two groups (p=0.829 Mann Whitney U) (Fig 7.3
A) The likelihood ratio for development of SIRS if  the IgG EndoCAb was below 57 
MU/ml is 3.65 (95% confidence interval 1.48-8.9) compared to those patients with an 
IgG EndoCAb above 57 MU/ml. O f the potential confounding variables considered 
(age, sex, ethnicity, CRP & MBL) only MBL level was significantly associated with the 
development of SIRS on univariate analysis. After binary logistic regression analysis 
with correction for the effects o f age, sex, CRP & MBL, Logio IgG EndoCAb remained 
independently associated with the development of SIRS in this population. Likewise, 
following logistic regression analysis, accounting for the above factors, low producing 
MBL-2 exon 1 genotypes remained significantly and independently associated with the 
development of SIRS (p=0.0003).
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In those children admitted with infection there were no significant differences in IgG or 
IgM EndoCAb levels between those children developing SIRS and those not (110 vs 80 
MU/ml; p=0.523 and 60 vs 83 p=.906 respectively, Fig 7.3 B). There was also no 
significant difference in the serum IgM & IgG EndoCAb levels in patients who had 
increasing severity o f infection (localized infection vs sepsis vs septic shock, p=0.4 
ANOVA test for both EndoCAb IgG & IgM (data not shown). O f the potential 
confounding variables (age, sex, ethnicity, CRP & MBL) only low MBL levels were 
associated with the development o f SIRS in this group (p<0.0001, Mann Whitney U) as 
previously reported.
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Fig. 7.3 Relationship of IgG and IgM EndoCAb to SIRS.
IgG (left two columns) and IgM (right two columns) EndoCAb serum levels are shown 
for A) 7 1 non-infected patients and B) 68 infected patients according to whether they 
did or did not develop SIRS in the first 48 hours following admission to PICU. In the 
non-infected patients (A) there was a significant difference in IgG EndoCAb between 
patients with and without SIRS (p = 0.009, Mann-Whitney U test).
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7.3.2 The effect of MBL on the development of SIRS is not affected by TNF-a, IL- 
6, IL-10, PAI 1, or ACE polymorphisms.
140 of the original 142 samples were successfully genotyped for TNF-a, IL-6, IL-10, 
plasma activator inhibitor 1 (PAI 1) and ACE promoter polymorphisms. The two 
samples that failed did not amplify by PCR for any of the polymorphisms.
Table 7.4 shows the observed and expected frequencies of all genotypes performed. All 
were in Hardy-Weinberg equilibrium. Observed genotypes did not differ significantly 
from those expected, apart from IL-6, where a significantly smaller number of patients 
than expected possessed the CC genotype and a larger number possessed the GG 
genotype.
Table 7.5 shows the presence of SIRS in all patients, and in those with a non-infective 
or infective cause for their admission. From this it can be seen that MBL deficient 
genotypes remains significantly associated with the development of SIRS in all groups. 
This relationship remained following logistic regression analysis, accounting for the 
above 5 polymorphisms, age, sex and race. Interestingly in this paediatric PICU 
population low IL-10 producers (genotype AA) and high IL-6 producers (genotype GG) 
were also overrepresented in those patients developing SIRS after a non infectious 
insult only, (p=0.046 and 0.0018 respectively). Following binary regression analyses 
these relationships were found to be present but independent of the MBL effect.
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Genotype Predicted frequency (%)
Observed 
frequency (%) in 
PICU group 
(n=140)
Significant or non 
significant 
difference in 
predicted and 
observed 
frequencies
MBL1
A/A (high) 59-62.8 64.3 n/s
A/O (intermediate) 34.4-35.8 34.3 n/s
O/O (low) 2.8-4.6 1.43 n/s
A/O & OO 37.2-40.4 35.7 n/s
TNFa -308 2
A/A (high) 1-16 5 n/s
G/A (intermediate) 16-40 26.4 n/s
G/G (low) 57-84 68.6 n/s
IL6 -1743
G/G (high) 31.8 -36 53.6
G/C (intermediate) 45.4-50.8 40.7 p<0.01
C/C (low) 18.5-31.8 5.7
IL10 -10824
G/G (high) 17-21.3 16.4 n/s
G/A (intermediate) 41.2-60 45 n/s
A/A (low) 23-37.5 38.6 n/s
ACE5
D/D (high) 24.1 22.9 n/s
I/D (intermediate) 51.5 47.9 n/s
I/I (low) 24.4 29.3 n/s
PAI l 6
4G/4G (high) 31-41 27.1 n/s
4G/5G 44-47.7 45 n/s
(intermediate)
5G/5G (low) 16-21.3 27.9 n/s
Table 7.4 Frequency of expected and observed genotypes for all polymorphisms 
studied. Apart from IL-6 there was no significant difference between observed 
genotype frequencies and those expected from published data. Genotype frequencies 
were taken from a combination o f studies as follows. 1 (Mead et al. 1997) (Garred et al. 
1999); 2(Reid et al. 2002); 3(Illig et al. 2004;Schluter et al. 2002) 4(Stanilova, Miteva, 
Karakolev, & Stefanov 2006), s(Harding, Baines, Brull, Vassiliou, Ellis, Hart, 
Thomson, Humphries, & Montgomery 2002); 6(Haralambous, Hibberd, Hermans, 
Ninis, Nadel, & Levin 2003;Menges, Hermans, Little, Langefeld, Boning, Engel, 
Sluijter, de Groot, & Hempelmann 2001).
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Genotype
(expected serum phenotype) All patients
Non-Infection Infection
All
No.
SIRS
No.(%)
Non-SIR
No.(%)S
p value All
No.
SIRS
No.(%)
Non-SIRS
No.(%)
p value 
12 All SIRS Non-SIRS
p value 
/.2
140 n=81 n=59 n=73 n=33 n=40 n=67 n=48 n=19
MBL
A/A (high) 90 (64.3%) 42 (52%) 48 (81%) 0.0003 52 19(57.6%) 33 (82.5%) 0.019 38 23 (47.9%) 15(78.9%) 0.02
A/O,O/O (intermediate/low) 50 (35.7%) 39 (48%) 11 (19%) 21 14 (42.4%) 7 (17.5%) 29 25 (52.1%) 4 (21.1%)
TNFa -308
A/A (high) 7 (5%) 3 (3.7%) 4 (6.8%) 0.57 3 1 (3%) 2 (5%) 0.19 4 2 (4.2%) 2 (10.5%) 0.48
G/A (intermediate) 37 (26.4%) 20 (24.7%) 17 (24.6%) 18 5 (15%) 13 (32.5%) 19 15(31.2%) 4 (21.5%)
G/G (low) 96 (68.6%) 58 (71.6%) 38 (64.4%) 52 27 (82%) 25 (62.5%) 44 31 (64.6%) 13 (68%)
IL6-174
G/G (high) 75 (53.6%) 48 (59.3%) 27 (45.8%) 0.22 42 25 (75.8%) 17 (42.: 0.0018 33 23 (47.9%) 10(52.6%) 0.5
G/C (intermediate) 57 (40.7%) 28 (34.6%) 29 (49.1%) 27 5 (15.2%) 22 (55%) 30 23 (47.9%) 7 (36.8%)
C/C (low) 8 (5.7%) 5 (6.1%) 3 (5.1%) 4 3 (9%) 1 (2.5%) 4 2 (4.2%) 2 (10.5%)
IL10 -1082
G/G (high) 23 (16.4%) 11 (13. 12 (20.4%) 0.12 9 2 (6.1%) 7 (17.5%) 0.046 14 9 (18.7%) 5 (26.3%) 0.73
G/A (intermediate) 63 (45%) 33 (40.8%) 30 (50.8%) 35 13 (39.4%) 22 (55%) 28 20 (41.7%) 8 (42.1%)
A/A (low) 54 (38.6%) 37 (45.7%) 17(28.8%) 29 18(54.5%) 11 (27.: 25 19 (39.6%) 6 (31.6%)
ACE
D/D (high) 32 (22.9%) 20 (24.7%) 12 (20.3%) 0.53 14 7 (21.2%) 7 (17.5%) 0.12 18 13(27.1%) 5 (26.3%) 0.86
I/D (intermediate) 67 (47.9%) 32 (39.5%) 35 (59.3%) 42 15(45.4%) 27 (67.5%) 25 17 (35.4%) 8 (42.1%)
I/I (low) 41 (29.3%) 29 (35.8%) 12 (20.3%) 17 11 (33.3%) 6 (15%) 24 18(37.5%) 6 (31.6%)
PAI 1
4G/4G (high) 38 (27.1%) 20 (24.7%) 18(30.5%) 0.72 21 6 (18.2%) 15 (37.: 0.09 17 14(29.2%) 3 (15.8%) 0.31
4G/5G (intermediate) 63 (45%) 37 (45.7%) 26 (44.1%) 33 15 (45.4%) 18 (45%) 30 22 (45.8%) 8 (42.1%)
5G/5G (low) 39 (27.9%) 24 (29.6%) 15 (25.4%) 19 12 (36.4%) 7 (17.5%) 20 12(25%) 8 (42.1%)
Table 7.5 Table of relationship of all genotypes studied to the development of early SIRS. All patients with all 6 genotype results are shown n=140 (of possible 142). 
Patients are then divided into those with an infective or non infective event precipitating admission to PICU. MBL variant alleles remain overrepresented in all groups of 
patients with SIRS. High IL6 (GG) and low IL10 (AA) producers are significantly overrepresented in those with non infectious SIRS. Multiple logistic regression analysis 
showed that the effect of MBL is still present even after taking into account age, sex, race and the above 5 additional polymorphisms.
7.4 Discussion
This chapter describes the influence of a range of polymorphisms on the development 
of SIRS. Logistic regression analysis, accounting for the polymorphisms detailed, and 
for age, sex and race, demonstrated that low producing MBL-2 exon 1 genotypes 
remained the only significant factor for the overall development of SIRS (p=0.0003). 
As expected from the results presented in chapter 6, MBL deficient genotypes remained 
significantly associated with the development of SIRS in those who were admitted with 
both infectious (sepsis) and non-infectious aetiologies and with the severity of sepsis.
Interestingly in our paediatric PICU population low IL-10 producers (genotype AA) 
and high IL-6 producers (genotype GG) were over-represented in those patients 
developing SIRS, but only after a non-infectious insult, (p=0.046 and 0.0018 
respectively). This in part concurs and in part contrasts, with the study by Stanilova 
which showed an over-representation of the IL-10-1082 A allele in adult ITU patients 
with sepsis (ie SIRS after an infectious insult) compared to controls. In Stanilova’s 
study although the A allele was associated with susceptibility to severe sepsis, once 
sepsis was established then the presence of the G allele was associated with higher IL- 
10 levels and mortality (Stanilova, et al., 2006). This may reflect differences between 
children and adults and in particular the reasons for admission to PICU.
Biologically it would seem plausible that low production of the anti-inflammatory IL- 
10 and over production of the pro-inflammatory IL-6, as detailed in this chapter, should 
be associated with SIRS, at least in some populations. This is interesting in the light of 
more recent studies which indicate that excessive anti-inflammation can also be 
disadvantageous. One such paper looking at children after cardiac bypass surgery 
demonstrated that pro-inflammatory cytokine production, in ex-vivo LPS stimulated
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whole blood, was lowest in those with the highest post-operative plasma interleukin-10 
levels. Patients with high circulating IL-10 had a more complicated post operative 
course (Allen et al., 2006). The balance between pro and anti- inflammation may be 
more important than levels per se. For example, children who are high IL-6 producers 
may be more inclined to develop SIRS which may be detrimental to the patient. 
However it may be that this potential for high IL6 production keeps the patient alive 
long enough to actually reach ICU. Future studies will have to address these issues 
before effective inflammatory modulation is used routinely in patient care.
The data presented here are also the first to investigate the levels of antibodies against 
endotoxin core in a mixed population of critically ill children. Overall, EndoCab levels 
were broadly similar levels to those seen in large adult studies (Bennett-Guerrero et al., 
2001; Strutz et al., 1999). In addition this work has shown that cases admitted 
following trauma or surgery (or for other non-infectious reasons), who go on to develop 
an early systemic inflammatory response, have lower IgG EndoCAb levels than do 
those who do not develop SIRS. Higher titres of EndoCAb exhibit anti-inflammatory 
effects in-vitro, for example IgG antibodies to endotoxin core increase the uptake of 
endotoxin by macrophages, opsonize bacteria, attenuate tumour necrosis factor-a 
production (Burd et al., 1993) and are protective in a lamb E coli model of sepsis 
(Hodgson et al., 1995). Furthermore increasing levels of IgG or IgM EndoCAb are 
associated with increasing ability to ‘neutralise’ endotoxin (Bennett-Guerrero et al., 
2001). This simple view must be considered with caution because levels of antibodies 
to endotoxin core fall in the presence of endotoxin (Rothenburger et al., 2001). 
Therefore low EndoCAb levels may simply reflect recent infection or exposure to 
endotoxin from other sources such as on-going poor gut perfusion i.e. it may fall further 
in patients with SIRS. O f course low EndoCAb may be a non-specific marker of illness
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rather than high EndoCAb being protective per se. While the mechanisms underlying 
these relationships remain unclear, it is probably appropriate to consider patients with 
low titres of EndoCAb as having a ‘reduced reserve’ against further exposure to 
endotoxin.
The observation from this study, that the risk o f SIRS is increased in critically ill 
children following trauma or surgery with lower EndoCAb levels, provides some 
support for the idea that high EndoCAb is protective, rather than that low EndoCAb 
reflects pre-exiting disease, as a high proportion o f these patients were previously 
healthy trauma cases.
The similarity observed in the EndoCAb levels in the infection sub-group, between 
patients who went on to develop SIRS or not, is also in keeping with studies in adults 
with sepsis where there is no clear relationship between initial EndoCAb and outcome 
(Goldie et al., 1995). The initial IgM EndoCAb concentrations in 146 adults with sepsis 
were higher in survivors in one study although this may have been explained by other 
factors (Goldie et al., 1995). A subset of patients with very low initial IgG EndoCAb 
had increased mortality. In 205 ICU adults with sepsis, a clear relationship was seen 
between low IgM EndoCAb and progression to septic shock, whilst rising IgG 
EndoCAb values were associated with a positive outcome. A study employing repeated 
sampling throughout episodes of infection (including mild cases that do not require 
intensive care) is required to define the relationship between EndoCAb level and 
progression to SIRS/ severe sepsis in children.
This study has several limitations. Firstly, it was not possible to collect data on the 
administration of plasma products to these patients. As these contain antibodies in the 
same range as the donor population this is a potential confounding factor that would 
tend to reduce the magnitude of any measured differences (Rashid et al., 2004). Plasma
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is not administered on our unit other than in the presence of established coagulopathy 
so this may be a small effect. More difficult is the fact that it was not possible to correct 
for the volume of resuscitation fluid administered to each individual. High volume 
administration of colloid or crystalloid is more likely to be required in patients 
developing SIRS and would be expected to reduce EndoCAb concentration by a simple 
dilutional effect. However, this is unlikely to be a major factor as on closer inspection 
of the data in the infected subgroup there was a trend for higher EndoCAb 
concentrations in patients meeting the criteria for SIRS. In addition, EndoCAb levels 
vary with age in children: IgM and IgG EndoCAb climb from 3 months, reaching adult 
values by one year. In this study there were no significant differences in age between 
the group that developed SIRS and those that did not. Furthermore, in the multivariate 
analysis of the non-infected group, age did not alter the effect of IgG EndoCAb on the 
development of SIRS. Lastly, numbers were too small to investigate an effect on 
mortality.
The hypothesis that EndoCAb has a direct protective role by ‘mopping-up’ endotoxin is 
appealing but is far from proven. This study opens up the possibility o f immunotherapy 
aimed at reducing systemic inflammation even after the patients have entered the ICU. 
Many questions remain including defining the factors that determine EndoCAb levels 
in an individual.
Whatever the mechanisms underlying the complex interplay between all these reported 
factors in the innate immune response, MBL deficiency remains consistently, and 
significantly, associated with sepsis and SIRS in many patient populations (Fidler et al. 
2004;Garred et al. 2003;Gordon et al. 2006) and in this further extension to a 
previously reported study remains so after accounting for various cytokine 
polymorphisms and serum EndoCab levels.
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CHAPTER 8
Final Discussion and Future W ork
This project was stimulated by the questions; why do individuals differ in their 
susceptibility to, and severity of, various infectious and non infectious diseases and 
could the role of inherited factors governing host response to infection and 
inflammation be important?
Over the last 18 years MBL has been shown to play an important role in innate 
immunity (Turner, 1996) and deficiency of MBL, due to gene mutations, has been 
associated with a large number o f infectious and autoimmune diseases (Garred et al., 
1995;Garred et al., 1997a;Hibberd et al., 1999;Summerfield et al., 1997;Ohlenschlaeger 
et al., 2004;Garred et al., 1999a). Just prior to the commencement of this work two 
papers were published which demonstrated that MBL plays a modifier role in adults 
with cystic fibrosis. In those who were MBL deficient, a faster progression to end stage 
lung disease (death or transplantation) and a reduction in lung function was seen 
(Gabolde et al., 1999;Garred et al., 1999b). There were however some discrepancies in 
whether this effect was seen in both hetero and  homozygotes for MBL deficiency or 
just those homozygous/compound heterozygotes for these defects. CF is a disease 
characterized mainly by lung involvement in which both infection and inflammation 
play major roles in disease pathophysiology. What was unclear from these two studies 
was whether MBL played a role by just by influencing the susceptibility to infection or 
whether it played a more complex role in the host’s inflammatory response. In order to 
look at this in more detail the work described in chapter 3 of this thesis was designed to 
look at a larger cohort of patients with CF and to include children as well as adults.
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This demonstrated, in the largest study to date, that MBL deficiency is associated with 
worse lung function in adults with 2 structural MBL mutations only. In older children a 
significantly increased risk of lung transplant or death was seen. However in the overall 
paediatric population (the youngest patients studied to date) no effect of MBL genotype 
on lung function was seen, suggesting that the effect of MBL may be masked in 
childhood whilst lung function is relatively preserved but becomes more apparent in 
later years with the expected decline in lung function. During the years over which this 
work was performed a number of other studies have confirmed the importance of MBL 
as a disease modifier o f CF (see table 3.4).
If MBL does play a role in CF and non CF lung disease (see 1.6.1.1) then the most 
plausible mechanism for this effect would involve the presence of MBL in the airway. 
MBL had not hitherto been shown to be present in human respiratory secretions. 
Chapter 4 was therefore designed to answer the question, can MBL reach the airway 
surface, by looking at the bronchoalveolar lavage fluids of children with acute and 
chronic lung diseases and in those without lung disease to act as a control group. In this 
chapter, I have demonstrated that MBL could be detected in the BAL of children with 
lung disease but none of the controls. In addition, a higher proportion of children with 
acute lung disease had MBL detected compared to those with chronic disease and MBL 
levels were highest in those with acute disease.
One of the original hypotheses from Garred’s work was that the effect of MBL 
deficiency on lung disease was due to the role that MBL plays in the susceptibility to 
infection, specifically Pseudomonas aeruginosa and Bcc. In a small number of patients 
(n=10) with CF and Bcc infection, an overrepresentation of MBL variant alleles was 
noticed (Garred et al., 1999b). Chapter 5 addressed this in 2 parts. Firstly MBL binding 
to various organisms from the Bcc complex was determined and it was seen that
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although MBL does bind to many Bcc organisms, binding patterns were not genomovar 
specific. Secondly, MBL genotypes were determined on a large cohort of CF patients 
infected with Bcc and no overrepresentation of MBL variant alleles were seen. In 
addition, in both the adult and paediatric CF cohorts no effect of MBL genotype was 
seen on the rate of, or first age of acquisition of, Pseudomonas aeruginosa infection. 
The implications of these findings are that MBL may not, in this case, be playing a role 
in governing susceptibility to infection but may be involved in other aspects of disease 
pathogenesis. In the case o f CF, a disease characterized by both infection and 
inflammation, it seems plausible that MBL may modulate the inflammatory response.
To address this further, in conditions where both infection and inflammation contribute 
to disease, a cohort of patients who were admitted to PICU with and without infection 
were followed to see who developed systemic inflammation within 48 hours and this 
information was correlated with MBL serum levels and gene mutations (Chapter 6). 
This demonstrated that indeed MBL deficiency, both genotype and phenotype, are 
significantly associated with the development of systemic inflammation. Understanding 
the mechanism involved may be explained by work using an ex-vivo model, in which it 
was shown that MBL can modulate production of proinflammatory cytokines from 
monocytes. Specifically, high levels o f MBL (>6000 ng/ml, as demonstrated in some of 
these PICU pts) were associated with a reduction, and low MBL levels (such as seen in 
MBL deficiency) with an increase, in these proinflammatory cytokines (Jack et al., 
2001b). To look at this in more detail, experiments described in the latter part of 
chapter 6 were initiated with the aim of looking at the effect of MBL on a wider range 
of pro and  anti-inflammatory cytokines, following stimulation of whole blood with a 
range of organisms seen in sepsis and CF. Unfortunately due to time constraints this 
piece of work was not completed and will therefore be explored further in future work.
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To determine whether the effect of MBL seen on the development of SIRS was solely 
due to MBL or potentially due to some confounding genes or antibodies known to play 
a role in the development o f inflammation, anti-endotoxin antibodies and a number of 
gene polymorphisms were investigated (chapter 7). By multiple logistic regression 
analysis, low producing MBL-2 exon 1 genotypes remained the only significant factor 
for the overall development o f SIRS (p=0.0003) after accounting for age, sex, ethnicity, 
TNF-a, IL-6, IL-10, angiotensin converting enzyme (ACE), plasma activator inhibitor 
1 (PAI-1) and antibodies to endotoxin core.
The implications from the work described here, together with that published in the 
literature suggests that MBL deficiency does in-fact play a role both in the 
susceptibility to infection and the subsequent inflammatory response.
Mechanisms of MBL’s actions
The underlying mechanism by how MBL acts is more fully understood in the 
pathogenesis o f infection than inflammation. Lack of MBL or MBL of lower 
oligomeric forms in serum, due to genetic mutations, reduces MBL binding to 
microorganisms thus there is a reduced direct opsonisation. In addition, reduced MBL- 
MASP interaction and subsequent complement activation will further reduce 
opsonisation and also terminal complement attack, thus less killing of microorganisms 
occurs and the risk of certain infectious diseases may increase. MBL deficiency may 
therefore be an important additional risk factor for infection when there are major 
predisposing factors (e.g. young age, neutropenia). Intensive care is an environment 
with many predispositions to infection: breeches in skin and airway, poor nutrition, gut
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hypoperfusion and acquired ‘immunoparalysis’ (Peters et al., 1999). MBL deficiency is 
likely also to be important in this scenario.
One could postulate that reduced complement activation would reduce inflammatory 
“byproducts” and thus inflammation should be reduced in patients with MBL 
deficiency. The study described here with patients in intensive care, however, found the 
converse and MBL deficiency was associated with an increase in the systemic 
inflammatory response to both infective (ie sepsis and severe sepsis) and non infective 
stimuli. This effect of MBL on the development of sepsis has subsequently been 
confirmed in a number o f studies involving adults, and most latterly neonates receiving 
intensive care (Garred and Madsen, 2004;Garred et al., 2003;Gordon et al., 2006;Eisen 
et al., 2006;de Beneditti et al., 2007) adding further weight to the suggestion that in 
some situations MBL also modulates inflammation possibly by modulation of the 
cytokine response (see full discussion in chapter 6).
Treatment
One patient with CF and end-stage respiratory disease has been treated with 
intravenous, serum-derived MBL (Garred et al., 2002). A recombinant product 
designed for systemic use has now passed a phase 1 safety and tolerability trial 
(Jensenius et al., 2003;Petersen et al., 2006) and trials are planned in the first instance 
involving neutropenic patients receiving chemotherapy. The data presented in chapter 
6, together with the other studies now reported in adult sepsis patients may provide 
evidence of another group in whom the potential of therapeutic use of MBL is 
indicated. Additionally the data presented in chapter 4 suggests that MBL can reach the 
airway and may have a role in host defense directly on the airway surface, which raises 
the possibility o f the topical route as a therapeutic option. Before this can be done, 
further work needs to be undertaken with ex-vivo models to look more closely at the
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exact mechanism by which MBL can modulate the inflammatory response. In addition 
the mechanism and time course of the appearance and breakdown of MBL in the serum 
and lung, together with how BAL levels may differ over time with specific disease 
states needs to be explored.
It is hoped that work described here may play a part in the further understanding of the 
complex nature of the host’s inflammatory responses to infectious and non infectious 
insults. Once understood, further developments in immunomodulatory treatments, that 
directly benefit patients, may become available.
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